US 2010.0086647A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0086647 A1 Kristiansen (43) Pub. Date: Apr. 8, 2010

(54) FEED OR FOOD PRODUCTS COMPRISING filed on Jan. 25, 2006, provisional application No. FUNGALMATERAL 60/690,496, filed on Jun. 15, 2005. (75) Inventor: Bjorn Kristiansen, Frederikstad (30) Foreign Application Priority Data (NO) May 13, 2005 (DK) ...... PA 2005 00710

Correspondence Address: Jun. 15, 2005 (DK). ... PA 2005 OO88O BROWDY AND NEIMARK, P.L.L.C. Jul. 15, 2005 (DK) ...... PCTFDKO5/OO498 624 NINTH STREET, NW Jan. 25, 2006 (DK)...... PA 2006 OO117 SUTE 300 WASHINGTON, DC 20001-5303 (US) Publication Classification 51) Int. Cl. (73)73) AssigneeA : MEDMUSHAS(DK) s HORSHOLM ( A2.3L I/28 (2006.01) A23K L/18 (2006.01) (21) Appl. No.: 11/914,318 A23K L/6 (2006.01) CI2P 19/04 (2006.01) (22) PCT Filed: May 11, 2006 AOIK 6L/00 (2006.01)

(86). PCT NO. PCT/DKO6/OO2S3 (52) U.S. Cl...... 426/62: 426/2: 119/230 S371 (c)(1) (57) ABSTRACT (2), (4) Date: Dec. 1, 2009 The present invention relates to feed and food compositions comprising material obtained by fermenting fungi of the Related U.S. Application Data Basidiomycetes family in a liquid medium. Interestingly,

(63) DK2005/000498,continuation inspart filed onof Jul.application 15, 2005. No. PCT RE"SEenhance Survival SEN"I", and/or support "ES"E"NE growth of normal, healthy (60) Provisional application No. 60/690,496, filed on Jun. animals. Furthermore, the compounds may modulate the 15, 2005, provisional application No. 60/761,744, microbial population in the digestive tract after oral intake. Patent Application Publication Apr. 8, 2010 Sheet 1 of 4 US 2010/0086647 A1

Fig. 1

Feed 2 (0.02 mg) D. Feed 1 (control)

Patent Application Publication Apr. 8, 2010 Sheet 2 of 4 US 2010/0086647 A1

Fig. 2

is

14

Feed 4 (2 mg) Feed 3 (0.2 mg)

Feed 2 (0.02 mg) Feed 1 (control) | |– |–

(*):-

We — Week???? 1-2 Week 1-3 Week 1-4–

Patent Application Publication Apr. 8, 2010 Sheet 3 of 4 US 2010/0086647 A1

Fig. 3

E. co K2

s culture time (h) Patent Application Publication Apr. 8, 2010 Sheet 4 of 4 US 2010/0086647 A1

Fig. 4

Bioactive agent

150 --ARC-5 --Kelly 100 ... v. T. s -- C-26 i -- FENIX E 50 2 US 2010/0O86647 A1 Apr. 8, 2010

FEED OR FOOD PRODUCTS COMPRISING merged fermentation of Lentinus edodes provides no growth FUNGALMATERAL advantage to laboratory animals. 0007. The patent application WO03/020944 describes a number of methods of purifying extracellular immunostimu 0001 All patent and non-patent references cited in the lating compounds from fungi grown in liquid culture. present application, are hereby incorporated by reference in 0008 Hatvani et al., describes a method of purifying a their entirety. compound, which may be Lenthionine from the culture medium of Lentinus edodes grown in liquid culture. The FIELD OF INVENTION document describes that the purified compound in vitro has antibacterial and anticandida effect against B. megaterium, S. 0002 The present invention relates to feed and food com staphylococcus, S. pyogenes and C. albicans. It is postulated positions comprising material obtained by fermenting fungi that it has no effect on a number of other microorganisms of the Basidiomycetes family in a liquid medium. Interest including E. coli and C. jejuni. ingly, Basidiomycetes grown in a liquid culture produce com 0009 Low survival rates of fish bred in fish farms is a pounds which, when used in feed or food compositions major problem. In particular, it has proven to be excessively enhance Survival and/or support growth of normal, healthy difficult to breed white fish, such as cod, in fish farms. How animals. Furthermore, the compounds may modulate the ever, other fish, Such as salmon and trout, which are routinely microbial population in the digestive tract after oral intake. bred in fish farms also have a high lethal rate. The same applies to shrimps and prawns bred in farms. BACKGROUND OF INVENTION 0010 For producers of farm animals, it is frequently desir 0003. It is known that health-promoting effects are attrib able to obtain the largest possible weight gain in animals. Also uted to glucans from fungi and yeasts. “Shiitake fungus lethality may be a problem. (Lentinus edodes) has been attributed effects which can be 0011 Health or well-being may be influenced by the exploited for many medicinal purposes such as immuno microbial population in the digestive tract. stimulation, anti-virus, anti-tumour, etc. Studies of lentinan 0012. Accordingly, there is a need for provision of feed have shown that it stimulates the immune system of the host and food products which may improve health, modulate the in a variety of ways, Such as activation of T helper cells, microbial population in the digestive tract, improve Survival increased production of Interleukin 1 and Interleukin 2, rates of animals and/or improve growth. increased antibody production in various forms of cancer, and decreasing the cholesterol level in the blood. (Herbs for SUMMARY OF INVENTION Health, January/February, 1997: K. Jones, “Shiitake: Medi 0013. One object of the present invention is to provide feed cine in a mushroom, p. 40-50, 54; Anticancer Res, Vol. and food products, which may improve Survival. 17(4A), 1997; H. Matsouka, “Lentinan potentiates immunity 0014) Another object of the invention is to provide feed and prolongs the survival time of some patients', p. 2751 and food products, which may improve growth. 2755; Adv Appl Microbiol, Vol. 39, 1993; S. C. Jong, 00.15 Yet another object of the invention is to provide feed “Medicinal and therapeutic value of the shiitake mushroom', and food products, which may modulate the microbial popu p. 153-184, Int J Immunopharmacol, Vol. 14, 1992: K. lation in the digestive tract. Irinoda, “Stimulation of microbiocidal host defense mecha 0016. In another aspect of the invention, a food product is nism against aerosol influenza virus infection by lentinan, p. provided which is a functional food, preferably either for 971-977. Jpn. J Cancer Res, Vol. 76(1), 1985; D. Herlyn, improving or maintaining health. Said functional food is pref "Monoclonal antibody-dependent murine macrophage-me erably Suitable for consumption by human beings. diated cytotoxicity against human tumors is stimulated by 0017. The above-mentioned feed and food products com lentinan, p. 37-42). prise a bioactive agent such as a Survival enhancing agent. 0004 One active ingredient of Lentinus edodes is termed lentinan, a polysaccharide based compound described as a FIGURE LEGENDS beta-(1,3) glucan backbone with beta-(1,6) side chains. 0005. “Solid-state' reactors are routinely used for cultur (0018 FIG. 1: positive effect of different amounts of the ing fungi such as Lentinus edodes. bioactive agent in feed on the weight increase of NOROC 0006. This is a technology which is used for many pur piglets. Feeds with 0.02, 0.2 and 2.0 mg bioactive agent/kg poses such as composting, production of biological products feed (see Table 4) were given to weaned piglets and feed Such as enzymes, soy sauce, acetic acid, and the like. For the without the bioactive agent was used as control. The weight production of lentinan, Lentinus edodes can be cultivated on increase of each animal was measured weekly and the aver a suitable solid matrix provided by stems of tree or chips of age weight increase was calculated (see Table 5). The experi wood to which is often added chemical compounds Support ment is described in detail in Example 5b. ing the growth of mycelium and development of the fruiting (0019 FIG. 2: positive effect of different amounts of the bodies, where most of the lentinan is localised. The fruiting bioactive agent in feed on the feed factor of NOROC piglets. bodies are harvested, either by hand or mechanically, and are Feeds with 0.02, 0.2 and 2.0 mg bioactive agent/kg feed (see Subsequently dried and ground to a powder which can be used Table 4) were given to weaned piglets and feed without the as it is, or used in tablets, or sent for further processing Such bioactive agent was used as control. The feed factor was as extraction of lentinan. It has been Suggested that extracts of determined for weeks 1, 1-2. 1-3 and 1-4 (see Table 6). The mushrooms may be a growth promoter when fed to chickens experiment is described in detail in Example 5b. (Guo et al., British Poultry Science, 2004, 45:684-694). How 0020 FIG. 3: bacteriostatic effect of different dilutions ever, Lobanoket al., 2003, Applied Biochemistry and Micro (1:10, 1:20 and 1:40) of the bioactive agent obtained by the biology, 39:60-64, have described that mycelium from sub method as described in example 1 on E. coli K12. A culture US 2010/0O86647 A1 Apr. 8, 2010

without the bioactive agent was used as control (Ref). The whole cell fermentation culture comprising both biomass and experiment is described in detail in Example 6. extracellular growth medium, said whole cell culture com 0021 FIG. 4: cancer-cell specific cytotoxicity of different prising said bioactive agent. concentrations of LentineX—comprising an embodiment of Bioactive agents comprising a Survival enhancing activity: the bioactive agent of the present invention—on 4 different Survival enhancement is an important parameter when e.g. human and mouse cancer cell lines. The MRC-5 cell line from treating an individual for a disease, or when rearing domestic normal human fetal lung fibroblasts was used as control. The animals or raising fish in industrial fish farms. Bioactive experiment is described in detail in Example 7. agents comprising a Survival enhancing effect are able to improve the Survival. Thus such a bioactive agent is also DEFINITIONS called a Survival enhancing agent. Functional food: A functional food is a food that goes beyond 0022 Mycelium: Mass of hyphae constituting the body simple nutrition and has at least one specific targeted action to (thallus) of the fungus. improve the health and/or well being of the host and/or pre Agaricus sp.: A basidiomycetous fungal species of the genus vent pathological states in the host. agaricus of the family agaricaceae and the order agaricales Probiotics: specific live microorganisms that have a beneficial and the Subclass agaricomycetidae. effect on the host. Schizophyllum sp.: A basidiomycetous fungal species of the Prebiotics: ingredients or compounds that have a beneficial genus schizophyllum of the family Schizophyllaceae and the effect on the microflora in the host itself. order agaricales and the Subclass agaricomycetidae. Synbiotics: mixtures of probiotics and prebiotics. Lentinus sp.: A basidiomycetous fungal species of the genus Probiotic shots: Probiotic shots contain concentrated doses of lentinus of the family polyporaceae and the order polyporales good bacteria that help to boost the immune system and aid and the Subclass agaricomycetidae. L. edodes is also termed in digestion. They are typically sold in multipacks of single Lentinula edodes, which is placed in the family Marasmi serve bottles of just over 3-ounces, each one intended to be aceae, in the order Agaricales and the Subclass agarico consumed in a single sitting. mycetidae. Polysaccharides: the term “polysaccharide' as used herein covers polysaccharides as well as polysaccharides containing Trametes sp.: A basidiomycetous fungal species of the genus and/or covalently linked to peptides, polypeptides or the like, trametes of the family polyporaceae and the order polypo Such as proteopolysaccharides. rales and the Subclass agaricomycetidae. Polysaccharides comprising monosaccharides: A polysac Ganoderma sp.: A basidiomycetous fungal species of the charide is said to comprise monosaccharides, wherein said genus ganoderma of the family ganodermataceae and the monosaccharides are covalently linked to form said polysac order polyporales and the Subclass agaricomycetidae. charide. Hydrolysing a polysaccharide will yield the Grifola sp.: A basidiomycetous fungal species of the genus monosaccharides that formed said polysaccharide in free grifola of the family meripilaceae and the order polyporales form. The monosaccharide content of a polysaccharide can and the Subclass agaricomycetidae. thus be determined by hydrolysing the polysaccharide and Fruiting bodies or fruit bodies: Any one of a variety of com measuring the presence of individual monosaccharides. The plex, spore-bearing fungal structures. monosaccharide content of a mixture of polysaccharides is Basidiomycete cell: A cell from a fungus of the class Basidi determined by determining the monosaccharide content of omycete of the Phylum Basidiomycota, wherein the cell can the entire mixture. be derived from any part of the fungus, such as fruiting body, Ratio: A polysaccharide or a mixture of polysaccharides are hyphae, spores and mycelium. The Basidiomycete cell can be said to comprise galactose, mannose, and glucose in a given a single hyphae, spores, aggregates of mycelium, or partly ratio, when hydrolysation of said polysaccharide or said mix differentiated mycelium, or comprised in fungal mycelium. ture of polysaccharide yields galactose, mannose and glucose Bioactive agent: Any agent, drug, compound, composition of in said given ratio. Galactose, mannose, and glucose in the matter or mixture which provides a beneficial pharmacologi ratio 1:a to b:c to d, means that for every part galactose, cal effect that can be demonstrated in-vivo or in vitro. This mannose is present in the range of a to b parts and glucose is includes beneficial pharmacological effects which can be present in the range of c to d parts, wherein a, b, c and d demonstrated in an individual on a diet comprising an edible indicates numerical values. Thus, by way of example a food, a food Supplement, Such as a composition of Vitamins, polysaccharide mixture comprising galactose, mannose, and a nutrient, or a nutraceutical comprising the bioactive agent. glucose in the ratio 1:5 to 25:1 to 50, means that for every part Also, the beneficial pharmacological effect can be observed galactose, the polysaccharide mixture comprises in the range in an individual being administered a medicament (drug), a of 5 to 25 parts mannose and in the range if 1 to 50 part combination of medicaments, a vaccine, or other beneficial glucose. agents comprising the bioactive agent. The bioactive agent Molecular weight: Every polysaccharide of a composition is can be provided in isolated and/or purified form, or in a solid said to have a molecular weight of at least a given value, when or liquid composition, Such as e.g. a solid composition com said composition has been purified using a filtration step prising Basidiomycete biomass resulting from a Submerged resulting in a molecular weight cut-off of said given value. cultivation (i.e. when the bioactive agent is produced intrac Similarly, every polysaccharide of a composition is said to ellularly), or a liquid composition, such as e.g. extracellular have a molecular weight within a given range, when said growth medium comprising said bioactive agent (i.e. when composition has been subjected to one or more filtration steps the bioactive agent is secreted to the extracellular medium). resulting in a lower molecular weight cut-off which is the The extracellular growth medium can be separated from the lower value of the range and an upper molecular weight biomass, or from a part of said biomass, by e.g. filtration or cut-off which is the upper value of the range. Said filtration centrifugation. There is also provided an Basidiomycete step may for example be ultrafiltration, microfiltration, ultra US 2010/0O86647 A1 Apr. 8, 2010 centrifugation or gel filtration. However, a composition Sumption preferably have a pleasant taste. Pleasant taste may wherein every polysaccharide has a molecular weight of at for example be determined by a test panel. least a given value or every polysaccharide is said to have a 0032. Depending on the animal for which the feed or food molecular weight within a given range may also be prepared product is intended it will have a different form. by other methods. Polypeptide: the term “polypeptide' as used herein covers 0033. In one embodiment of the invention the feed product proteins, peptides and polypeptides, wherein said proteins, is an aquatic animal feed product, Such as a fish feed product peptides or polypeptides may or may not have been post or a shellfish product. A fish feed product may be any con translationally modified. Post-translational modification may ventional fish feed further comprising the above-mentioned for example be phosphorylation, methylation, glucosylation, biomass, extracellular liquid or extracellular composition. 0023. When used herein, the terms “feed” or “food, Thus for example fish feed may consist of compressed pellets include feed or food additives, feed or food supplements or or a dry powder. For fish larvae the feed may be a fine powder, feed or food premixes. such as a powder with a particle size in the range of 80 to 500 0024. When used herein, the term “liquid culture' is used um, depending on the size of the larvae. Fish feed may pref to indicate all forms of non-solid culture, including Sub erably comprise in the range of 40 to 80%, such as 70 to 80% merged culture and Suspension culture. proteins, in the range of 5 to 40%, such as 5 to 15% lipids and 0025 “Fermentation, cultivation” and “culturing” are in the range of 5 to 40%, such as 5 to 15% carbohydrates. Fish used interchangeably herein. feed may be prepared from a number of different sources, for example from fish meal, meal of other marine species and/or 0026. When used herein the terms “biomass” and “extra Soya. Many freshwater fish, Such as salmon or trout, are fed cellular are intended to described the cell-associated and this kind of fish feed, when bred in a fish farm. Certain aquatic non-cell-associated fractions of the liquid culture, respec animals prefer life food for at least part of their life cycle, in tively. particular young fish larvae may prefer life food. This is in 0027 “removal of the biomass” indicates that a substantial particular true for marine fish, such as cods, turbot, haddock, part of the biomass is removed, preferably more than half, sea bass or sea bream. Young cod larvae, preferably eat live such as more than 90%, i.e. more than 96%, such as more than feed roughly until day 35-40 after hatching and thus the feed 99% of the biomass is removed product may in one embodiment be comprised within a living 0028. When used herein, the term “animal' in intended to microorganism. Said living microorganism may for example include Zooplankton, as well as artemia and rotifers, but not be plankton, such as Zoo plankton, for example it may be microorganisms. selected from the group consisting of artemia, rotifers (rota toria) and Calanus. Later in life marine fish feed may be the DETAILED DESCRIPTION OF THE INVENTION feed described above. Food or Feed Product 0034. The aquatic animal feed product, may also for example be feed for Crustacea, such as for Malacostraca, for 0029. In one embodiment of the invention the food or feed example Eumalacostraca, Such as Eucarida, Such as Deca product comprises extracellular material comprising a Sur poda, for example Natantia, such as Penaeoidea, for example vival enhancing agent derived from a liquid culture of a penaeidae, for example Penaeus. Certain Crustacea, such as fungus of the class of Basidiomycetes. Preferred Basidi crustaceans of the family Penaeida may also prefer live feed omycetes to be used with the present invention are described at least during part of their life cycle. Thus, for example larvae herein below in the section “Fungi'. Suitable methods for of Penaeida preferably eat live feed. Such as microorganisms, cultivating Basidiomycetes in liquid culture are described for example plankton, Such as Zoo plankton, for example herein below in the section “Methods of liquid cultivation'. artemia, rotifer or Calanus. Later in life Penaeida may be fed The extracellular material may for example be the extracel with dry feed, for example feed similar to the fish feed lular liquid obtained after removal of biomass or an extracel described above. lular composition isolated from the extracellular liquid com 0035. Thus in on embodiment of the invention, the feed prising a Survival enhancing agent. Methods of isolating product is a Zooplankton feed product, such as an artemia or compositions comprising a Survival enhancing agent are rotifer or Calanus feed product. Zooplankton are very small described herein below in the section “Isolating a composi organisms and hence Zoo plankton feed products in general tion comprising a Survival enhancing agent'. In one embodi consist of very Small particles. Zooplankton feed products ment of the invention, the feed or food product does not may be an emulsion of an organic phase in an aqueous phase. comprise living animals, however, the product may comprise Preferably, the organic phase comprises the Survival enhanc living microorganisms. ing agent. The organic phase may be any organic solvent, 0030. In another embodiment of the invention the feed preferably an organic solvent which is not toxic to Zooplank product may comprise biomass derived from a liquid culture ton. The organic phase may thus for example be marine oil, of a fungus of the class of Basidiomycetes. Useful Basidi such as fish oil or train oil, such as cod liver oil or whale oil or omycetes and methods of cultivating them are described Vegetable oil. Such as Soy oil or calamus oil. The aqueous herein below. This embodiment is particularly relevant for phase may for example be water, Such as sea water or lake fish feed products, farm animal feed products or shell fish water. Illustrative examples of methods for preparing Such products. emulsion are described herein below in the section “Preparing 0031. The food or feed product may be any product suit feed or food product able for oral consumption, preferably food, feed, drink or a 0036. In another embodiment of the invention the feed supplement for food or feed. Thus the food or feed product product is a farm animal feed product. By the term “farm should preferably have a taste acceptable to the animal spe animal' is meant animals bred on farms mainly for produc cies for which it is intended. Food products for human con tion purposes, for example for the production of meat, milk, US 2010/0O86647 A1 Apr. 8, 2010 eggs or wool. Examples of farm animals include cattle, pigs, Longevity enhancing agent sheep, goat, poultry, Such as turkey, chickens or ducks. 0043. The survival enhancing agent preferably comprises 0037 Pig feed may be in the form of conventional concen polysaccharides and/or polypeptides, more preferably both trates prepared from various plant products, including beets, polysaccharides and polypeptides. grains, such as barley, wheat or oat, Soy, Such as Soy proteins 0044. In one embodiment of the invention it is preferred or vegetable oil/fat. Other sources may also be available. The that the Survival enhancing agent comprises one or more Survival enhancing agent may be admixed with the feed as a polypeptides and a mixture of polysaccharides. Said polypep dry powder or dry pellets or it may be admixed with the feed tides may optionally be covalently linked to polysaccharides. in liquid form. The biomass may also be directly mixed with It is however also comprised within the present invention that the feed said polypeptides are either not associated with said polysac 0038 Poultry feed products, such as chicken feed prod charides or that said polypeptides are associated with said ucts, frequently comprise various vegetarian products such as polysaccharides in a non-covalent manner. corn, maize, grains, such as wheat, barley or oat and/or soy 0045 Thus the survival enhancing agent preferably com bean meal, as well as animal products such as fish meal and/or prises polysaccharides which may or may not be pro animal fat. It is preferred that the growth medium for growing teopolysaccharides, or the Survival enhancing agent may the fungus, such as Lentinin, for producing a feed product, comprise a mixture of both. Such as a poultry feed product, is not obtained from washing 0046. The survival enhancing agent may be comprised grain. within a crude extracellular liquid, obtained directly by 0039. In one embodiment of the invention the product is a removal of biomass after cultivation of a Basidiomycete in food product. The food product may for example be a nutri liquid culture. However, the Survival enhancing agent may tional Supplement. The nutritional Supplement could be in the also be comprised within isolated or purified extracellular form of a liquid or a solid, Such as a pill, lozenge or tablet. The compositions, i.e. they have been Subjected to one or more liquid could be intended for direct intake or it could be purification steps. In a preferred embodiment they have been intended for adding to drinks or food. The liquid may in one purified from liquid growth medium of a fungal mycelium preferred embodiment be the crude extracellular liquid using at least one purification step comprising a size fraction obtained after fermentation and removal of biomass. The ation. Methods of purification are described in more detail Solid could be a dry powder for example prepared as below. described herein below in the section “Preparing food or feed 0047. In a preferred embodiment, the survival enhancing product’. agent essentially consists of polysaccharides and optionally 0040. In yet another embodiment of the invention the polypeptides, more preferably the Survival enhancing agent product is a pet feed product, such as a nutritional Supplement essentially consists of polysaccharides and polypeptides. Fre for pets. The nutritional supplement for pets could be similar quently, the extracellular composition is a liquid composi to nutritional Supplements for human beings. Herein the term tion, and it is then preferred that the composition essentially 'pet' is used to designate animals, which are kept in captivity consists of polysaccharides and optionally polypeptides dis by human beings for other purposes than production. The pet Solved in an aqueous solution optionally comprising salts and feed product will be dependent on the pet. In general the buffer. extracellular liquid, the extracellular composition and/or the 0048. The polysaccharides of the survival enhancing biomass may be added to conventional food for said pet. The agent preferably comprise the monosaccharides glucose, pet may preferably be a mammal, for example dogs, cats, mannose and galactose. horses, hamsters, rabbits or guinea pigs. However, the pet 0049. In a preferred embodiment the survival enhancing may also be fish, birds, reptiles or other animals. agent comprises polysaccharides, wherein the majority of the 0041. In yet another embodiment of the invention the polysaccharides, preferably at least 60%, more preferably at product is a feed product for an animal used in competitions. least 70%, even more preferably at least 80%, yet more pref In this embodiment, it is preferred that the feed product may erably at least 90%, even more preferably at least 95%, yet enhance the performance of animals in competitions and more preferably essentially all polysaccharides, most prefer optionally reduce stress. Examples of animals used in com ably every polysaccharide has a molecular weight above petitions include camels, horses, such as racing horses or polo 10,000 Da, preferably above 30,000 Da, more preferably horses or dogs, such as greyhounds. Feed for these animals above 40,000 Da, even more preferably above 50,000 Da, for will depend on the nature of the animal, but may generally example at least 100,000 Da, such as at least 300,000 Da, for comprise the extracellular liquid, the extracellular composi example at least 1,000,000 Da. In one embodiment of the tion, the biomass and/or the compositions isolated from bio invention the majority of polysaccharides, preferably every mass as described by the present invention added to a con polysaccharide of the Survival enhancing agent has a molecu ventional feed for said pet. lar weight within the range of 10,000 to 3,000,000 Da, for Survival Enhancing Agent example within the range of 30,000 to 3,000,000, such as within the range of 40,000 to 3,000,000, for example within 0042. The invention relates to food or feed products com the range of 50,000 to 3,000,000, such as in the range of prising a bioactive agent, Such as a Survival enhancing agent. 50,000 to 100,000, for example in the range of 100,000 to In some embodiments the Survival enhancing agent may also 300,000, such as in the range of 300,000, to 1,000,000, for be one or more of the following: example in the range of 1,000,000 to 3,000,000. Growth enhancing agent 0050 Preferably, the survival enhancing agent has been Health enhancing agent (for example in a functional food, as purified by a method involving at least one size fractionation described herein) step. Thus it is preferred, that the Survival enhancing agent has Modulator of a microbial population (for example in a func been purified using at least one size fractionation step tional food, as described herein) wherein molecules, such as polysaccharides with a nominal US 2010/0O86647 A1 Apr. 8, 2010 molecular weight above a given cut-off are separated from range of 1 to 20, even more preferably in the range of 2 to 15, molecules, such as polysaccharides with a nominal molecular yet more preferably in the range of 2 to 14, Such as in the range weight below said cut-off. By way of example, if the size of 8 to 17, for example in the range of 9 to 16, such as in the fractionation is ultrafiltration or microfiltration a membrane range of 10 to 15, for example in the range of 11 to 14, such with said cut-off may be used. If the size fractionation is gel as approximately 12.6+/- 1.3, for example 12.6+/- 1.3 parts filtration a gel with said molecular weight cut off may be glucose for every part galactose. chosen or a particular elution fraction may be used. In one 0057. It is even more preferred that the mixture comprises embodiment of the invention the larger molecular weight a ratio of mannose to galactose as indicated herein above and fraction is used, wherein the cut-off preferably is 10,000 Da. a ratio of glucose to galactose in a ratio as indicated herein more preferably 30,000 Da, even more preferably 40,000 Da. above. yet more preferably 50,000 Da. 0058. In embodiments of the invention, wherein the 0051. In another embodiment of the invention, the survival polysaccharides comprise mannose and glucose it is pre enhancing agent has been purified by a method involving one ferred that they comprise in the range of 0.1 to 30, such as in or more size fractionation steps, wherein a resulting fraction the range of 0.1 to 0.25, for example in the range of 0.25 to comprises polysaccharides with a nominal molecular weight 0.5, such as in the range of 0.5 to 0.75, for example in the below a given cut-off and above a given cut-off. By way of range of 0.75 to 1, such as in the range of 1 to 5, for example example, if the size fractionation is ultrafiltration or micro in the range of 5 to 10, such in the range of 10 to 20, for filtration, then first one fractionation step using a membrane example in the range of 20 to 30 parts glucose for every part with the lower molecular weight cut off may be performed. mannose. Preferably the polysaccharides comprise in the The larger molecular weight fraction may be collected and range of 0.5 to 2 parts glucose for every part mannose, more Subjected to a second ultrafiltration or microfiltration using a preferably 13.4+/-0.4 parts mannose 12.6+/- 1.3 part glu membrane with the upper molecular weight cut off. After the COSC. second filtration step the lower molecular weight fraction 0059. In a very preferred embodiment of the invention the may be collected. If gel filtration is used a particular elution Survival enhancing agent comprises a mixture of polysaccha fraction may be used. If ultracentrifugation is used, a mem rides comprising the monosaccharides galactose, mannose, brane with the lower molecular cut-off and a membrane with and glucose in the ratio 1:5 to 25:1 to 50, more preferably the upper molecular weight cut-off may be used. 1:13.4+/-0.4:12.6+/- 1.3. 0052. The survival enhancing agent according to the 0060. In another embodiment of the invention the survival present invention may comprise a mixture of polysaccha enhancing agent comprises a mixture of polysaccharides, rides, wherein said mixture comprises the monosaccharides wherein the polysaccharides within said mixture having a galactose, mannose, and glucose in the ratio 1:5 to 25:1 to 50. molecular weight in the range of 50,000 to 100,000 comprises Thus, the ratio reflects the ratio within the entire mixture of in the range of 3 to 15, preferably in the range of 4 to 14, more polysaccharides. It is thus feasible that each individual preferably in the range of 5 to 13, even more preferably in the polysaccharide within the mixture comprises a different ratio range of 6 to 12, yet more preferably in the range of 7 to 11, of the monosaccharides. even more preferably in the range of 7.9 to 9.9, for example 0053. The ratio may in general be determined by degrad approximately 8.9 parts mannose for every part galactose. In ing the entire mixture of polysaccharides into monosaccha this embodiment it is preferred that the polysaccharides hav rides and Subsequently determining the concentration of each ing a molecular weight in the range of 50,000 to 100,000 of said monosaccharides. Polysaccharides may be degraded comprises in the range of 1 to 5, preferably in the range of 2 to their constituent monosaccharides by hydrolysis, for to 4, even more preferably in the range of 2.5 to 3.5, such as example by hydrolysis in a strong acid, Such as HC1. The approximately 2.9 parts glucose for every part galactose. It is hydrolysate may be analysed by any conventional method preferred that the polysaccharides of said Survival enhancing available to the skilled person, for example by HPLC, mass agent having a molecular weight in the range of 50,000 to spectrometry or NMR. 100,000 Da comprise the monosaccharides galactose, man 0054. In one embodiment of the invention the polysaccha nose, and glucose in the ratio 1:4 to 14:1 to 5, preferably the rides comprise the monosaccharides glucose and mannose. In ratio is approximately 1:8.9:2.9. another embodiment of the invention the polysaccharides 0061. In another embodiment of the invention the survival comprise the monosaccharides glucose and galactose. In a enhancing agent comprises a mixture of polysaccharides, preferred embodiment of the invention, the polysaccharides wherein the polysaccharides within said mixture having a of the Survival enhancing agent comprise the monosaccha molecular weight in the range of 100,000 to 300,000 com rides galactose, mannose and glucose. prises in the range of 3 to 15, preferably in the range of 3 to 14, 0055. It is preferred that the mixture of polysaccharides more preferably in the range of 3 to 13, even more preferably comprises in the range of 5 to 25, preferably in the range of 5 in the range of 3 to 12, yet more preferably in the range of 4 to 20, more preferably in the range of 5 to 17, even more to 11, even more preferably in the range of 5 to 10, yet more preferably in the range of 6 to 15, yet more preferably in the preferably in the range of 6.3 to 8.3, for example approxi range of 7 to 14, such as in the range of 10 to 17, for example mately 7.3 parts mannose for every part galactose. In this in the range of 11 to 16, such as in the range of 12 to 15, for embodiment it is preferred that the polysaccharides having a example in the range of 13 to 14. Such as approximately molecular weight in the range of 100,000 to 300,000 com 13.4+/-0.4, for example 13.4+/-0.4 parts mannose for every prising in the range of 1 to 5, preferably in the range of 2 to 4. part galactose. even more preferably in the range of 2.5 to 3.5, such as 0056. It is preferred that the mixture of polysaccharides approximately 2.9 parts glucose for every part galactose. It is comprises in the range of 1 to 50, preferably in the range of 1 preferred that the polysaccharides of said Survival enhancing to 40, more preferably in the range of 1 to 30, even more agent having a molecular weight in the range of 50,000 to preferably in the range of 1 to 25, yet more preferably in the 100,000 Da comprise the monosaccharides galactose, man US 2010/0O86647 A1 Apr. 8, 2010 nose, and glucose in the ratio 1:3 to 13:1 to 5, preferably the the range of 20 to 1000 ug/L, for example in the range of 25 ratio is approximately 1:7.3:2.9. to 1000 ug/L, such as in the range of 25 to 100 g/L, for 0062. In another embodiment of the invention the survival example in the range of 25 to 35ug/L polypeptide, preferably enhancing agent comprises a mixture of polysaccharides, soluble polypeptide. It is preferred that the survival enhancing wherein the polysaccharides within said mixture having a agent comprising the aforementioned concentration of molecular weight in the range of 300,000 to 1,000,000 com polypeptide, comprises in the range of 0.1 to 2, more prefer prising in the range of 3 to 16, preferably in the range of 5 to ably in the range of 0.5 to 1.5, even more preferably around 1 15, more preferably in the range of 5 to 14, even more pref mg/ml polysaccharide. If the Survival enhancing agent com erably in the range of 6 to 13, yet more preferably in the range prises more or less polysaccharide it is preferred that the of 7 to 12, even more preferably in the range of 8.9 to 10.9, for amount of polypeptide is proportionally reduced or example approximately 9.9 parts mannose for every part enhanced. galactose. In this embodiment it is preferred that the polysac 0067. In one embodiment of the invention the extracellular charides having a molecular weight in the range of 300,000 to liquid and/or the Survival enhancing agent comprises in the 1,000,000 comprising in the range of 1 to 5, preferably in the range of 90 to 99% glucose, such as approximately 98.9% range of 2 to 4, even more preferably in the range of 2.5 to 3.5, glucose, in the range of 1 to 10% mannose, such as approxi Such as approximately 3.1 parts glucose for every part galac mately 1% mannose, very Small amounts of galactose, Such as tose. It is preferred that the polysaccharides of said survival approximately 0.1% galactose. It is comprised within this enhancing agent having a molecular weight in the range of embodiment that at least some of the Sugars are present as a 300,000 to 1,000,000 Da comprise the monosaccharides monomer, thus up to 80%, such as in the range of 60 to 80% galactose, mannose, and glucose in the ratio 1:5 to 15:1 to 5. may be free glucose. In this embodiment the extracellular preferably the ratio is approximately 1:9.9:3.1. liquid and/or the Survival enhancing agent preferably also 0063. In another embodiment of the invention the survival comprises in the range of 20 to 400 mg/l protein, such as in the enhancing agent comprises a mixture of polysaccharides, range of 50 to 150 mg/l, for example in the range of 80 to 100 wherein the polysaccharides within said mixture having a mg/l. Such as approximately 90 mg/l protein. molecular weight of at least 1,000,000 comprising in the range of 3 to 17, preferably in the range of 4 to 16, more 0068. In one preferred embodiment of the present inven preferably in the range of 5 to 15, even more preferably in the tion, such as in a functional food, the Survival enhancing agent range of 6 to 14, yet more preferably in the range of 7 to 13, is not eritadenine. even more preferably in the range of 8 to 12, even more 0069. In one embodiment, the survival enhancing agent is preferably in the range of 9.3 to 11.3, for example approxi a polysaccharide, Such as a polysaccharide having a molar mately 10.3 parts mannose for every part galactose. In this ratio of galactose:mannose:glucose of 1:10 to 20:30 to 50, embodiment it is preferred that the polysaccharides having a such as 1:12 to 18:35 to 45; for example 1:14 to 16:38 to 42, molecular weight of at least 1,000,000 comprising in the such as 1: about 15: about 40, for example 1:15:40. range of 1 to 5, preferably in the range of 2 to 4, even more 0070 Accordingly, in one embodiment of the present preferably in the range of 2.5 to 3.5, such as approximately invention, the Survival enhancing agent comprises one or 2.9 parts glucose for every part galactose. It is preferred that more polypeptides and/or a mixture of polysaccharides, the polysaccharides of said Survival enhancing agent having a wherein the majority of the polysaccharides of the agent has molecular weight in the range of at least 1,000,000 Dacom a molecular weight of at least 10,000 Da and wherein said one prise the monosaccharides galactose, mannose, and glucose or more polypeptides and/or said mixture of polysaccharides in the ratio 1:4 to 1:5 to 15:1 to 5, preferably the ratio is comprises the monosaccharides galactose, mannose and glu approximately 1:10.3:2.9. cose in the ratio (galactose:mannose:glucose) of 1:0 to 25:1 to 0064. Determination of the monosaccharide content of 50, such as 1:10 to 20:30 to 50, such as 1:12 to 18:35 to 45; for polysaccharides with a molecular weight within a given range example 1:14 to 16:38 to 42, such as 1: about 15: about 40, for may be determined by fractionating the liquid comprising the example 1:15:40. Survival enhancing agent according to size for example by 0071. In another embodiment, the survival enhancing ultrafiltration, microfiltration, ultracentrifugation or gelfiltra agent according to the present invention has a molar ratio of tion. galactose:mannose:glucose of 1:0.5 to 5:6 to 12. Such as 1:1 0065. The survival enhancing agent according to the to 4:7 to 11; for example 1:1.5 to 3.5:7.5 to 10, such as 1:2.0 invention preferably comprises polypeptides. The term to 3.0:7.5 to 9.5, for example 1:2.2 to 2.8:8.0 to 9.0, such as 1: polypeptide as used herein covers both proteins, peptides and about 2.5:8.0 to 9.0, for example 1:2.5:8.0 to 9.0, such as polypeptides. Said polypeptides may be in free form, they 1:25:86. may be covalently linked to a polysaccharide or they may be 0072 Accordingly, in another embodiment of the present non-covalently associated with a polysaccharide or a mixture invention, the Survival enhancing agent according to the of the aforementioned. invention comprises one or more polypeptides and/or a mix 0066. It is preferred that the survival enhancing agent ture of polysaccharides, wherein the majority of the polysac comprises sufficient polypeptide in order to allow for oral charides of the composition has a molecular weight of at least administration of the Survival enhancing agent. If the Survival 10,000 Da and wherein said one or more polysaccharides enhancing agent comprises too little polypeptide, then no or and/or said mixture of polysaccharides comprises the little immune modulation is obtained in an individual after monosaccharides galactose, mannose and glucose in the ratio oral administration of the Survival enhancing agent to said (galactose:mannose:glucose) of 1:0 to 25:1 to 50, for example individual. It is therefore preferred that the survival enhanc 1:0.5 to 5:6 to 12, such as 1:1 to 4:7 to 11: for example 1:1.5 ing agent of the invention comprises at least 10 ug/L, more to 3.5:7.5 to 10, such as 1:2.0 to 3.0:7.5 to 9.5, for example preferably at least 20LL/L, even more preferably at least 25 1:2.2 to 2.8:8.0 to 9.0, such as 1: about 2.5:8.0 to 9.0, for ug/L, for example in the range of 10 to 1000 ug/L. Such as in example 1:2.5:8.0 to 9.0, such as 1:2.5:8.6. US 2010/0O86647 A1 Apr. 8, 2010

Helicobacter pylori 0078. In another embodiment the subject having the Heli 0073 Helicobacter is a gram-negative bacterium with cobacter infection is suffering from, or at risk of developing, polar flagella, using oxygen as an electron acceptor, which cancer of the gastrointestinal tract. As stated above, the por cannot utilize carbohydrates as an energy source. Helico tions of the gastrointestinal tract where cancer may be present bacter is used herein interchangeably with “Helicobacter or may develop are any areas where the gastrointestinal tract sp.”. In a preferred embodiment the Helicobacter sp. is Heli is exposed to acid-pepsin gastric juice, including esophagus, cobacter pylori. stomach, duodenum and after gastroenterostomy, the 0074. In one embodiment, the present invention provides jejunum. As used herein the term "cancer of the gastrointes methods for preventing or inhibiting or reducing the growth tinal tract' is used as one of ordinary skill in the art would of Helicobacter by administering the bioactive agent accord recognize the term. Examples of "cancer of the gastrointes ing to the present invention. The bioactive agent can be tinal tract include, but are not limited to, neoplasias (or administered to an individual in need thereof alone or in neoplasms), hyperplasias, dysplasias, metaplasias or hyper combination with other therapeutic agents like antibiotics and trophies. The neoplasms may be benign or malignant, and inhibitors of acid secretion. By the phrase “in combination' they may originate from any cell type, including but not with therapeutic agents is meant herein that one or more limited to epithelial cells of various origin, muscle cells and bioactive agent(s) according to the present invention is endothelial cells. administered to the individual thus treated before and/or dur 007.9 The treatment can be used for patients with a pre ing (including concurrently with) and/or after treatment of an existing Helicobacter infection, or for patients pre-disposed individual with one or more therapeutic agents. In all cases of to a Helicobacter infection. Additionally, the bioactive agent combination treatment described herein, the bioactive agent of the present invention can be used to alleviate symptoms of can be administered in the form of food. In all cases of a Helicobacter infection in patients, or as a preventative mea combination treatment described herein, the combination Sure in patients. may be in the form of kit-in-part systems, wherein the com 0080. As used herein, the phrase Helicobacter infection is bined active Substances may be used for simultaneous, used to mean an interaction between Helicobacter and the sequential or separate administration. In all cases, it is pre host organism (subject). The infections may be localized, ferred that any of the herein-mentioned medicaments are meaning that the Helicobacter grows and remains near the administered in pharmaceutically effective amounts, i.e. an point of initial interaction. The infection may also be gener administration involving a total amount of each active com alized, where the Helicobacter may become more wide ponent of the medicament or pharmaceutical composition or spread beyond the initial point of interaction, including method that is sufficient to show a meaningful patient benefit. spreading to the Surrounding tissue or organ and even being The combination of a bioactive agent according to the present distributed and growing throughout the entire host organism. invention and therapeutic agents provide improvements over As used herein the term interaction (of a host and Helico therapy with the therapeutic agent alone, in particular for bacter) is used to mean a process where the Helicobacter patients that do not respond to therapy with the therapeutic grows in or around a particular tissue. Helicobacter is con agent alone or in combination with other treatment regimes. sidered to have infected the subject if the bacteria is able to 0075 Thus, the present invention provides a method of penetrate the Surface of cells of a particular tissue and grow treating an infection with Helicobacter in a subject, particu within the cells of the tissue. An example of this type of larly human Subjects, comprising administering a therapeu infection includes, but is not limited to Helicobacterpenetrat tically effective amount of a bioactive agent according to the ing and growing within the epithelial cells lining the lumen of present invention alone or in combination with other thera the stomach. Additionally, the Helicobacter can also be said peutic agents. to have infected the host organism by growing extracellularly 0076. In one embodiment, the other therapeutic agent is an to the tissue cells. antibiotic. In another embodiment the antibiotic is amoxicil I0081. The method of the current invention comprises lin. In a further embodiment the antibiotic is clarithromycin. administering an antibacterially effective amount of the bio In yet another embodiment the antibiotic is metronidazole. In active agent to treat a Helicobacter infection. As used herein, another embodiment the therapeutic agent is an inhibitor of “an antibacterially effective amount to treat a Helicobacter acid secretion like an H2 inhibitor or a proton pump inhibitor. infection' is intended to mean an amount affective to prevent, In a further embodiment the H inhibitor is omeprazol. Fur inhibit, retard or reverse the growth of Helicobacter, and/or ther embodiments of the invention provide methods where reduce the number of viable Helicobacter cells within the one or more antibiotic is co-administered with an inhibitor of stomach or at a site of infection. “Antibacterially effective acid secretion. amount to treat a Helicobacterinfection' is also used to mean 0077. In one embodiment of the invention the subject hav an amount effective to kill, reduce or ameliorate any existing ing a Helicobacter infection is suffering from a peptic ulcer. infections of Helicobacter. Thus, according to the present Peptic ulcers, as contemplated in the current invention invention, an “antibacterially effective amount to treat a Heli include, but are not limited to, circumscribed breaks in the cobacter infection of the bioactive agent of the present continuity of the mucosal layer of the gastrointestinal tract. invention can be used as a treatment of a pre-existing Heli These breaks in the continuity of the mucosal layer can cobacter infection. Effective amounts for use in these treat include breaks that do not extend below the epithelium, also ments can completely or partially prevent a pre-existing Heli referred to as “erosions' or breaks that do extend below the cobacter infection from spreading to Surrounding tissue and epithelium. The peptic ulcers may be acute, or chronic. Fur beyond, and they can also be used to slow the growth and/or ther, peptic ulcers can be located in any part of the gastrointes spread rate of the Helicobacter in the subject. Furthermore, tinal tract that is exposed to acid-pepsin gastric juice, includ the “antibacterially effective amounts to treat a Helicobacter ing esophagus, stomach, duodenum and after infection of the bioactive agent of the current invention can gastroenterostomy, the jejunum. prevent a Helicobacter infection in Subjects. Another aspect US 2010/0O86647 A1 Apr. 8, 2010

of an “antibacterially effective amount to treat a Helicobacter imab and showed no appreciable tumor remission or regres infection', as used in the current invention, means that the Sion. In other embodiments, the patient has relapsed after bioactive agent administered to the Subject is capable of pre receiving rituximab therapy. venting or reducing the cellular or physiological damage to I0086. In another aspect, the present invention provides a the infected or Surrounding tissue, caused by the toxins pro method of treating cancer in a Subject comprising co-admin duced by the Helicobacter. istering a therapeutically effective amount of an anti-CD20 0082 In still another aspect, the phrase “antibacterially monoclonal antibody and a therapeutically effective amount of a bioactive agent according to the present invention, effective amount to treat a Helicobacter infection' can be wherein administering the bioactive agent results in an opti used to mean an amount of the administered bioactive agent mal immunological response. that can reduce or prevent the formation or efficacy of the I0087. In another aspect, the present invention provides a virulence of the Helicobacter. By virulence is meant the method for treating cancer in a Subject comprising co-admin ability of the Helicobacter to combat the host organism's or istering a monoclonal antibody that binds to a Her-2/neu cells natural defenses to the Helicobacter infection. receptor and a bioactive agent according to the present inven tion. In one embodiment, the Subject is a human patient. The Antibody Therapy monoclonal antibody can e.g. be trastuzumab. I0088. One aspect of the present invention provides a 0083. In one embodiment, the present invention provides method of treating cancer in a Subject comprising co-admin methods for enhancing the antitumor activity of antibody istering a monoclonal antibody that binds to a cytotoxic T therapy by administering a bioactive agent according to the lymphocyte-associated antigen 4 (CTLA-4) and a bioactive present invention in combination with the antibody therapy. agent according to the present invention. In certain embodi By the phrase “in combination with antibody therapy is ments, the Subject is a human patient. In one embodiment of meant herein that one or more bioactive agent(s) according to the present invention, the anti-CTLA-4 monoclonal antibody the present invention is administered to the individual thus is administered at a dose of 3 mg/kg every three weeks for treated before and/or during (including concurrently with) four cycles and the bioactive agent is administered one to five and/or after treatment of an individual with a therapeutic times weekly for up to eight weeks. The present invention antibody. In all cases of combination treatment described also provides embodiments where the dose of the bioactive herein, the bioactive agent can be administered in the form of agent is from 10 to 500 mulg/kg/dose. food. In all cases of combination treatment described herein, 0089. One of the mechanisms associated with the antitu the combination may be in the form of kit-in-part systems, mor activity of monoclonal antibody therapy is antibody wherein the combined active substances may be used for dependent cellular cytotoxicity (ADCC). In ADCC, mono simultaneous, sequential or separate administration. In all clonal antibodies bind to a target cell (e.g. cancer cell) and cases, it is preferred that any of the herein-mentioned medi specific effector cells expressing receptors for the mono caments are administered in pharmaceutically effective clonal antibody (e.g. NK cells, monocytes and granulocytes) amounts, i.e. an administration involving a total amount of bind the monoclonal antibody/target cell complex resulting in each active component of the medicament or pharmaceutical target cell death. A bioactive agent according to the present composition or method that is sufficient to show a meaningful invention is believed to enhance effector cell function, patient benefit. The combination of a bioactive agent accord thereby increasing monoclonal antibody therapy efficacy. ing to the present invention and therapeutic monoclonal anti Thus, the dose and Schedule of bioactive agent administration bodies provide improvements over monoclonal antibody in combination with MAbs can be based on the ability of the therapy alone, in particular for patients that do not respond to bioactive agent to elevate parameters associated with differ monoclonal antibody therapy alone or in combination with entiation and functional activity of cell populations mediating other treatment regimes. ADCC, including but not limited to, NK cells, macrophages 0084 Thus, the present invention provides a method of and neutrophils. These parameters can be evaluated using treating cancer in a Subject, particularly human Subjects, assays of NK, macrophage and neutrophil cell cytotoxicity, comprising co-administering a therapeutically effective ADCC (NK cell fraction or total mononuclear cells, or effec amount of a monoclonal antibody and a therapeutically effec tor molecules essential to the ability of cells to implement tive amount of a bioactive agent according to the present ADCC (e.g., FasL, granzymes and perforin). invention. 0090 Combination therapy with a bioactive agent accord 0085. In one embodiment, the monoclonal antibody is an ing to the present invention and a monoclonal antibody may in anti-CD20 monoclonal antibody. In another embodiment, the one embodiment be indicated when a first line treatment has monoclonal antibody is rituximab. In another embodiment, failed and may be considered as a second line treatment. methods of the present invention treat non-Hodgkin’s lym However, based on the enhanced antitumor activity of the phoma. Further embodiments of the present invention pro bioactive agent in combination with a monoclonal antibody, vide methods where monoclonal antibody rituximab and a the present invention also provides using the combination as bioactive agent according to the present invention are admin a first line treatment in patient populations that are newly istered once weekly for e.g. up to eight consecutive weeks. In diagnosed and have not been previously treated with antican another embodiment, the rituximab is administered once cer agents “de novo patients' and patients that have not pre weekly and the a bioactive agent according to the present viously received any monoclonal antibody therapy "naive invention is administered up to five times weekly for up to patients.” eight consecutive weeks. Another embodiment of present 0091 Abioactive agent according to the present invention invention provides that the bioactive agent dose is from 10 to is also useful in combination therapy with monoclonal anti 500 mulg/kg/dose. In certain embodiments of the present bodies in the absence of any directantibody mediated ADCC invention, the patient has previously been treated with ritux of tumor cells. Antibodies that block an inhibitory signal in US 2010/0O86647 A1 Apr. 8, 2010 the immune system can lead to augmented immune Preferred is e.g. gemtuzumab ozogamicin (Mylotarg) or other responses. Examples include (1) antibodies against mol antibodies attached to calicheamicin, or BL22. ecules of the B7R family that have inhibitory function such as, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), 0094. It is preferred that the antibody is targeted to a mol programmed death-1 (PD-1), B and T lymphocyte attenuator ecule known to be associated with cancerous processes. For (BTLA); (2) antibodies against inhibitory cytokines like example, the antibody may bind specifically one or more of IL-10, TGFP; and (3) antibodies that deplete or inhibit func the following targets: vascular endothelial growth factor-A tions of suppressive cells like anti-CD25 or CTLA-4. For (VEGF-A), epidermal growth factor receptor (EGFR), CD20 example, anti-CTLA4 mAbs in both mice and humans are antigen, the HER2 protein, the CD52 antigen, the VEGF thought to either Suppress function of immune-suppressive protein, erbB-2, EGFR, erbB-2, cathepsin L, cyclin E. Ras, regulatory T cells (Tregs) or inhibit the inhibitory signal p53, BCR-ABL, Bcl-2, caspase-3. transmitted through binding of CTLA-4 on T cells to B7-1 or 0.095 Table 1 is a non-exclusive list of monoclonal anti B7-2 molecules on APCs or tumor cells. CTLA-4 is bodies approved or being tested for which combination expressed transiently on the surface of activated T cells and therapy with a bioactive agent according to the present inven constitutively expressed on Treg cells. Cross-linking tion is possible. Other preferred antibodies may be selected CTLA-4 leads to an inhibitory signal on activated T cells, and antibodies against CTLA-4 block the inhibitory signal on T from, but are not restricted to, the group consisting of: cells leading to sustained T cell activation (Phanet al., PNAS, Alemtuzumab (Campath), bevacizumab (Avastin, Genentech 100:8372-8377, 2003.) Inc.). OncoScint (Such as for colorectal and ovarian cancer), 0092 Preferred antibodies for use in the combination ProstaScint (Such as for prostate cancer), Tositumomab therapy: Although monoclonal antibodies are preferred, any (Bexxar), of the embodiments described herein may also use polyclonal Cetuximab (Erbitux, ImClone Systems Inc.), Gemtuzumab antibodies instead of, or in combination with, monoclonal oZogamicin (Mylotarg), Rituximab (Rituxan, Rochef Genen antibodies. In one embodiment of the combination invention, tech), anti-erbB-2 schv, Ibritumomab tiuxetan (Zevalin), naked antibodies (i.e. antibodies without any drug or radio Panitumumab (formerly known as “ABX-EGF, Abgenix, active material attached to them) are used. In another embodi Fremont Calif.), Ibritumomab tiuxetan (Zevalin), EMD ment of the present invention, conjugated antibodies are used (joined e.g. to one or more of a chemotherapy drug, a radio 72000 (Vanhoefer et al., J. Clin Oncol 2004; 22:175-184), active particle, or a toxin). For example, the antibody used Ibritumomab Tioxetan, and Trastuzumab (Herceptin). may be a conjugated monoclonal antibody. Another preferred 0096. Further suitable antibodies and protocols for use of embodiment uses one or more of a chemolabeled mono any of the antibodies described herein can be found in e.g. US clonal antibody, a monoclonal antibody with radioactive par patent applications no. US2005/0244413 (Adolf et al.) and ticles attached, an immunotoxin. us20050265966 (Wane et al.), U.S. Pat. No. 5,338,661 (Jens 0093 Preferred immunotoxins include, but are not enius), and “Recombinant Polyclonal Antibodies for Cancer restricted to, an antibody attached to one or more of a bac Therapy” (Sharon et al., Journal of Cellular Biochemistry terial toxins such as diphtherial toxin (DT) or pseudomonal 96:305-313 (2005)), both of which are incorporated herein by exotoxin (PE40), a plant toxin Such as ricin A or saporin. reference.

TABLE 1. Target Drug Name Clinical Indication Company IL-2RC(CD25) Zenapax transplant Roche IL-1R AMG108 osteoarthritis Amgen RANK-L AMG162 Osteoporosis Amgen Blys LympoSTAT-B SLE, RA HGS CD4OL (CD39) initiated AID Celltech IDEC TRAIL-R1 HGS-ETR1 C8CES HGS TRAIL-R2 HGS-ETR2 Solid tumors HGS CD30 SGN3O NHL Seattle Genetics CD40 SGN4O MM Seattle Genetics HER2 Herceptin Breast cancer Genentech ABX-EGF CRC, NSCLC, RCC Abgenix EMD72OOO Solid tumors Merck MDX-214 EGF-R-positive Medarex OS Erbitux CRC Imclone VEGF-R CDP791 Solid tumors Celltech PDGF-R CDP860 Solid tumors Celltech/ZymoGenetics CD11a (CL) Raptiva psoriasis Genentech C4-Integrin Antegrin CD, MS PDL, Biogen-IDEC C4-B7 Integrin MLMO2 CD, UC Millenium C.5 B3 Integrin Vitaxin psoriasis, prostate cancer AMELilly Amevive psoriasis Biogen/IDEC CD152 CTLA-4, Ig RA Bristol Meyers CD152 CTLA-4 C8CES Medarex CD49a Integrin C1 RALuous Biogen/IDEC CD49e Integrin C.5 C8CES Protein Design Labs MUC1 Theragyn US 2010/0O86647 A1 Apr. 8, 2010 10

TABLE 1-continued Target Drug Name Clinical Indication Company MUC18 (TIM-like) ABX-MA1 melanoma TAG-72 Mucin Anatumomab C8CES CD3 Ecromeximab melanoma Kyowa Hakko TRX4 type1 IDDM TolerRx Nuvion UC PDL OrthoCloneOKT3 organ transplant Ortho biotech CD4 HuMax-CD4 T-cell lymphoma GenMab CD19 MT103 NHL Medimmune CD64 (Fe GR1) AntiCD64 C8CES Medarex CD33 MyloTarg AML Celltch/Whyeth ZAmyl AML Protein Design Labs CD22 ymphocide NHL, AID Immunomedics CEA CEA-Cide C8CES Immunomedics CD2O Rituxan NHL Genentech CD52 Campath MS, NHL, T-cell lymph Genzyme, IDEX CD44 Bivatuzumab C8CES Boehringer Ingetheim CD23 (Fe Ep R) DEC152 allerhic asthma, rhinitis Biogen/IDEC LRR: CD14 COSIC14 Sepsis ICOS EpCAM Panorex colorectal cancer CentOcor Lewis-Y-Ag SGN15 C8CES Seattle Genetics CD8O B7.1 psoriasis/NHL Biogen/IDEC

0097 Dosage of the bioactive agent may be varied as cells (DCs) in vivo and in vitro (Mushiake et al. Cancer known to one skilled in the art and as disclosed in detail Immunol. Immunother. 2005 February: 54 (2) 120-128). elsewhere herein. Preferably, administration is intravenous 0101 The survival period of Colon-26-bearing mice administration or oral administration. Antibodies may also be treated with S-1 and Lentinan was significantly more pro given intravenously in one embodiment, for example co longed than that of mice treated with S-1 alone (P<0.05). formulated with the bioactive agent. For example, the anti 0102) The frequency of CD86"DCs infiltrated into Colon body and/or bioactive agent may be given at a dosage of 5 26 was increased in mice treated with S-1 and lentinan, and mg/kg, every other week, or may be administered with a 400 splenic DCs harvested from mice treated with S-1+LNT mg/m loading dose and weekly doses of 250 mg/m over 1 showed more potent T-cell proliferation activity than that of hour. DCs from mice treated with S-1 alone (P<0.05). Cytochrome P450 0103) Furthermore, the activity of cytotoxic T lympho cytes (CTLs) in splenocytes of mice treated with S-1 and 0098. It has been shown, that the polysaccharide Lentinan Lentinan was specific and more potent than that of CTLS from from Lentinus edodes and polysaccharides from Agaricus mice treated with S-1 alone (P<0.05). blazei can suppress the expression of cytochrome P450s 0104. The results suggest that modulation of specific (CYPs) and thus can prevent cancer (Hashimoto et al. Biosci. immunity with Lentinan has a significant role in enhanced Biotechnol. Biochem. 2004, 66 (7) 1610-1614 and Okamoto anti-tumour effects through the modification of DC function. et al. Biofactors 2004 21 (1-4) 407-09 both of which are The combination therapy of S-1 and bioactive agents accord incorporated herein by reference). P450s are a class of drug ing to the invention presents a promising chemoimmuno and Xenobiotic-metabolizing enzymes mainly expressed in therapy, which may lead to better survival for cancer patients. the liver. Carcinogens such as polyaromatic hydrocarbons Thus in one embodiment the present invention is directed to a and heterocyclic amines are metabolized to their carcino combination therapy of S-1 and the bioactive agent according genic forms by CYPs. Moreover the suppression of P450 to this invention in cancer patients. In all cases of combination caused by polysaccharides, such as Lentinan, is advantageous therapy described herein, the bioactive agent can be admin for chemotherapy patients, as it prolongs the duration and istered in the form of food. intensifies the action of drugs. 0099 Thus in one embodiment the present invention is Functional Food directed to a bioactive agent capable of Suppressing the expression of P450s. In a further embodiment the bioactive 0105. In one embodiment of the present invention, the agent of the present invention is used in a combination food is a functional food, preferably suitable for human therapy with a chemotherapeutic drug. In all cases of combi beings. Said functional food comprises any of the agents nation therapy described herein, the bioactive agent can be described herein, preferably a Survival enhancing agent, a administered in the form of food. longevity enhancing agent, a health enhancing agent and/or a modulator of a microbial population. More preferably, said Dendritic Cells agent is a health enhancing agent and/or a modulator of a microbial population. It is preferred that the functional food is 0100. It has been demonstrated that chemoimmuno suitable for at least weekly oral intake, such as for daily oral therapy using S-1, an oral fluoropyrimidine anticancer drug, intake. Alternatively, said functional food product may be combined with lentinan is effective in modifying dendritic suitable for use in parenteral or enteral nutrition, preferably in US 2010/0O86647 A1 Apr. 8, 2010

combination with formulations comprising other nutrients yogurt, a low-fat yogurt. Said yogurt-based product may for known to one skilled in the art. example be fermented with Lactobacillus bulgaricus and/or 0106 Products according to the invention may be used for Streptococcus thermophilus. promoting health of human beings, for example for maintain 0114. In another preferred embodiment of the present ing, strengthening or promoting bone or cardiovascular invention, said dairy product is a cultured dairy product, Such health. In one preferred embodiment of the present invention, as a cultured fluid (for example drinkable yogurt/yogurt the functional food can be used for the prevention or reduc Smoothies, kefir, probiotic shots); a non-drinkable yogurt (for tion of osteoporosis. In another preferred embodiment of the example in a cup or tubes); and/or another non-pourable present invention, regular consumption of said functional cultured dairy product (for example cottage cheese, cream food. Such as for example once a day, twice a day, or three cheese, dairy dips or sour cream). times a day, leads to a reduction of the risk of diseases such as 0.115. In another preferred embodiment of the present colds, coughs and reduces tiredness and fatigue. invention, said dairy product is another type of dairy product, 0107 While the method of administration or consumption Such as selected from the group consisting of refrigerated may vary, the functional food is preferably ingested by a dips and sour cream, ice cream, cream, low-fat cream-re human as an ingredient of his or her daily diet. Any of the placement, fermented milk such as kefir, fermented bever agents described herein can be combined with a liquid ages, such as drinkable yogurt and kefir. vehicle. Such as water, milk, vegetable oil, juice and the like, or with an ingestible solid or semi-solid foodstuff. For Health Drink example, they may be mixed into foods such as milk shakes, 0116. In another preferred embodiment of the present milk shake mixes, breakfast drinks, juices, flavored drinks, invention, the functional food according to the present inven flavored drink mixes, yogurts, puddings, ice creams, ice tion is a health drink. Said health drink is in one embodiment milks, frostings, frozen yogurts, cheesecake fillings, candy fruit juice-based, which may be concentrated as a 'squash'. bars, including "health bars' Such as granola and fruit bars, to be diluted to taste. Said fruit juice or squash preferably gums, hard candy, mayonnaise, pastry fillings such as fruit comprises concentrated fruit juice. Preferred fruit juices fillings or cream fillings, cereals, breads, stuffings, dressings include, but are not restricted to, citrus fruit juices Such as and instant potato mixes. The present invention thus relates to orange, grapefruit, lemon or lime, or combinations thereof. In a method of producing a functional food composition, com another preferred embodiment, said fruit juice or squash com prising mixing any of the agents described herein (for prises (preferably concentrated) berry juice(s). Such as from example lentinan) with a foodstuff. raspberries, strawberries, blackberries, loganberries, cranber 0108 For example, said functional food product may be ries, redcurrants, blackcurrants, blueberries, or combinations selected from the group of meal replacers, dietary Supple thereof, and/or combinations with citrus fruit juices. In ments, ice-cream, sauces, dressing, spreads, bars, Sweets, another preferred embodiment, said fruit juice or squash com Snacks, cereals and beverages. prises juice(s) from one or more of Pineapple, Passion Fruit, 0109. In another preferred embodiment, said functional Mango, apple, pear, apricot, Pomegranate, guava, tomato food is dietary Supplement, preferably Suitable for ingestion and/or combinations with any other types of fruit juices. in pill, capsule, tablet or liquid form. Preferred juice bases are selected from the following group: 0110. In one embodiment, products according to the 0117 Apple invention are prepared whereby any of the agents described 0118 Apricots herein (such as an agent from Lentinus) is added to the food 0119 Banana product such that the level of the agent is between 5 to 5000 0120 Blackberries mg per 100 g product. 0121 Blueberries (0.122 Carambola (Starfruit) Dairy Product (0123 cherries 0111. In one preferred embodiment of the present inven 0.124 Dates tion, the functional food is a dairy product. Thus, said func (0.125 Figs tional food may for example be selected from any of the 0.126 fruit cocktail following: 0.127 grape cultured dairy products, yogurts, cottage cheese, cream 0.128 grapefruit cheese, dairy dips, sour cream, milkshakes, Butter, Marga 0129. Kiwi Fruit rine, Low-fat spreads, Cheese, Cottage cheese, Cheese 0.130 Lemons spread, Cheese “strings' for children. Cheese slices, yogurt, 0131 Mandarin Orange Yogurt-based carbonated drinks, drinkable yogurts, low-fat 0.132. Mangos yogurts, refrigerated dips, Sour cream, Ice cream, Cream, 0.133 melon Low-fat cream-replacement, Fermented milk Such as kefir. 0.134 Nectarines 0112. In one preferred embodiment of the present inven 0135) Orange tion, said dairy product is a cheese-based product, Such as 0.136 Papaya selected from low-fat cheese, hard cheese, soft cheese, cot 0.137 Peaches tage cheese, cheese spread, cheese “strings' for children or 0138 Pear cheese slices suitable for sandwiches. 0139 Pineapple 0113. In another preferred embodiment of the present 0140 Plantain invention, said dairy product is a yogurt-based product, Such 0.141 Plum as selected from a set yogurt, a runny or pourable yogurt, a 0.142 Raspberries yogurt-based carbonated drink, a drinking or drinkable 0.143 strawberries US 2010/0O86647 A1 Apr. 8, 2010 12

0144) Tangerines lowing bread types: malted wheats, milk breads, bran-en (0145 watermelon riched and mixed grain breads. The bread may be any shape, or combinations thereof. Such as e.g. cob, coburg, cottage, cholla, bloomer, barrel, 0146 Further preferred juice bases are selected from the batch, Sandwich, tin, Vienna or farmhouse. In one preferred following group: embodiment of the present invention, said bread is selected 0147 Apple from any of the following bread types: 0148 Carrot Wholemeal bread 0149 Cranberry Brown bread (O150 Grape Wheatgerm bread (bread containing added processed wheat 0151. Grapefruit (pink or white) germ of no less than 10%) 0152 Lemon Softgrainbread (made from white flour with additional grains O153 Lime of softened rye and wheat to increase the fibre content (pref 0154) Orange erably by 30%) compared with conventional white bread) (O155 Pineapple Granary breads 0156 Pineapple Maltbreads O157 Prune 0169. In another preferred embodiment of the present 0158 Tangerine invention, said bread is selected from any of the following 0159 Tomato bread types: or combinations thereof. 0160 Said health drink may also be water-based, such as a Ciabatta mineral water-based product, such as flavoured mineral water-based products. Said flavouring is preferably from fruit 0170 pitta juices and/or other natural products. aa 0161 In one preferred embodiment of the present inven cholla tion, said health drink is an energy shot comprising Sugars and other energy-providing products, such as comprised in an 25 Focaccia or 30 cl bottle. 0171 Soda Bread or brown soda bread (made using 0162. In another preferred embodiment of the present wholemeal flour) invention, said health drink is an alcoholic beverage. Such as rye breads a dairy-based alcoholic beverage. baguette or French stick 0163. In another preferred embodiment of the present croissants invention, said health drink is a meal replacement drinks. bagel 0164. It is envisaged that the health drink of the present 0172. In another preferred embodiment of the present invention may also be manufactured as a concentrate or pre invention, said bread is a flat bread, such as selected from any mix, ready for making up to the drink at a later stage, prefer of the following bread types: Chapattis, Paratas and Roti, ably by the consumer. Mexican tortilla, flat “wrap' or flour tortilla, pancakes. Solid Functional Food 0173. In another preferred embodiment of the present invention, the functional food is a morning Snack or bakery 0.165. In one preferred embodiment of the present inven product. Said bakery product may be either sweet or savoury, tion, the functional food is a Solid functional food, such as for example savoury. selected from the group consisting of Biscuits/crackers, 0.174 Preferred bakery products include, but are not breakfast cereal, Soup, muesli, Chewing gum, Sweets (such as restricted to: rolls and baps, toasting products such as muffins, boiled sweets), fresh bakery products (fresh bread, cakes, crumpets and pikelets, Scones, teacakes, buns and other muffins, waffles etc.), dry bakery products (crispbread, bis fruited products, hot plate products such as pancakes and cuits, crackers etc.), cereal products (breakfast cereals, fibre griddle Scones, waffles and potato cakes, hot cross buns. and sterol enriched flours, mueslis, cereal based and muesli croissants, brioches, pain-au-chocolat, bagels, American bars, such bars possibly containing chocolate, pasta products, sweet muffins and other semi-sweetbread products. Snacks etc.), bran products (granulated and/or toasted bran products, flavoured and/or sterol coated bran products and Vegetable Oil-Based Product bran-bran mixes etc.). 0166 In another preferred embodiment of the present 0.175. In another preferred embodiment of the present invention, said solid functional food is a ready mix (prefer invention, the functional food is a vegetable oil-based product ably in powder form), either for baking (e.g. breads, cakes, (spreads, Salad oils, mayonnaise etc.) muffins, waffles, pizzas, pancakes) or for cooking (e.g. Soups, sauces, desserts, puddings) to be used in preparing or manu Frozen Confectionery Products facturing of foods 0176). In another preferred embodiment of the present 0167. In another preferred embodiment of the present invention, the functional food is a frozen confectionary prod invention, said solid functional food is a meat product (sau uct. For the purpose of the invention the term frozen confec sages, meat-balls, cold cuts etc.) tionery product includes milk containing frozen confections 0.168. In another preferred embodiment of the present Such as ice-cream, frozen yogurt, sherbet, Sorbet, ice milk and invention, said solid functional food is a bread or morning frozen custard, water-ices, granitas and frozen fruit purees. product/bakery snack. Thus, said bread may be white, brown (0177 Preferably the level of solids in the frozen confec or wholemeal bread. In another preferred embodiment of the tion (e.g. Sugar, fat, flavouring etc) is more than 3 wt %, more present invention, said bread may be selected from the fol preferred from 10 to 70 wt %, for example 40 to 70 wt %. US 2010/0O86647 A1 Apr. 8, 2010

0.178 Ice-cream will typically comprise 2 to 20 wt % of use in the above-mentioned shots are any of the following: fat, 0 to 20 wt % of sweeteners, 2 to 20 wt % of non-fat milk Enterococcus faecalis. Escherichia coli, Saccharomyces bou components and optional components such as emulsifiers, lardii, Saccharomyces cerevisiae and/or Streptococcus ther stabilisers, preservatives, flavouring ingredients, vitamins, mophilus. minerals, etc, the balance being water. Typically ice-cream 0.184 The agent(s) according to the present invention may will be aerated e.g. to an overrun of 20 to 400%, more general be also combined with other ingredients in a dietary Supple 40 to 200% and frozen to a temperature of from -2 to -200 ment, such as e.g. botanical Supplements and/or in a vitamin degrees C., more general -10 to -30 degrees C. Ice-cream E capsules, or in a selenium pill. Further preferred combina normally comprises calcium at a level of about 0.1 wt %. tion in said dietary Supplements may be with e.g. one or more 0179 A typical size of an average serving of frozen con of the following: antioxidant(s), vitamin C, vitamin E, beta fectionery material is 66 g. The agent according to the present CarOtene invention may be encapsulated or combined with emulsifiers, 0185. The functional food of the invention can further detergents or other agents to ensure solubilisation and stabi encompass other healthy components such as for example lisation of the substance in the product. Vitamins A, B, C, D, E, minerals such as calcium, potassium, magnesium, iron, copper, Zinc, Selenium and anti-oxidants Meal Replacers Such as tocopherols, polyphenols. For example, the func tional food may comprise an agent according to the invention 0180. In another preferred embodiment of the present (such as lentinan) together with vitamin C, the combination invention, the functional food is a meal replacer. Meal capable of causing a reduction in colds and flu in the indi replacer drinks are typically based on a liquid base which may vidual ingesting said functional food. for example be thickened by means of gums or fibers and 0186. In a preferred embodiment, compositions of the whereto a cocktail of minerals and vitamins are added. The invention may comprise further ingredients which are drink can be flavoured to the desired taste e.g. fruit or choco believed to reduce or prevent osteoporosis. Examples of such flavour. A typical serving size may be 330 ml or 330 g. The ingredients are calcium, Vitamin D. magnesium etc. agent according to the present invention may be encapsulated 0187 Preferred embodiments of suitable functional foods or combined with emulsifiers, detergents or other agents to of the invention are described herein below: ensure solubilisation and stabilisation of the substance in the 0188 Beverage comprising any of the agents described beverage. herein in an amount of 0.1-5%, preferably 0.5-1%. 0181 Meal replacer snacks or bars often comprise a 0189 Fresh bakery product comprising any of the agents matrix of edible material wherein the agent according to the described herein in an amount of 0.9-1.6%, preferably 2.4- present invention can be incorporated. For example the 10%, and more preferably 3–5%. matrix may be fat based (e.g. couverture or chocolate) or may 0.190 Dry bakery product comprising any of the agents be based on bakery products (bread, dough, cookies etc) or described herein in an amount of 1.0-20%, preferably 3.2- may be based on agglomerated particles (rice, grain, nuts, 15% and more preferably 4.4-10% raisins, fruit particles). A typical size for a Snack or meal 0191 Cereal product comprising any of the agents replacement bar could be 20-200 g, generally from 40 to 100 described herein in an amount of 0.8-20%, preferably 1.6- g. Further ingredients may be added to the product e.g. fla 16%, more preferably 2-10% vouring materials, vitamins, minerals etc. 0.192 Bran product comprising any of the agents described herein in an amount of 4%-25%, preferably 6-20% Combinations 0193 Dairy or non-dairy product (e.g. fermented cereal product) comprising any of the agents described herein in an 0182. In one aspect of the present invention, the functional amount of 0.1-20%, preferably 0.8-8% food comprises an agent according to the present invention in 0194 Vegetable oil based product comprising any of the combination with another Survival enhancing agent, longev agents described herein in an amount of 0.6-1.6%, preferably ity enhancing agent, health enhancing agent and/or a modu 2.6-10%, more preferably 2.6-5% lator of a microbial population. 0.195 Meat product comprising any of the agents 0183 For example, one preferred embodiment of said described herein in an amount of 0.1-16%, preferably 0.2- functional food is a food comprising one or more of the agents 5%. according to the present invention and a probiotic, such as in 0196. Dairy product comprising: any of the agents a probiotic “shot'. Another preferred embodiment of the functional food is a food comprising the compounds accord described herein in an amount of 0.1-16%, preferably 0.2- ing to the present invention and a prebiotic, Such as in a 5%. prebiotic “shot'. Another preferred embodiment of the func 0.197 Thus, in one embodiment, the present invention is tional food is a food comprising the compounds according to concerned with use of any of the agents described herein in the present invention and a symbiotic, such as in a symbiotic the manufacture of a functional food. Such as any of the “shot'. In one preferred embodiment of the present invention, functional foods described herein. preferred bacteria for use in the above-mentioned shots are any of the following: Lactobacillus sp., Such as L. acidophi Survival lus, L. casei, L. fermentum, L. johnsonii, L. lactis, L. plan 0.198. In one embodiment of the invention it is preferred tarum, L. reuteri, L. rhamnosus and/or L. Salivarius. In that the food or feed product is capable of improving survival, another preferred embodiment of the present invention, pre preferably after oral intake. Thus when the feed product ferred bacteria for use in the above-mentioned shots are any of according to the invention is fed to one group of animals, the the following: Bifidobacterium sp., such as B. bifidium, B. lethal rate should be lower than in a similar control group fed breve, B. lactis, and/or B. longum. In another preferred on a similar diet. The lethal rate is determined as the percent embodiment of the present invention, preferred bacteria for age of dead animals after a predetermined time. US 2010/0O86647 A1 Apr. 8, 2010

(0199 Preferably, the lethal rate is at least 1.2, such as 1.5, ics, for example virginiamycin. Preferably the weight gain is for example 2. Such as 3, for example 5. Such as 10 times at least 5%, such as at least 10%, for example at least 15% lower in animals fed with a feed product according to the larger. present invention. 0200. In particular, the above-mentioned reduction in Modulation of Microbial Population lethal rate is observed in aquatic animals, preferably in cods, 0212. In one embodiment of the invention it is preferred salmonids, gadids or penaeids, more preferably in cods after that the food or feed product is capable of modulating the 1 week, such as after 2 weeks, for example after 3 weeks, such microbial population in at least part of the digestive tract, in as after approximately 30-45 days, wherein said aquatic ani particular after oral intake. The digestive tract may depending mal has been fed with a feed product according to the inven on the animal species comprise the crop, oesophagus, proven tion during the entire period. triculus, gizzard, duodenum, jejunum, ileum and caecae. 0201 In another embodiment of the invention the above Preferably the food or feed product is capable of at least mentioned reduction in lethal rate is observed in a farm ani modulating the microbial population in the intestine. mal, preferably chicken or pigs after 2 weeks, such as 1 0213 Modulation of the microbial population in the intes months, such as 2 months, for example 3 months, wherein tine may include one or more of the following (A-G), wherein said farm animal has been fed with the product for at least 2 the percent modulation may be in comparison with either the weeks, such as for the entire period. animal/human being before being fed the feed or food prod 0202 In particular, the above-mentioned reduction in uct according to the invention or another similar animal or lethal rate is preferably observed in chicken 35 days after human being, which is not fed the feed or food product, hatching, wherein the chickens have been fed the feed product preferably an animal or human being which is on a similar according to the invention continuously since hatching. diet lacking the Survival enhancing agent according to the 0203. In another embodiment the above-mentioned reduc invention: tion in lethal rate is preferably observed in piglets 28 days A. Reduction of the overall number of bacteria in the intes after weaning, wherein the piglets have been fed the feed tine, preferably the reduction is to 90% or less, such as to 80% product according to the invention continuously since wean or less, for example to 70% or less, such as to 60% or less, for 1ng. example to 50%. This may for example be determined by 0204 Methods for investigating survival are described in preparing an intestinal sample and determining the size of the the Examples below. bacterial population. B. Reduction of the number of Salmonella, such as Salmo Enhanced Growth nella enterica, preferably reduction in the number of Salmo nella in the intestine. Preferably the reduction is to 90% or 0205. In one embodiment of the invention it is preferred less, such as to 80% or less, for example to 70% or less, such that the food or feed product is capable of improving growth, as to 60% or less, for example to 50% or less, such as 40% or preferably after oral intake. In particularitis preferred that the less, for example to 30% or less, such as 20% or less for food or feed product is capable of improving growth in young example to 10% or less, such as 5% or less, for example to 1%. animals. This may for example be determined by preparing an intes 0206 Preferably, when the feed product according to the tinal sample and determining presence of Salmonella. present invention is fed to one group of animals, the average C. Reduction of the number of Clostridium perfingens, pref weight gain is higher than in a similar control group fed on a erably reduction in the number of Clostridium perfingens in similar diet. The average weight gain may be determined as the intestine. Preferably the reduction is to 90% or less, such the difference in weight gain between the groups divided by as to 80% or less, for example to 70% or less, such as to 60% the average weight in the control group. The weight may be or less, for example to 50% or less, such as 40% or less, for the weight of the living animals or the market weight. example to 30% or less, such as 20% or less for example to 0207 More preferably, the average weight gain is at least 10% or less, such as 5% or less, for example to 1%. This may 13%, more preferably at least 15%, such as at least 20%, for for example be determined by preparing an intestinal sample example at least 25% and determining presence of Clostridium perfiringens. 0208 Preferably, above mentioned weight gain is D. Reduction of the number of Camphylobacter jejuni, pref obtained in farm animals, such as chicken or pig, at the age of erably reduction in the number of Camphylobacter jejuni in 2 weeks. Such as 3 weeks, for example 4 weeks, such as 2 the intestine. Preferably the reduction is to 90% or less, such months, wherein the animals are fed the feed product con as to 80% or less, for example to 70% or less, such as to 60% tinuously from day 0, such as from day 1, for example from or less, for example to 50% or less, such as 40% or less, for day 4, such as from day 7 after birth/hatching example to 30% or less, such as 20% or less for example to 0209. In particular, the above-mentioned average weight 10% or less, such as 5% or less, for example to 1%. This may gain is preferably observed in chicken 35 days after hatching, for example be determined by preparing an intestinal sample wherein the chickens have been fed the feed product accord and determining presence of Camphylobacter jejuni. ing to the invention continuously since hatching. E. Reduction of the number of coccids, preferably reduction 0210. In another embodiment the above-mentioned in the number of coccids in the intestine. Preferably the reduc weight gain is preferably observed in piglets 28 days after tion is to 90% or less, such as to 80% or less, for example to weaning, wherein the piglets have been fed the feed product 70% or less, such as to 60% or less, for example to 50% or according to the invention continuously since weaning. less, such as 40% or less, for example to 30% or less, such as 0211. In one embodiment animals fed with the feed prod 20% or less for example to 10% or less, such as 5% or less, for uct according to the present invention obtain a larger weight example to 1%. This may for example be determined by gain than animals fed on another nutritionally similar diet preparing an intestinal sample and determining presence of comprising traditional growth stimulators, such as antibiot coccids. US 2010/0O86647 A1 Apr. 8, 2010

F. No or minor reduction in the number of Lactobacillus sp., 0222. In a very preferred embodiment of the present preferably reduction to no less than 80%, such as no less than invention the fungus belongs to the class of basidiomycetes, 90%, for example to no less than 95%, such as to no less than Such as a fungus of the genus Lentinus, Such as Lentinus 98%. This may for example be determined by preparing an edodes. intestinal sample and determining presence of Lactobacillus. 0223) Lentinus edodes deposited under IHEM 18992 with G. No or minor reduction in the number of Bifidobacterium the Belgian Coordinated Collections of Microorganism sp., preferably reduction to no less than 80%, such as no less (BCCM), 14 Rue J. Wytsman, B-1050 Bruxelles, Belgium, than 90%, for example to no less than 95%, such as to no less represents one preferred strain of Lentinus edodes. Further than 98%. This may for example be determined by preparing strains of Lentinus edodes are available from culture collec an intestinal sample and determining presence of Bifidobac tions such as ATCC (AmericanType Culture Collection, P.O. terium. Box 1549, Manassas, Va. 20108, USA), CBC (Centraalbu reau voor Schimmelcultures, PO Box 85167,3508 AD Utre cht, THE NETHERLANDS) and DSMZ (Deutsche Sam Fungi mlung von Mikroorganismen and Zellkulturen GmbH, 0214. In a preferred embodiment of the present invention Mascheroder Weg 1b, 3.8124 Braunschweig GERMANY). the Survival enhancing agent disclosed herein have been pro 0224. Additionally relevant Lentinus species, besides duced by a fungus. Preferably, the Survival enhancing agent Lentinus edodes, includes Lentinus species such as: Lentinus has been purified from the extracellular environment of a albovelutinus G. Stev. (1964)=Rhodocybe albovelutina (G. fungus. Even more preferably the fungus, preferably a fungal Stev.) E. Horak (1971); Lentinus anthocephalus (Lev.) mycelium, has been cultivated in a liquid growth medium and Pegler; Lentinus badius Bres.: Lentinus castoreus Fr. (1838) said Survival enhancing agent has been purified from said =Lentinellus ursinus (Fr.) Kühner (1926); Lentinus liquid growth medium. chrysopeplus Berk. & M. A. Curtis (1869)=Cyptotrama 0215. It is thus preferred that the survival enhancing agent asprata (Berk.) Redhead & Ginns (1980); Lentinus cochlea of the invention has been produced by a method comprising tus Fr.: Lentinus concinnus Pat. Lentinus delicatus G. Stev. the steps of (1964)=Marasmius delicatus (G. Stev.) E. Horak (1971); Lentinus fasciatus Berk. Lentinus hepatotrichus Berk. 0216 i) cultivating a fungus, such as a fungal myce (1859)=Lentinellus ursinus (Fr.) Kühner (1926); Lentinus lium, in a liquid growth medium, and hyracinus Kalchbr. (1880)=Lentinellus ursinus (Fr.) Kühner 0217 ii) isolating the composition from said liquid (1926); Lentinus lepideus sensu Colenso (1891); Lentinus growth medium lepideus (Fr.) Fr. (1825)=Lentinus suffrutescens (Brot.) Fr. 0218. By fungal mycelium is intended any fungal biom (1825); Lentinus novaezelandiae Berk. (1855)=Lentinellus ass, which can be grown in a submerged culture. The fungal ursinus (Fr.) Kuhner (1926); Lentinus pulvinulus Berk. biomass may be in the form of single hyphae, spores, aggre (1859)=Lentinellus pulvinulus (Berk.) Pegler (1965); Lenti gates of mycelium, and partly differentiated mycelium. nus punctaticeps Berk. & Broome (1883); Lentinus punctati 0219. The liquid growth medium may be any of the liquid ceps cf. sensu Petersen, Nicholl & Hughes (1997); Lentinus growth media described herein below. pygmaeus Colenso (1887)=Lentinus zelandicus Sacc. & Cub. 0220. The fungus may be any fungus, preferably a fungus (1887); Lentinus Sajor-caju (Fr.) Fr.: Lentinus squarrulosus forming a fungal mycelium, more preferably the fungus is a Mont.: Lentinus Strigosus (Schwein.) Fr. (1825); Lentinus filamentous fungus. Even more preferably, the fungus may be suffrutescens (Brot.) Fr. (1825); and Lentinus tuber-regium selected from the group consisting of Agaricus sp., Such as Fr.: Lentinus zelandicus Sacc. & Cub. (1887) (Ref: http:// Agaricus bisporus, Cordiceps sinensis, Flammulina veluti nzfungi.landcareresearch.co.nz). pes, Ganoderma lucidum, Grifola frondosa, Lentinus edodes, Pleurotus Ostreatus, Schizophyllum commune, Sclerotina Methods of Liquid Cultivation sclerotium, Trametes (Coriolus) versicolor, Tremellafiucifor 0225 Preferably, the Basiomyctes, such as Lentinus sp. or mis, Agaricus blazei, Agrocybe aegerita, Agrocybe cylindra Agaricus sp. are cultivated in a liquid growth medium. cea, Albatrellus confluens, Armillariella mellea, Auricularia 0226 Cultivating the fungus in a liquid growth medium in auriculajudae, Auricularia polytricha, Collybia maracula, general involves dissolving nutrient compounds required for Cordiceps militari, Dendropolyporus umbellatus, Fomes growth of said fungus in water, transferring the solution to a fomentarius, Fomes pinicola, Ganoderma applanatum, bioreactor and inoculating the bioreactor with cells or spores Ganoderma tsugae, Hericium erinaceus, Hypsizygus mar of the fungus, Such as a fungal mycelium, or fractions thereof, moreus, Inonotus obliquus, Laetiporus sulphurous, Lenzites to be cultivated. This is done understerile conditions and with betulinus, Leucopaxillus giganteus, Lyophyllum cineras control of the environment in order to give the fungus a cens, Omphalina epichysium, Oudemansiella mucida, Panel Suitable chemical and physical environment. Cultivating lus serotinus, Piptoporus betulinus, Phellinus linteus, Pheli fungi in liquid growth medium is also termed “liquid state' nus pini, Pholiota nameko, Pleurotus citrinopileatus, cultivation. Pleurotus pulmonarius, Sarcedon asparatus, Trametes Sua 0227 During “liquid-state' cultivation the medium with volens, Volvariella volvacea and Wolfiporia cocos. the fungal biomass is preferably agitated to reduce the occur 0221. Yet more preferably, the fungus is selected from the rence of gradients and to ensure oxygen availability to the group consisting of Agaricus sp., Such as Agaricus bisporus, Submerged cells. When fungi are grown in a bioreactor, oxy Agaricus blazei, Cordiceps sinensis, Flammulina velutipes, gen may be supplied to the liquid medium and the level of Ganoderma lucidum, Grifola frondosa, Lentinus edodes, dissolved oxygen may be controlled by known methods. Pleurotus Ostreatus, Schizophyllum commune, Sclerotina 0228. The liquid growth medium is an aqueous solution, sclerotium, Trametes (Coriolus) versicolor and Tremella fuci preferably sterile water, comprising nutrient compounds. The formis. liquid medium Supports fungal growth and preferably stimu US 2010/0O86647 A1 Apr. 8, 2010

lates the production of extracellular compounds, such as 0234. The content of the shake flasks can be used for immune modulating agents. The liquid growth medium may inoculating a bioreactor. In that case, the reactor comprises a comprise one or more typical ingredients required for growth sterile solution of nutrient compounds and nutrient salts in of microbial organisms such as malt extract, yeast extract, water for mono-culture cultivation of basidiomycete fungal peptone, glucose, Sucrose, Sucrose, salts providing phos mycelium, or fractions thereof. Such as Lentinus fungal phate, magnesium and potassium, corn-steep liquor and Vita mycelium, Such as Lentinus edodes. mins such as thiamine. More preferably, the medium com 0235. The bioreactor fermentation period is typically in prises Sucrose, corns steep liquor, phosphate and magnesium the range of from 50 hours to 300 hours, preferably in the for mycelium growth and production of polysaccharides. range of from 80 hours to 270 hours, and the temperature is 0229. In a preferred embodiment for liquid cultivation the kept constant in the range of 18 to 32° C., preferably in the medium comprises malt extract. This embodiment is in par area of from 22 to 31°C., such as a temperature of about 23° ticular relevant for production of food or feed products com C., for example 24°C., such as 25°C., for example 26°C., prising biomass or a composition isolated from biomass. such as 27°C., for example 28° C., such as 29° C., for More preferably the medium may comprise malt extract, a example 30°C. The temperature may also be from 18 to 37 Sugar source and an amino acid source, even more preferably C., preferably from 23 to 32° C. such as about 25° C. malt extract, glucose, yeast extract and peptone. The malt 0236. The reactor is fitted with an inlet for supplying air to extract may preferably be at a concentration in the range of 1 the fermentation broth, and the fermentation broth is prefer to 20, such as 1 to 10, for example 2 to 4 g/l. Glucose may ably kept under continuous agitation either as a result of the preferably be at a concentration of less than 18 g/l. Such as in addition of air, or by means of a mixer device suitable for the range of 10 to 18, for example in the range of 13 to 17 g/l. providing a good mixing of the content of the reactor. Peptone may preferably be at a concentration of less than 9, 0237. It is preferred to adjust the pH of the growth medium Such as in the range of 1 to 9, for example in the range of 3 to to from about 3 to about 7, such as a pH of from about 4.5 to 7 g/l. Yeast extract may preferably be in a concentration of in about 6.5, for example a pH of about 6, before the growth the range of 1 to 10, preferably around 3 g/l. medium is inoculated with fungal mycelium, or fractions 0230. For inoculation of the growth medium, fungal thereof. Such as L. edodes mycelium. After the initial adjust mycelium, Such as Lentinus edodes mycelium from agar ment, pH may be dropped naturally during the course of the plates containing for example malt extract, yeast extract, pep fermentation, or controlled at a particular value in the range tone and glucose can be used. Fungi can initially be cultivated pH 3 to 7, using addition of Suitable pH-control agents, such onagarplates comprising the above nutrient compounds Sup as acid and base. The temperature of the growth medium is porting the growth of the fungus. The plates are inoculated preferably in the range of from 18 to 32°C., preferably in the with mycelium and incubated at least until a visible growth is area of from 22 to 31°C., such as a temperature of about 23° evident on the plates. Dependent on the fungus, this usually C., for example 24°C., such as 25°C., for example 26°C., can take from about 7 days to about 24 days or from about 10 such as 27°C., for example 28° C., such as 29° C., for to 30 days, typically 14 days or up to 20 days, at a temperature example 30°C. The temperature may also be from 18 to 37 in the range of from 18 to 32°C., preferably in the area of from C., preferably from 23 to 32° C. such as about 25° C. 22 to 30° C., such as a temperature of about 23°C. to 27°C., 0238 Samples can be obtained from the bioreactor and such as around 25°C. analysed for biomass, metabolic products and nutrient com 0231. As an alternative to inoculation with mycelium from pounds, the determinations of which can assist the operator of agar plates, inoculation of the growth medium can be carried the bioreactor in the running of the fermentation process. out by using mycelium from a fermentation broth in e.g. a Typical analyses routinely carried out are determination of shake flask medium comprising nutrient compounds Support biomass, residual Sugar concentration and extracellular ing cell growth. polysaccharide concentration. A person skilled in the art 0232 Shake flasks for cultivating fungal mycelium can knows the methods for analysis which can be employed in initially be inoculated with the mycelium which is cultivated this respect. on agar plates. The mycelium is taken from the plates and transferred aseptically to shake flasks containing sterile water Isolating a Composition Comprising a Survival Enhancing comprising dissolved nutrient compounds and nutrient salts Agent Supporting the growth of the fungal mycelium. A typical 0239 Preferably, the method for preparing the products growth medium contains Sucrose, corn steep liquor, phos according to the invention involves a step of purifying the phate and a magnesium. The amount of inoculation material extracellular fraction of the liquid growth medium from the which gives the highest production of extracellular lentinan fungal mycelium. The extracellular fraction of the liquid fer can be selected following initial experiments. mentation medium is also termed the Supernatant and this 0233. The time for incubation of the shake flasks depends fraction can be separated from the fungal mycelium by e.g. on the specific fungus. Typically, the shake flasks can be centrifugation or filtration, or indeed by any other means incubated by shaking for 6 to 21 days, preferably from 7 to 18 available for obtaining a liquid fraction essentially without days, more preferably from 8 to 14 days at a temperature in any fungal mycelium present therein. The term "essentially the range of from 18 to 32°C., preferably in the area of from without any fungal mycelium present therein” shall denote 22 to 30° C., such as a temperature of about 23° C., for that the concentration of fungal mycelium, including frac example 24°C., such as 25°C., for example 26°C., such as tions thereof, has been reduced at least by a factor of 10, such 27°C., for example 28°C., such as 29°C., for example 30° C. as reduced by a factor of at least 10, for example a factor of The shake flasks may also be incubated from 8-25 days, more at least 10, such as reduced by a factor of at least 10°. preferably from 10-20 days, more preferably from 12-18 0240. The methods for preparing the products according days. The temperature may also be from 18 to 37°C., pref to the invention may further comprise isolating an extracel erably from 23 to 32° C. such as about 25°C. lular composition comprising a Survival enhancing agent. In US 2010/0O86647 A1 Apr. 8, 2010

preferred embodiments of the invention the isolation com enhancing agent may be further isolated from the biomass. prises at least one size fractionation step. Preferably, this size Said composition may for example be isolated by means of fractionation step is performed on the extracellular fraction. extraction. This size fractionation step may ensure that every polysac 0249. In one aspect there is provided a bioactive agent as charide of the composition has a molecular weight of at least disclosed in the items herein below: a given value (see also herein above). The size fractionation 0250) 1. The bioactive agent according to a first item com step may be any size fraction known to the skilled person, for prises or consists of an agent selected from an oligosaccha example ultracentrifugation, ultrafiltration, microfiltration or ride, a polysaccharide and an optionally glycosylated gelfiltration. Thus in a preferred embodiment of the inven polypeptide. tion, the composition is purified from a liquid growth medium 0251 2. The bioactive agent according to item 1, wherein by a method involving one or more purification steps selected the bioactive agent comprises or consists of a polysaccha from the group consisting of ultracentrifugation, ultrafiltra ride. tion, microfiltration and gelfiltration. Preferably, the purifica 0252) 3. The bioactive agent according to item 1, wherein tion step(s) are selected from the group consisting of ultrafil the bioactive agent comprises or consists of an oligosac tration, microfiltration and ultracentrifugation, even more charide. preferably from the group consisting of ultrafiltration and 0253 4. The bioactive agent according to item 1, wherein microfiltration. the bioactive agent comprises or consists of an optionally 0241 Ultrafiltration is a membrane process where the glycosylated polypeptide. membrane fractionates components of a liquid according to 0254 5. The bioactive agent according to item 2, wherein size. The membrane configuration is normally cross-flow the polysaccharide is a homopolymer. wherein the liquid containing the relevant components are 0255 6. The bioactive agent according to item 2, wherein flowing across the membrane. Some of the liquid, containing the polysaccharide is a heteropolymer. components Smaller than the nominal pore size of the mem 0256 7. The bioactive agent according to items 2, wherein brane will permeate through the membrane. Molecules larger the polysaccharide comprises glucose monosaccharide than the nominal pore size will be retained. The desired prod units, optionally in combination with further monosaccha uct may be in the retentate or the filtrate. If the ultrafiltration ride units selected from the group of units consisting of is performed in order to prepare a composition, wherein every glucuronic acid, galactose, mannose, arabinose and Xylose, polysaccharide within said composition has a molecular including any combination thereof. weight above a given value, the desired product is in the retentate. If a serial fractionation is made, the product may be (0257 8. The bioactive agent according to item 7, wherein in the retentate or filtrate. the further monosaccharide units are all glucuronic acid. 0242 Microfiltration is a membrane separation process 0258 9. The bioactive agent according to item 7, wherein similar to UF but with even larger membrane pore size allow the further monosaccharide units are all galactose. ing larger particles to pass through. 0259 10. The bioactive agent according to item 7, wherein 0243 Gel filtration is a chromatographic technique in the further monosaccharide units are all mannose. which particles are separated according to size. The filtration 0260 1 1. The bioactive agent according to item 7, wherein medium will typically be small gel beads which will take up the further monosaccharide units are all arabinose. the molecules that can pass through the bead pores. Larger 0261 12. The bioactive agent according to item 7, wherein molecules will pass through the column without being taken the further monosaccharide units are all Xylose. up by the beads. 0262. 13. The bioactive agent according to item 7, wherein 0244 Gel-filtration, ultrafiltration or microfiltration may the further monosaccharide units are glucuronic acid and for example be performed as described in R Hatti-Kaul and B galactose. Mattiasson (2001), Downstream Processing in Biotechnol 0263. 14. The bioactive agent according to item 7, wherein ogy, in Basic Biotechnology, eds C Ratledge and B Kris the further monosaccharide units are glucuronic acid and tiansen, Cambridge University Press) pp. 189. aOSC. 0245. A non-limiting method of preparing the products 0264. 15. The bioactive agent according to item 7, wherein according to the invention is described in example 1. the further monosaccharide units are glucuronic acid and 0246. In another embodiment the extracellular composi arabinose. tion may be isolated by precipitation, Such as precipitation 0265 16. The bioactive agent according to item 7, wherein with alcohol. Such as ethanol and/or chromatographic meth the further monosaccharide units are glucuronic acid and ods. This may for example be performed essentially as Xylose. described in WO2003/020944. It is also comprised within the 0266 17. The bioactive agent according to item 7, wherein invention that the extracellular composition is isolated by the further monosaccharide units are galactose and man sequentially performing two or more of above-mentioned OS. methods. By way of example the composition may be isolated 0267 18. The bioactive agent according to item 7, wherein by first performing a size fractionation step followed by pre the further monosaccharide units are galactose and arabi cipitation. OS. 0247 The feed or food product according to the invention 0268. 19. The bioactive agent according to item 7, wherein may also be prepared using the biomass, which comprises the the further monosaccharide units are galactose and Xylose. fungal mycelium. Biomass may be prepared as described 0269. 20. The bioactive agent according to item 7, wherein above, except that the fungal mycelium rather than the extra the further monosaccharide units are mannose and arabi cellular material is used. OS. 0248. Once the biomass is obtained it may be employed as 0270 21. The bioactive agent according to item 7, wherein Such, it may be dried or a composition comprising a Survival the further monosaccharide units are mannose and Xylose. US 2010/0O86647 A1 Apr. 8, 2010

0271 22. The bioactive agent according to item 7, wherein 0293 44. The bioactive agent according to item 38, the further monosaccharide units are arabinose and Xylose. wherein the further monosaccharide units are glucuronic 0272 23. The bioactive agent according to item 7, wherein acid and galactose. the further monosaccharide units are glucuronic acid, 0294 45. The bioactive agent according to item 38, galactose and mannose. wherein the further monosaccharide units are glucuronic 0273 24. The bioactive agent according to item 7, wherein acid and mannose. the further monosaccharide units are glucuronic acid, 0295 46. The bioactive agent according to item 38, galactose and arabinose. wherein the further monosaccharide units are glucuronic 0274. 25. The bioactive agent according to item 7, wherein acid and arabinose. the further monosaccharide units are glucuronic acid, 0296 47. The bioactive agent according to item 38, galactose and Xylose. wherein the further monosaccharide units are glucuronic 0275 26. The bioactive agent according to item 7, wherein acid and Xylose. the further monosaccharide units are glucuronic acid, man 0297 48. The bioactive agent according to item 38, nose and arabinose. wherein the further monosaccharide units are galactose 0276 27. The bioactive agent according to item 7, wherein and mannose. the further monosaccharide units are glucuronic acid man 0298 49. The bioactive agent according to item 38, nose and Xylose. wherein the further monosaccharide units are galactose 0277 28. The bioactive agent according to item 7, wherein and arabinose. the further monosaccharide units are glucuronic acid, ara 0299 50. The bioactive agent according to item 38, binose and Xylose. wherein the further monosaccharide units are galactose 0278. 29. The bioactive agent according to item 7, wherein and Xylose. the further monosaccharide units are galactose, mannose 0300 51. The bioactive agent according to item 38, and arabinose. wherein the further monosaccharide units are mannose and 0279 30. The bioactive agent according to item 7, wherein arabinose. the further monosaccharide units are galactose, mannose 0301 52. The bioactive agent according to item 38, and Xylose. wherein the further monosaccharide units are mannose and 0280 31. The bioactive agent according to item 7, wherein Xylose. the further monosaccharide units are galactose, arabinose 0302 53. The bioactive agent according to item 38, and Xylose. wherein the further monosaccharide units are arabinose 0281. 32. The bioactive agent according to item 7, wherein and Xylose. the further monosaccharide units are mannose, arabinose and Xylose. 0303 54. The bioactive agent according to item 38, 0282. 33. The bioactive agent according to item 7, wherein wherein the further monosaccharide units are glucuronic the further monosaccharide units are glucuronic acid, acid, galactose and mannose. galactose, mannose and arabinose. 0304 55. The bioactive agent according to item 38, 0283 34. The bioactive agent according to item 7, wherein wherein the further monosaccharide units are glucuronic the further monosaccharide units are glucuronic acid, acid, galactose and arabinose. galactose, mannose and Xylose. 0305 56. The bioactive agent according to item 38, 0284 35. The bioactive agent according to item 7, wherein wherein the further monosaccharide units are glucuronic the further monosaccharide units are glucuronic acid, acid, galactose and Xylose. galactose, arabinose and Xylose. 0306 57. The bioactive agent according to item 38, 0285 36. The bioactive agent according to item 7, wherein wherein the further monosaccharide units are glucuronic the further monosaccharide units are glucuronic acid, man acid, mannose and arabinose. nose, arabinose and Xylose. 0307 58. The bioactive agent according to item 38, 0286 37. The bioactive agent according to item 7, wherein wherein the further monosaccharide units are glucuronic the further monosaccharide units are galactose, mannose, acid mannose and Xylose. arabinose and Xylose. 0308 59. The bioactive agent according to item 38, 0287 38. The bioactive agent according to item 2, wherein wherein the further monosaccharide units are glucuronic the backbone of the polysaccharide comprises glucose acid, arabinose and Xylose. monosaccharide units in combination with further 0309 60. The bioactive agent according to item 38, monosaccharide units selected from the group of units wherein the further monosaccharide units are galactose, consisting of glucuronic acid, galactose, mannose, arabi mannose and arabinose. nose and Xylose, including any combination thereof. 0310 61. The bioactive agent according to item 38, 0288 39. The bioactive agent according to item 38, wherein the further monosaccharide units are galactose, wherein the further monosaccharide units are all glucu mannose and Xylose. ronic acid. 0311) 62. The bioactive agent according to item 38, 0289 40. The bioactive agent according to item 38, wherein the further monosaccharide units are galactose, wherein the further monosaccharide units are all galactose. arabinose and Xylose. 0290 41. The bioactive agent according to item 38, 0312 63. The bioactive agent according to item 38, wherein the further monosaccharide units are all mannose. wherein the further monosaccharide units are mannose, 0291 42. The bioactive agent according to item 38, arabinose and Xylose. wherein the further monosaccharide units are all arabinose. 0313 64. The bioactive agent according to item 38, 0292 43. The bioactive agent according to item 38, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are all xylose. acid, galactose, mannose and arabinose. US 2010/0O86647 A1 Apr. 8, 2010

0314 65. The bioactive agent according to item 38, 0335 86. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are mannose and acid, galactose, mannose and Xylose. Xylose. 0315 66. The bioactive agent according to item 38, 0336 87. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are mannose and acid, galactose, arabinose and Xylose. glucose. 0316 67. The bioactive agent according to item 38, 0337 88. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are arabinose acid, mannose, arabinose and Xylose. and Xylose. 0317 68. The bioactive agent according to item 38, 0338 89. The bioactive agent according to item 69, wherein the further monosaccharide units are galactose, wherein the further monosaccharide units are arabinose mannose, arabinose and Xylose. and glucose. 0318, 69. The bioactive agent according to item 2, wherein 0339 90. The bioactive agent according to item 69, the backbone of the polysaccharide comprises a plurality wherein the further monosaccharide units are Xylose and of monosaccharide units, and wherein the side chains of the glucose. polysaccharide comprises further monosaccharide units 0340 91. The bioactive agent according to item 69, Selected from the group of units consisting of glucuronic wherein the further monosaccharide units are glucuronic acid, galactose, mannose, arabinose Xylose and glucose, acid, galactose and mannose. including any combination thereof. 0341 92. The bioactive agent according to item 69, 0319 70. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are all glucu acid, galactose and arabinose. ronic acid. 0342 93. The bioactive agent according to item 69, 0320 71. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are all galactose. acid, galactose and Xylose. 0321 72. The bioactive agent according to item 69, 0343 94. The bioactive agent according to item 69, wherein the further monosaccharide units are all mannose. wherein the further monosaccharide units are glucuronic 0322 73. The bioactive agent according to item 69, acid, galactose and glucose. wherein the further monosaccharide units are all arabinose. 0344. 95. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic 0323 74. The bioactive agent according to item 69, acid, mannose and arabinose. wherein the further monosaccharide units are all xylose. 0345 96. The bioactive agent according to item 69, 0324 75. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are all glucose. acid mannose and Xylose. 0325 76. The bioactive agent according to item 69, 0346 97. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are glucuronic acid and galactose. acid mannose and glucose. 0326 77. The bioactive agent according to item 69, 0347 98. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are glucuronic acid and mannose. acid, arabinose and Xylose. 0327 78. The bioactive agent according to item 69, 0348 99. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are glucuronic acid and arabinose. acid, arabinose and glucose. 0328 79. The bioactive agent according to item 69, 0349 100. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are glucuronic acid and Xylose. acid, Xylose and glucose. 0329 80. The bioactive agent according to item 69, 0350 101. The bioactive agent according to item 69, wherein the further monosaccharide units are glucuronic wherein the further monosaccharide units are galactose, acid and glucose. mannose and arabinose. 0330 81. The bioactive agent according to item 69, 0351 102. The bioactive agent according to item 69, wherein the further monosaccharide units are galactose wherein the further monosaccharide units are galactose, and mannose. mannose and Xylose. 0331 82. The bioactive agent according to item 69, 0352 103. The bioactive agent according to item 69, wherein the further monosaccharide units are galactose wherein the further monosaccharide units are galactose, and arabinose. mannose and glucose. 0332 83. The bioactive agent according to item 69, 0353 104. The bioactive agent according to item 69, wherein the further monosaccharide units are galactose wherein the further monosaccharide units are galactose, and Xylose. arabinose and Xylose. 0333 84. The bioactive agent according to item 69, 0354 105. The bioactive agent according to item 69, wherein the further monosaccharide units are galactose wherein the further monosaccharide units are galactose, and glucose. arabinose and glucose. 0334 85. The bioactive agent according to item 69, 0355 106. The bioactive agent according to item 69, wherein the further monosaccharide units are mannose and wherein the further monosaccharide units are galactose, arabinose. Xylose and glucose. US 2010/0O86647 A1 Apr. 8, 2010 20

0356 107. The bioactive agent according to item 69, 0377 128. The bioactive agent according to item 69, wherein the further monosaccharide units are mannose, wherein the further monosaccharide units are glucuronic arabinose and Xylose. acid, galactose, mannose, Xylose and glucose. 0357 108. The bioactive agent according to item 69, 0378 129. The bioactive agent according to item 69, wherein the further monosaccharide units are mannose, wherein the further monosaccharide units are glucuronic arabinose and glucose. acid, galactose, arabinose Xylose and glucose. 0358 109. The bioactive agent according to item 69, 0379 130. The bioactive agent according to item 69, wherein the further monosaccharide units are mannose, wherein the further monosaccharide units are glucuronic Xylose and glucose. acid, mannose, arabinose Xylose and glucose. 0359 110. The bioactive agent according to item 69, 0380 131. The bioactive agent according to item 69, wherein the further monosaccharide units are arabinose, wherein the further monosaccharide units are galactose, Xylose and glucose. mannose, arabinose Xylose and glucose. 0360 111. The bioactive agent according to item 69, 0381 132. The bioactive agent according to item 2, wherein the further monosaccharide units are glucuronic wherein the polysaccharide comprises a repetitive back acid, galactose, mannose and arabinose. bone macromonomer comprising from 2 to 6. Such as 2, 3, 0361) 112. The bioactive agent according to item 69, 4, 5 or 6 different monosaccharide units and having from 1 wherein the further monosaccharide units are glucuronic to 3 monosaccharide units selected from glucose, mannose acid, galactose, mannose and Xylose. and galactose. 0362 113. The bioactive agent according to item 69, 0382. 133. The bioactive agent according to item 2, wherein the further monosaccharide units are glucuronic wherein the polysaccharide comprises an average of from acid, galactose, mannose and glucose. 1 to 1000 monosaccharide units in the backbone between 0363 114. The bioactive agent according to item 69, each branching point, such as from 2 to 1000 monosaccha wherein the further monosaccharide units are glucuronic ride units, for example from 3 to 1000 monosaccharide acid, galactose, arabinose and Xylose. units, such as from 4 to 1000 monosaccharide units, for 0364. 115. The bioactive agent according to item 69, example from 5 to 1000 monosaccharide units, such as wherein the further monosaccharide units are glucuronic from 6 to 1000 monosaccharide units, for example from 7 acid, galactose, arabinose and glucose. to 1000 monosaccharide units, such as from 8 to 1000 0365) 116. The bioactive agent according to item 69, monosaccharide units, for example from 9 to 1000 wherein the further monosaccharide units are glucuronic monosaccharide units, such as from 10 to 1000 monosac acid, galactose, Xylose and glucose. charide units, for example from 11 to 1000 monosaccha 0366 117. The bioactive agent according to item 69, ride units, such as from 12 to 1000 monosaccharide units, wherein the further monosaccharide units are glucuronic for example from 13 to 1000 monosaccharide units, such as acid, mannose, arabinose and Xylose. from 14 to 1000 monosaccharide units, for example from 0367 118. The bioactive agent according to item 69, 15 to 1000 monosaccharide units, such as from 20 to 1000 wherein the further monosaccharide units are glucuronic monosaccharide units, for example from 25 to 1000 acid, mannose, arabinose and glucose. monosaccharide units, such as from 30 to 1000 monosac 0368 119. The bioactive agent according to item 69, charide units, for example from 40 to 1000 monosaccha wherein the further monosaccharide units are glucuronic ride units, such as from 50 to 1000 monosaccharide units, acid, mannose, Xylose and glucose. for example from 60 to 1000 monosaccharide units, such as 0369 120. The bioactive agent according to item 69, from 70 to 1000 monosaccharide units, for example from wherein the further monosaccharide units are glucuronic 80 to 1000 monosaccharide units, such as from 90 to 1000 acid, arabinose, Xylose and glucose. monosaccharide units, for example from 100 to 1000 0370 121. The bioactive agent according to item 69, monosaccharide units, such as from 2 to 500 monosaccha ride units, for example from 3 to 500 monosaccharide wherein the further monosaccharide units are galactose, units, such as from 4 to 500 monosaccharide units, for mannose, arabinose and Xylose. example from 5 to 500 monosaccharide units, such as from 0371) 122. The bioactive agent according to item 69, 6 to 500 monosaccharide units, for example from 7 to 500 wherein the further monosaccharide units are galactose, monosaccharide units, such as from 8 to 500 monosaccha mannose, arabinose and glucose. ride units, for example from 9 to 500 monosaccharide 0372 123. The bioactive agent according to item 69, units, such as from 10 to 500 monosaccharide units, for wherein the further monosaccharide units are galactose, example from 11 to 500 monosaccharide units, such as mannose, Xylose and glucose. from 12 to 500 monosaccharide units, for example from 13 0373) 124. The bioactive agent according to item 69, to 500 monosaccharide units, such as from 14 to 500 wherein the further monosaccharide units are galactose, monosaccharide units, for example from 15 to 500 arabinose, Xylose and glucose. monosaccharide units, such as from 20 to 500 monosac 0374 125. The bioactive agent according to item 69, charide units, for example from 25 to 500 monosaccharide wherein the further monosaccharide units are mannose, units, such as from 30 to 500 monosaccharide units, for arabinose, Xylose and glucose. example from 40 to 500 monosaccharide units, such as 0375 126. The bioactive agent according to item 69, from 50 to 500 monosaccharide units, for example from 60 wherein the further monosaccharide units are glucuronic to 500 monosaccharide units, such as from 70 to 500 acid, galactose, mannose, arabinose and Xylose. monosaccharide units, for example from 80 to 500 0376) 127. The bioactive agent according to item 69, monosaccharide units, such as from 90 to 500 monosac wherein the further monosaccharide units are glucuronic charide units, for example from 100 to 500 monosaccha acid, galactose, mannose, arabinose and glucose. ride units, such as from 2 to 250 monosaccharide units, for US 2010/0O86647 A1 Apr. 8, 2010 21

example from 3 to 250 monosaccharide units, such as from monosaccharide units, such as from 14 to 25 monosaccha 4 to 250 monosaccharide units, for example from 5 to 250 ride units, for example from 15 to 25 monosaccharide monosaccharide units, such as from 6 to 250 monosaccha units, such as from 20 to 25 monosaccharide units, such as ride units, for example from 7 to 250 monosaccharide from 2 to 20 monosaccharide units, for example from 3 to units, such as from 8 to 250 monosaccharide units, for 20 monosaccharide units, such as from 4 to 20 monosac example from 9 to 250 monosaccharide units, such as from charide units, for example from 5 to 20 monosaccharide 10 to 250 monosaccharide units, for example from 11 to units, such as from 6 to 20 monosaccharide units, for 250 monosaccharide units, such as from 12 to 250 example from 7 to 20 monosaccharide units, such as from monosaccharide units, for example from 13 to 250 8 to 20 monosaccharide units, for example from 9 to 20 monosaccharide units, such as from 14 to 250 monosac monosaccharide units, such as from 10 to 20 monosaccha charide units, for example from 15 to 250 monosaccharide ride units, for example from 11 to 20 monosaccharide units, such as from 20 to 250 monosaccharide units, for units, such as from 12 to 20 monosaccharide units, for example from 25 to 250 monosaccharide units, such as example from 13 to 20 monosaccharide units, such as from from 30 to 250 monosaccharide units, for example from 40 14 to 20 monosaccharide units, for example from 15 to 20 to 250 monosaccharide units, such as from 50 to 250 monosaccharide units, such as from 2 to 18 monosaccha monosaccharide units, for example from 60 to 250 ride units, for example from 3 to 18 monosaccharide units, monosaccharide units, such as from 70 to 250 monosac Such as from 4 to 18 monosaccharide units, for example charide units, for example from 80 to 250 monosaccharide from 5 to 18 monosaccharide units, such as from 6 to 18 units, such as from 90 to 250 monosaccharide units, for monosaccharide units, for example from 7 to 18 monosac example from 100 to 250 monosaccharide units, such as charide units, such as from 8 to 18 monosaccharide units, from 2 to 100 monosaccharide units, for example from 3 to for example from 9 to 18 monosaccharide units, such as 100 monosaccharide units, such as from 4 to 100 monosac from 10 to 18 monosaccharide units, for example from 11 charide units, for example from 5 to 100 monosaccharide to 18 monosaccharide units, such as from 12 to 18 units, such as from 6 to 100 monosaccharide units, for monosaccharide units, for example from 13 to 18 example from 7 to 100 monosaccharide units, such as from monosaccharide units, such as from 14 to 18 monosaccha 8 to 100 monosaccharide units, for example from 9 to 100 ride units, for example from 15 to 18 monosaccharide monosaccharide units, such as from 10 to 100 monosac units, such as from 2 to 16 monosaccharide units, for charide units, for example from 11 to 100 monosaccharide example from 3 to 16 monosaccharide units, such as from units, such as from 12 to 100 monosaccharide units, for 4 to 16 monosaccharide units, for example from 5 to 16 example from 13 to 100 monosaccharide units, such as monosaccharide units, such as from 6 to 16 monosaccha from 14 to 100 monosaccharide units, for example from 15 ride units, for example from 7 to 16 monosaccharide units, to 100 monosaccharide units, such as from 20 to 100 Such as from 8 to 16 monosaccharide units, for example monosaccharide units, for example from 25 to 100 from 9 to 16 monosaccharide units, such as from 10 to 16 monosaccharide units, such as from 30 to 100 monosac monosaccharide units, for example from 11 to 16 charide units, for example from 40 to 100 monosaccharide monosaccharide units, such as from 12 to 16 monosaccha units, such as from 50 to 100 monosaccharide units, for ride units, for example from 13 to 16 monosaccharide example from 60 to 100 monosaccharide units, such as units, such as from 14 to 16 monosaccharide units, for from 70 to 100 monosaccharide units, for example from 80 example from 15 to 16 monosaccharide units, such as from to 100 monosaccharide units, such as from 90 to 100 2 to 14 monosaccharide units, for example from 3 to 14 monosaccharide units, such as from 2 to 50 monosaccha monosaccharide units, such as from 4 to 14 monosaccha ride units, for example from 3 to 50 monosaccharide units, ride units, for example from 5 to 14 monosaccharide units, Such as from 4 to 50 monosaccharide units, for example Such as from 6 to 14 monosaccharide units, for example from 5 to 50 monosaccharide units, such as from 6 to 50 from 7 to 14 monosaccharide units, such as from 8 to 14 monosaccharide units, for example from 7 to 50 monosac monosaccharide units, for example from 9 to 14 monosac charide units. Such as from 8 to 50 monosaccharide units, charide units, such as from 10 to 14 monosaccharide units, for example from 9 to 50 monosaccharide units, such as for example from 11 to 14 monosaccharide units, such as from 10 to 50 monosaccharide units, for example from 11 from 12 to 14 monosaccharide units, for example from 13 to 50 monosaccharide units, such as from 12 to 50 to 14 monosaccharide units, such as from 2 to 12 monosac monosaccharide units, for example from 13 to 50 charide units, for example from 3 to 12 monosaccharide monosaccharide units, such as from 14 to 50 monosaccha units, such as from 4 to 12 monosaccharide units, for ride units, for example from 15 to 50 monosaccharide example from 5 to 12 monosaccharide units, such as from units, such as from 20 to 50 monosaccharide units, for 6 to 12 monosaccharide units, for example from 7 to 12 example from 25 to 50 monosaccharide units, such as from monosaccharide units, such as from 8 to 12 monosaccha 30 to 50 monosaccharide units, for example from 40 to 50 ride units, for example from 9 to 12 monosaccharide units, monosaccharide units, such as from 2 to 25 monosaccha Such as from 10 to 12 monosaccharide units, for example ride units, for example from 3 to 25 monosaccharide units, from 11 to 12 monosaccharide units, such as from 2 to 10 Such as from 4 to 25 monosaccharide units, for example monosaccharide units, for example from 3 to 10 monosac from 5 to 25 monosaccharide units, such as from 6 to 25 charide units, such as from 4 to 10 monosaccharide units, monosaccharide units, for example from 7 to 25 monosac for example from 5 to 10 monosaccharide units, such as charide units. Such as from 8 to 25 monosaccharide units, from 6 to 10 monosaccharide units, for example from 7 to for example from 9 to 25 monosaccharide units, such as 10 monosaccharide units, such as from 8 to 10 monosac from 10 to 25 monosaccharide units, for example from 11 charide units, for example from 9 to 10 monosaccharide to 25 monosaccharide units, such as from 12 to 25 units, such as from 2 to 8 monosaccharide units, for monosaccharide units, for example from 13 to 25 example from 3 to 8 monosaccharide units, such as from 4 US 2010/0O86647 A1 Apr. 8, 2010 22

to 8 monosaccharide units, for example from 5 to 8 weight in the range of from 10,000 g/mol to about 450,000 monosaccharide units, such as from 6 to 8 monosaccharide g/mol, for example a molecular weight in the range of from units, for example from 7 to 8 monosaccharide units in the 10,000 g/mol to about 400,000 g/mol, such as a molecular backbone between each branching point. weight in the range of from 10,000 g/mol to about 350,000 0383) 134. The bioactive agent according to item 2, g/mol, for example a molecular weight in the range of from wherein the polysaccharide has a molecular weight in the 10,000 g/mol to about 300,000 g/mol, such as a molecular range of from 5,000 g/mol to about 1,000,000 g/mol, such as weight in the range of from 10,000 g/mol to about 250,000 a molecular weight in the range of from 5,000 g/mol to about g/mol, for example a molecular weight in the range of from 900,000 g/mol, for example a molecular weight in the range 10,000 g/mol to about 200,000 g/mol, such as a molecular of from 5,000 g/mol to about 800,000 g/mol, such as a weight in the range of from 10,000 g/mol to about 100,000 molecular weight in the range of from 5,000 g/mol to about g/mol, for example a molecular weight in the range of from 900,000 g/mol, for example a molecular weight in the range 10,000 g/mol to about 80,000 g/mol, such as a molecular of from 5,000 g/mol to about 800,000 g/mol, such as a weight in the range of from 10,000 g/mol to about 60,000 molecular weight in the range of from 5,000 g/mol to about g/mol, for example a molecular weight in the range of from 750,000 g/mol, for example a molecular weight in the range 10,000 g/mol to about 50,000 g/mol, such as a molecular of from 5,000 g/mol to about 700,000 g/mol, such as a weight in the range of from 10,000 g/mol to about 40,000 molecular weight in the range of from 5,000 g/mol to about g/mol, for example a molecular weight in the range of from 1270,000 g/mol, for example a molecular weight in the range 10,000 g/mol to about 35.000 g/mol, such as a molecular of from 5,000 g/mol to about 600,000 g/mol, such as a weight in the range of from 10,000 g/mol to about 30,000 molecular weight in the range of from 5,000 g/mol to about g/mol, for example a molecular weight in the range of from 550,000 g/mol, for example a molecular weight in the range 10,000 g/mol to about 25.000 g/mol, such as a molecular of from 5,000 g/mol to about 500,000 g/mol, such as a weight in the range of from 10,000 g/mol to about 20,000 molecular weight in the range of from 5,000 g/mol to about g/mol, for example a molecular weight in the range of from 450,000 g/mol, for example a molecular weight in the range 10,000 g/mol to about 15.000 g/mol, such as a molecular of from 5,000 g/mol to about 400,000 g/mol, such as a weight in the range of from 15,000 g/mol to about 1,000,000 molecular weight in the range of from 5,000 g/mol to about g/mol, such as a molecular weight in the range of from 15,000 350,000 g/mol, for example a molecular weight in the range g/mol to about 900,000 g/mol, for example a molecular of from 5,000 g/mol to about 300,000 g/mol, such as a weight in the range of from 15,000 g/mol to about 800,000 molecular weight in the range of from 5,000 g/mol to about g/mol, such as a molecular weight in the range of from 15,000 250,000 g/mol, for example a molecular weight in the range g/mol to about 900,000 g/mol, for example a molecular of from 5,000 g/mol to about 200,000 g/mol, such as a weight in the range of from 15,000 g/mol to about 800,000 molecular weight in the range of from 5,000 g/mol to about g/mol, such as a molecular weight in the range of from 15,000 100,000 g/mol, for example a molecular weight in the range g/mol to about 750,000 g/mol, for example a molecular of from 5,000 g/mol to about 80,000 g/mol, such as a molecu weight in the range of from 15,000 g/mol to about 700,000 lar weight in the range of from 5,000 g/mol to about 60,000 g/mol, such as a molecular weight in the range of from 15,000 g/mol, for example a molecular weight in the range of from g/mol to about 1270,000 g/mol, for example a molecular 5,000 g/mol to about 50,000 g/mol, such as a molecular weight in the range of from 15,000 g/mol to about 600,000 weight in the range of from 5,000 g/mol to about 40,000 g/mol, such as a molecular weight in the range of from 15,000 g/mol, for example a molecular weight in the range of from g/mol to about 550,000 g/mol, for example a molecular 5,000 g/mol to about 35.000 g/mol, such as a molecular weight in the range of from 15,000 g/mol to about 500,000 weight in the range of from 5,000 g/mol to about 30,000 g/mol, such as a molecular weight in the range of from 15,000 g/mol, for example a molecular weight in the range of from g/mol to about 450,000 g/mol, for example a molecular 5,000 g/mol to about 25.000 g/mol, such as a molecular weight in the range of from 15,000 g/mol to about 400,000 weight in the range of from 5,000 g/mol to about 20,000 g/mol, such as a molecular weight in the range of from 15,000 g/mol, for example a molecular weight in the range of from g/mol to about 350,000 g/mol, for example a molecular 5,000 g/mol to about 15.000 g/mol, such as a molecular weight in the range of from 15,000 g/mol to about 300,000 weight in the range of from 5,000 g/mol to about 10,000 g/mol, such as a molecular weight in the range of from 15,000 g/mol, for example a molecular weight in the range of from g/mol to about 250,000 g/mol, for example a molecular 10,000 g/mol to about 1,000,000 g/mol, such as a molecular weight in the range of from 15,000 g/mol to about 200,000 weight in the range of from 10,000 g/mol to about 900,000 g/mol, such as a molecular weight in the range of from 15,000 g/mol, for example a molecular weight in the range of from g/mol to about 100,000 g/mol, for example a molecular 10,000 g/mol to about 800,000 g/mol, such as a molecular weight in the range of from 15,000 g/mol to about 80,000 weight in the range of from 10,000 g/mol to about 900,000 g/mol, such as a molecular weight in the range of from 15,000 g/mol, for example a molecular weight in the range of from g/mol to about 60,000 g/mol, for example a molecular weight 10,000 g/mol to about 800,000 g/mol, such as a molecular in the range of from 15,000 g/mol to about 50,000 g/mol, such weight in the range of from 10,000 g/mol to about 750,000 as a molecular weight in the range of from 15,000 g/mol to g/mol, for example a molecular weight in the range of from about 40,000 g/mol, for example a molecular weight in the 10,000 g/mol to about 700,000 g/mol, such as a molecular range of from 15,000 g/mol to about 35.000 g/mol, such as a weight in the range of from 10,000 g/mol to about 1270,000 molecular weight in the range of from 15,000 g/mol to about g/mol, for example a molecular weight in the range of from 30,000 g/mol, for example a molecular weight in the range of 10,000 g/mol to about 600,000 g/mol, such as a molecular from 15,000 g/mol to about 25.000 g/mol, such as a molecular weight in the range of from 10,000 g/mol to about 550,000 weight in the range of from 15,000 g/mol to about 20,000 g/mol, for example a molecular weight in the range of from g/mol, for example a molecular weight in the range of from 10,000 g/mol to about 500,000 g/mol, such as a molecular 20,000 g/mol to about 1,000,000 g/mol, such as a molecular US 2010/0O86647 A1 Apr. 8, 2010

weight in the range of from 20,000 g/mol to about 900,000 g/mol, such as a molecular weight in the range of from 25,000 g/mol, for example a molecular weight in the range of from g/mol to about 60,000 g/mol, for example a molecular weight 20,000 g/mol to about 800,000 g/mol, such as a molecular in the range of from 25,000 g/mol to about 50,000 g/mol, such weight in the range of from 20,000 g/mol to about 900,000 as a molecular weight in the range of from 25,000 g/mol to g/mol, for example a molecular weight in the range of from about 40,000 g/mol, for example a molecular weight in the 20,000 g/mol to about 800,000 g/mol, such as a molecular range of from 25,000 g/mol to about 35.000 g/mol, such as a weight in the range of from 20,000 g/mol to about 750,000 molecular weight in the range of from 25,000 g/mol to about g/mol, for example a molecular weight in the range of from 30,000 g/mol, for example a molecular weight in the range of 20,000 g/mol to about 700,000 g/mol, such as a molecular from 30,000 g/mol to about 1,000,000 g/mol, such as a weight in the range of from 20,000 g/mol to about 1270,000 molecular weight in the range of from 30,000 g/mol to about g/mol, for example a molecular weight in the range of from 900,000 g/mol, for example a molecular weight in the range 20,000 g/mol to about 600,000 g/mol, such as a molecular of from 30,000 g/mol to about 800,000 g/mol, such as a weight in the range of from 20,000 g/mol to about 550,000 molecular weight in the range of from 30,000 g/mol to about g/mol, for example a molecular weight in the range of from 900,000 g/mol, for example a molecular weight in the range 20,000 g/mol to about 500,000 g/mol, such as a molecular of from 30,000 g/mol to about 800,000 g/mol, such as a weight in the range of from 20,000 g/mol to about 450,000 molecular weight in the range of from 30,000 g/mol to about g/mol, for example a molecular weight in the range of from 750,000 g/mol, for example a molecular weight in the range 20,000 g/mol to about 400,000 g/mol, such as a molecular of from 30,000 g/mol to about 700,000 g/mol, such as a weight in the range of from 20,000 g/mol to about 350,000 molecular weight in the range of from 30,000 g/mol to about g/mol, for example a molecular weight in the range of from 1270,000 g/mol, for example a molecular weight in the range 20,000 g/mol to about 300,000 g/mol, such as a molecular of from 30,000 g/mol to about 600,000 g/mol, such as a weight in the range of from 20,000 g/mol to about 250,000 molecular weight in the range of from 30,000 g/mol to about g/mol, for example a molecular weight in the range of from 550,000 g/mol, for example a molecular weight in the range 20,000 g/mol to about 200,000 g/mol, such as a molecular of from 30,000 g/mol to about 500,000 g/mol, such as a weight in the range of from 20,000 g/mol to about 100,000 molecular weight in the range of from 30,000 g/mol to about g/mol, for example a molecular weight in the range of from 450,000 g/mol, for example a molecular weight in the range 20,000 g/mol to about 80,000 g/mol, such as a molecular of from 30,000 g/mol to about 400,000 g/mol, such as a weight in the range of from 20,000 g/mol to about 60,000 molecular weight in the range of from 30,000 g/mol to about g/mol, for example a molecular weight in the range of from 350,000 g/mol, for example a molecular weight in the range 20,000 g/mol to about 50,000 g/mol, such as a molecular of from 30,000 g/mol to about 300,000 g/mol, such as a weight in the range of from 20,000 g/mol to about 40,000 molecular weight in the range of from 30,000 g/mol to about g/mol, for example a molecular weight in the range of from 250,000 g/mol, for example a molecular weight in the range 20,000 g/mol to about 35.000 g/mol, such as a molecular of from 30,000 g/mol to about 200,000 g/mol, such as a weight in the range of from 20,000 g/mol to about 30,000 molecular weight in the range of from 30,000 g/mol to about g/mol, for example a molecular weight in the range of from 100,000 g/mol, for example a molecular weight in the range 20,000 g/mol to about 25.000 g/mol, such as a molecular of from 30,000 g/mol to about 80,000 g/mol, such as a weight in the range of from 25,000 g/mol to about 1,000,000 molecular weight in the range of from 30,000 g/mol to about g/mol, such as a molecular weight in the range of from 25,000 60,000 g/mol, for example a molecular weight in the range of g/mol to about 900,000 g/mol, for example a molecular from 30,000 g/mol to about 50,000 g/mol, such as a molecular weight in the range of from 25,000 g/mol to about 800,000 weight in the range of from 30,000 g/mol to about 40,000 g/mol, such as a molecular weight in the range of from 25,000 g/mol, for example a molecular weight in the range of from g/mol to about 900,000 g/mol, for example a molecular 30,000 g/mol to about 35.000 g/mol, such as a molecular weight in the range of from 25,000 g/mol to about 800,000 weight in the range of from 40,000 g/mol to about 1,000,000 g/mol, such as a molecular weight in the range of from 25,000 g/mol, such as a molecular weight in the range of from 40,000 g/mol to about 750,000 g/mol, for example a molecular g/mol to about 900,000 g/mol, for example a molecular weight in the range of from 25,000 g/mol to about 700,000 weight in the range of from 40,000 g/mol to about 800,000 g/mol, such as a molecular weight in the range of from 25,000 g/mol, such as a molecular weight in the range of from 40,000 g/mol to about 1270,000 g/mol, for example a molecular g/mol to about 900,000 g/mol, for example a molecular weight in the range of from 25,000 g/mol to about 600,000 weight in the range of from 40,000 g/mol to about 800,000 g/mol, such as a molecular weight in the range of from 25,000 g/mol, such as a molecular weight in the range of from 40,000 g/mol to about 550,000 g/mol, for example a molecular g/mol to about 750,000 g/mol, for example a molecular weight in the range of from 25,000 g/mol to about 500,000 weight in the range of from 40,000 g/mol to about 700,000 g/mol, such as a molecular weight in the range of from 25,000 g/mol, such as a molecular weight in the range of from 40,000 g/mol to about 450,000 g/mol, for example a molecular g/mol to about 1270,000 g/mol, for example a molecular weight in the range of from 25,000 g/mol to about 400,000 weight in the range of from 40,000 g/mol to about 600,000 g/mol, such as a molecular weight in the range of from 25,000 g/mol, such as a molecular weight in the range of from 40,000 g/mol to about 350,000 g/mol, for example a molecular g/mol to about 550,000 g/mol, for example a molecular weight in the range of from 25,000 g/mol to about 300,000 weight in the range of from 40,000 g/mol to about 500,000 g/mol, such as a molecular weight in the range of from 25,000 g/mol, such as a molecular weight in the range of from 40,000 g/mol to about 250,000 g/mol, for example a molecular g/mol to about 450,000 g/mol, for example a molecular weight in the range of from 25,000 g/mol to about 200,000 weight in the range of from 40,000 g/mol to about 400,000 g/mol, such as a molecular weight in the range of from 25,000 g/mol, such as a molecular weight in the range of from 40,000 g/mol to about 100,000 g/mol, for example a molecular g/mol to about 350,000 g/mol, for example a molecular weight in the range of from 25,000 g/mol to about 80,000 weight in the range of from 40,000 g/mol to about 300,000 US 2010/0O86647 A1 Apr. 8, 2010 24 g/mol, such as a molecular weight in the range of from 40,000 g/mol to about 200,000 g/mol, such as a molecular weight in g/mol to about 250,000 g/mol, for example a molecular the range of from 75,000 g/mol to about 100,000 g/mol, for weight in the range of from 40,000 g/mol to about 200,000 example a molecular weight in the range of from 75,000 g/mol, such as a molecular weight in the range of from 40,000 g/mol to about 80,000 g/mol, a molecular weight in the range g/mol to about 100,000 g/mol, for example a molecular of from 100,000 g/mol to about 1,000,000 g/mol, such as a weight in the range of from 40,000 g/mol to about 80,000 molecular weight in the range of from 100,000 g/mol to about g/mol, such as a molecular weight in the range of from 40,000 900,000 g/mol, for example a molecular weight in the range g/mol to about 60,000 g/mol, for example a molecular weight of from 100,000 g/mol to about 800,000 g/mol, such as a molecular weight in the range of from 100,000 g/mol to about in the range of from 40,000 g/mol to about 50,000 g/mol, such 900,000 g/mol, for example a molecular weight in the range as a molecular weight in the range of from 50,000 g/mol to of from 100,000 g/mol to about 800,000 g/mol, such as a about 1,000,000 g/mol, such as a molecular weight in the molecular weight in the range of from 100,000 g/mol to about range of from 50,000 g/mol to about 900,000 g/mol, for 750,000 g/mol, for example a molecular weight in the range example a molecular weight in the range of from 50,000 of from 100,000 g/mol to about 700,000 g/mol, such as a g/mol to about 800,000 g/mol, such as a molecular weight in molecular weight in the range of from 100,000 g/mol to about the range of from 50,000 g/mol to about 900,000 g/mol, for 1270,000 g/mol, for example a molecular weight in the range example a molecular weight in the range of from 50,000 of from 100,000 g/mol to about 600,000 g/mol, such as a g/mol to about 800,000 g/mol, such as a molecular weight in molecular weight in the range of from 100,000 g/mol to about the range of from 50,000 g/mol to about 750,000 g/mol, for 550,000 g/mol, for example a molecular weight in the range example a molecular weight in the range of from 50,000 of from 100,000 g/mol to about 500,000 g/mol, such as a g/mol to about 700,000 g/mol, such as a molecular weight in molecular weight in the range of from 100,000 g/mol to about the range of from 50,000 g/mol to about 1270,000 g/mol, for 450,000 g/mol, for example a molecular weight in the range example a molecular weight in the range of from 50,000 of from 100,000 g/mol to about 400,000 g/mol, such as a g/mol to about 600,000 g/mol, such as a molecular weight in molecular weight in the range of from 100,000 g/mol to about the range of from 50,000 g/mol to about 550,000 g/mol, for 350,000 g/mol, for example a molecular weight in the range example a molecular weight in the range of from 50,000 of from 100,000 g/mol to about 300,000 g/mol, such as a g/mol to about 500,000 g/mol, such as a molecular weight in molecular weight in the range of from 100,000 g/mol to about the range of from 50,000 g/mol to about 450,000 g/mol, for 250,000 g/mol, for example a molecular weight in the range example a molecular weight in the range of from 50,000 of from 100,000 g/mol to about 200,000 g/mol, such as a g/mol to about 400,000 g/mol, such as a molecular weight in molecular weight in the range of from 200,000 g/mol to about the range of from 50,000 g/mol to about 350,000 g/mol, for 300,000 g/mol, for example a molecular weight in the range example a molecular weight in the range of from 50,000 of from 300,000 g/mol to about 400,000 g/mol, such as a g/mol to about 300,000 g/mol, such as a molecular weight in molecular weight in the range of from 400,000 g/mol to about the range of from 50,000 g/mol to about 250,000 g/mol, for 500,000 g/mol, for example a molecular weight in the range example a molecular weight in the range of from 50,000 of from 500,000 g/mol to about 600,000 g/mol, such as a g/mol to about 200,000 g/mol, such as a molecular weight in molecular weight in the range of from 700,000 g/mol to about the range of from 50,000 g/mol to about 100,000 g/mol, for 800,000 g/mol, for example a molecular weight in the range example a molecular weight in the range of from 50,000 of from 800,000 g/mol to about 900,000 g/mol, such as a g/mol to about 80,000 g/mol, such as a molecular weight in molecular weight in the range of from 900,000 g/mol to about the range of from 50,000 g/mol to about 60,000 g/mol, for 1,000,000 g/mol. example a molecular weight in the range of from 75,000 0384 135. The bioactive agent according to item 2, g/mol to about 1,000,000 g/mol, such as a molecular weight wherein the polysaccharide comprises a structural compo in the range of from 75,000 g/mol to about 900,000 g/mol, for nent selected from the group of components consisting of example a molecular weight in the range of from 75,000 (1-3)-alpha-D-glucan: g/mol to about 800,000 g/mol, such as a molecular weight in (1-3)-alpha-D-glucan with (1-6)-beta branching; the range of from 75,000 g/mol to about 900,000 g/mol, for (1-3)-alpha-D-glucan with (1-6)-alpha branching; example a molecular weight in the range of from 75,000 (1-3)-alpha-D-glucan with (1-4)-beta branching; g/mol to about 800,000 g/mol, such as a molecular weight in (1-3)-alpha-D-glucan with (1-4)-alpha branching; the range of from 75,000 g/mol to about 750,000 g/mol, for (1-3)-beta-D-glucan: example a molecular weight in the range of from 75,000 (1-3)-beta-D-glucan with (1-6)-beta branching: g/mol to about 700,000 g/mol, such as a molecular weight in (1-3)-beta-D-glucan with (1-6)-alpha branching; the range of from 75,000 g/mol to about 1270,000 g/mol, for (1-3)-beta-D-glucan with (1-4)-beta branching: example a molecular weight in the range of from 75,000 (1-3)-beta-D-glucan with (1-4)-alpha branching; g/mol to about 600,000 g/mol, such as a molecular weight in (1-4)-alpha-D-glucan: the range of from 75,000 g/mol to about 550,000 g/mol, for example a molecular weight in the range of from 75,000 (1-4)-alpha-D-glucan with (1-6)-beta branching; g/mol to about 500,000 g/mol, such as a molecular weight in (1-4)-alpha-D-glucan with (1-6)-alpha branching; the range of from 75,000 g/mol to about 450,000 g/mol, for (1-4)-alpha-D-glucan with (1-4)-beta branching; example a molecular weight in the range of from 75,000 (1-4)-alpha-D-glucan with (1-4)-alpha branching; g/mol to about 400,000 g/mol, such as a molecular weight in (1-4)-beta-D-glucan: the range of from 75,000 g/mol to about 350,000 g/mol, for (1-4)-beta-D-glucan with (1-6)-beta branching: example a molecular weight in the range of from 75,000 (1-4)-beta-D-glucan with (1-6)-alpha branching; g/mol to about 300,000 g/mol, such as a molecular weight in (1-4)-beta-D-glucan with (1-4)-beta branching; the range of from 75,000 g/mol to about 250,000 g/mol, for (1-4)-beta-D-glucan with (1-4)-alpha branching; example a molecular weight in the range of from 75,000 (1-6)-beta-D-glucan: US 2010/0O86647 A1 Apr. 8, 2010 25

(1-6)-beta-D-glucan with (1-6)-beta branching: 0399. 150. The bioactive agent according to item 2, (1-6)-beta-D-glucan with (1-6)-alpha branching; wherein the polysaccharide comprises a structural compo (1-6)-beta-D-glucan with (1-4)-beta branching: nent comprising (1-4)-alpha-D-glucan with (1-4)-alpha (1-6)-beta-D-glucan with (1-4)-alpha branching; branching. (1-6)-alpha-D-glucan: 0400 151. The bioactive agent according to item 2, wherein the polysaccharide comprises a structural compo (1-6)-alpha-D-glucan with (1-6)-beta branching; nent comprising (1-4)-beta-D-glucan. (1-6)-alpha-D-glucan with (1-6)-alpha branching; 0401 152. The bioactive agent according to item 2, (1-6)-alpha-D-glucan with (1-4)-beta branching; wherein the polysaccharide comprises a structural compo (1-6)-alpha-D-glucan with (1-4)-alpha branching; nent comprising (1-4)-beta-D-glucan with (1-6)-beta 0385) 136. The bioactive agent according to item 2, branching. wherein the polysaccharide comprises a structural compo 04.02 153. The bioactive agent according to item 2, nent comprising (1-3)-alpha-D-glucan. wherein the polysaccharide comprises a structural compo 0386 137. The bioactive agent according to item 2, nent comprising (1-4)-beta-D-glucan with (1-6)-alpha wherein the polysaccharide comprises a structural compo branching. nent comprising (1-3)-alpha-D-glucan with (1-6)-beta 0403 154. The bioactive agent according to item 2, branching. wherein the polysaccharide comprises a structural compo 0387 138. The bioactive agent according to item 2, nent comprising (1-4)-beta-D-glucan with (1-4)-beta wherein the polysaccharide comprises a structural compo branching. nent comprising (1-3)-alpha-D-glucan with (1-6)-alpha 0404 155. The bioactive agent according to item 2, branching. wherein the polysaccharide comprises a structural compo 0388 139. The bioactive agent according to item 2, nent comprising (1-4)-beta-D-glucan with (1-4)-alpha wherein the polysaccharide comprises a structural compo branching. nent comprising (1-3)-alpha-D-glucan with (1-4)-beta 04.05 156. The bioactive agent according to item 2, branching. wherein the polysaccharide comprises a structural compo 0389) 140. The bioactive agent according to item 2, nent comprising (1-6)-beta-D-glucan. wherein the polysaccharide comprises a structural compo 0406 157. The bioactive agent according to item 2, nent comprising (1-3)-alpha-D-glucan with (1-4)-alpha wherein the polysaccharide comprises a structural compo branching. nent comprising (1-6)-beta-D-glucan with (1-6)-beta 0390 141. The bioactive agent according to item 2, branching. wherein the polysaccharide comprises a structural compo 0407 158. The bioactive agent according to item 2, nent comprising (1-3)-beta-D-glucan. wherein the polysaccharide comprises a structural compo 0391) 142. The bioactive agent according to item 2, nent comprising (1-6)-beta-D-glucan with (1-6)-alpha wherein the polysaccharide comprises a structural compo branching. nent comprising (1-3)-beta-D-glucan with (1-6)-beta 0408 159. The bioactive agent according to item 2, branching. wherein the polysaccharide comprises a structural compo 0392) 143. The bioactive agent according to item 2, nent comprising (1-6)-beta-D-glucan with (1-4)-beta wherein the polysaccharide comprises a structural compo branching. nent comprising (1-3)-beta-D-glucan with (1-6)-alpha 04.09 160. The bioactive agent according to item 2, branching. wherein the polysaccharide comprises a structural compo nent comprising (1-6)-beta-D-glucan with (1-4)-alpha 0393. 144. The bioactive agent according to item 2, branching. wherein the polysaccharide comprises a structural compo 0410 161. The bioactive agent according to item 2, nent comprising (1-3)-beta-D-glucan with (1-4)-beta wherein the polysaccharide comprises a structural compo branching. nent comprising (1-6)-alpha-D-glucan. 0394. 145. The bioactive agent according to item 2, 0411 162. The bioactive agent according to item 2, wherein the polysaccharide comprises a structural compo wherein the polysaccharide comprises a structural compo nent comprising (1-3)-beta-D-glucan with (1-4)-alpha nent comprising (1-6)-alpha-D-glucan with (1-6)-beta branching. branching. 0395. 146. The bioactive agent according to item 2, 0412 163. The bioactive agent according to item 2, wherein the polysaccharide comprises a structural compo wherein the polysaccharide comprises a structural compo nent comprising (1-4)-alpha-D-glucan. nent comprising (1-6)-alpha-D-glucan with (1-6)-alpha 0396) 147. The bioactive agent according to item 2, branching. wherein the polysaccharide comprises a structural compo 0413 164. The bioactive agent according to item 2, nent comprising (1-4)-alpha-D-glucan with (1-6)-beta wherein the polysaccharide comprises a structural compo branching. nent comprising (1-6)-alpha-D-glucan with (1-4)-beta 0397 148. The bioactive agent according to item 2, branching. wherein the polysaccharide comprises a structural compo 0414) 165. The bioactive agent according to item 2, nent comprising (1-4)-alpha-D-glucan with (1-6)-alpha wherein the polysaccharide comprises a structural compo branching. nent comprising (1-6)-alpha-D-glucan with (1-4)-alpha 0398. 149. The bioactive agent according to item 2, branching. wherein the polysaccharide comprises a structural compo 0415 166. The bioactive agent according to item 2, nent comprising (1-4)-alpha-D-glucan with (1-4)-beta wherein the polysaccharide backbone comprises a plural branching. ity of monosaccharide units linked by a chemical bond US 2010/0O86647 A1 Apr. 8, 2010 26

Selected from the group consisting of (1-6)-beta bonds, 0432 183. The bioactive agent according to any of items (1-4)-beta bonds, (1-3)-beta bonds, (1-2)-beta bonds, 166 to 178, wherein the polysaccharide side chains com (1-1)-beta bonds, 1-beta-1-alpha bonds, 1-alpha-1-alpha prise a plurality of monosaccharide units linked by (1-2)- bonds, 1-alpha-1-beta bonds, (1-2)-alpha bonds, (1-3)-al beta bonds. pha bonds, (1-4)-alpha bonds and (1-6)-alpha bonds. 0433 184. The bioactive agent according to any of items 0416) 167. The bioactive agent according to item 2, 166 to 178, wherein the polysaccharide side chains com wherein the polysaccharide backbone comprises a plural prise a plurality of monosaccharide units linked by (1-1)- ity of monosaccharide units linked by (1-6)-beta bonds. beta bonds. 0417 168. The bioactive agent according to item 2, 0434, 185. The bioactive agent according to any of items wherein the polysaccharide backbone comprises a plural 166 to 178, wherein the polysaccharide side chains com ity of monosaccharide units linked by (1-4)-beta bonds. prise a plurality of monosaccharide units linked by 1-beta 0418 169. The bioactive agent according to item 2, 1-alpha bonds. wherein the polysaccharide backbone comprises a plural 0435 186. The bioactive agent according to any of items ity of monosaccharide units linked by (1-3)-beta bonds. 166 to 178, wherein the polysaccharide side chains com 0419 170. The bioactive agent according to item 2, prise a plurality of monosaccharide units linked by 1-al wherein the polysaccharide backbone comprises a plural pha-1-alpha bonds. ity of monosaccharide units linked by (1-2)-beta bonds. 0436 187. The bioactive agent according to any of items 0420, 171. The bioactive agent according to item 2, 166 to 178, wherein the polysaccharide side chains com wherein the polysaccharide backbone comprises a plural prise a plurality of monosaccharide units linked by 1-al ity of monosaccharide units linked by (1-1)-beta bonds. pha-1-beta bonds. 0421 172. The bioactive agent according to item 2, 0437. 188. The bioactive agent according to any of items wherein the polysaccharide backbone comprises a plural 166 to 178, wherein the polysaccharide side chains com ity of monosaccharide units linked by 1-beta-1-alpha prise a plurality of monosaccharide units linked by (1-2)- bonds. alpha bonds. 0422 173. The bioactive agent according to item 2, 0438 189. The bioactive agent according to any of items wherein the polysaccharide backbone comprises a plural 166 to 178, wherein the polysaccharide side chains com ity of monosaccharide units linked by 1-alpha-1-alpha prise a plurality of monosaccharide units linked by (1-3)- bonds. alpha bonds. 0423) 174. The bioactive agent according to item 2, 0439) 190. The bioactive agent according to any of items wherein the polysaccharide backbone comprises a plural 166 to 178, wherein the polysaccharide side chains com ity of monosaccharide units linked by 1-alpha-1-beta prise a plurality of monosaccharide units linked by (1-4)- bonds. alpha bonds. 0424 175. The bioactive agent according to item 2, 0440 191. The bioactive agent according to any of items wherein the polysaccharide backbone comprises a plural 166 to 178, wherein the polysaccharide side chains com ity of monosaccharide units linked by (1-2)-alphabonds. prise a plurality of monosaccharide units linked by (1-6)- 0425 176. The bioactive agent according to item 2, alpha bonds. wherein the polysaccharide backbone comprises a plural 0441) 192. The bioactive agent according to any of items 2 ity of monosaccharide units linked by (1-3)-alpha bonds. to 191, wherein the polysaccharide is a heteropolymer 0426 177. The bioactive agent according to item 2, comprising two or more different monosaccharides in the wherein the polysaccharide backbone comprises a plural main chain, Such as 3 different monosaccharides in the ity of monosaccharide units linked by (1-4)-alphabonds. main chain, for example 4 different monosaccharides in the 0427 178. The bioactive agent according to item 2, main chain, Such as different monosaccharides in the main wherein the polysaccharide backbone comprises a plural chain, for example 6 different monosaccharides in the main ity of monosaccharide units linked by (1-6)-alpha bonds. chain. 0428 179. The bioactive agent according to any of items 0442) 193. The bioactive agent according to item 192, 166 to 178, wherein the polysaccharide further comprises wherein the polysaccharide further comprises two or more side chains comprising a plurality of monosaccharides different monosaccharides in the side chains, such as 3 Selected from the group consisting of (1-6)-beta bonds, different monosaccharides in the side chains, for example (1-4)-beta bonds, (1-3)-beta bonds, (1-2)-beta bonds, 4 different monosaccharides in the side chains, such as 5 (1-1)-beta bonds, 1-beta-1-alpha bonds, 1-alpha-1-alpha different monosaccharides in the side chains, for example bonds, 1-alpha-1-beta bonds, (1-2)-alpha bonds, (1-3)-al 6 different monosaccharides in the side chains. pha bonds, (1-4)-alpha bonds and (1-6)-alpha bonds. 0443) 194. The bioactive agent according to any of items 7, 0429, 180. The bioactive agent according to any of items 38 and 69, wherein the ratio R=a/b between a) the number 166 to 178, wherein the polysaccharide side chains com of glucose monosaccharides and b) the number of further prise a plurality of monosaccharide units linked by (1-6)- monosaccharides is about 0.0001, for example about beta bonds. 0.0005, such as about 0.001, for example about 0.005, such 0430 181. The bioactive agent according to any of items as about 0.01, for example about 0.05, such as about 0.1, 166 to 178, wherein the polysaccharide side chains com for example about 0.2, such as about 0.3, for example about prise a plurality of monosaccharide units linked by (1-4)- 0.4, such as about 0.5, for example about 0.6, such as about beta bonds. 0.7, for example about 0.8, such as about 0.9, for example 0431 182. The bioactive agent according to any of items about 1; such as from 1:10000 to 1, such as from 2:10000 166 to 178, wherein the polysaccharide side chains com to 1; for example from 4:10000 to 1; such as from 10:10000 prise a plurality of monosaccharide units linked by (1-3)- to 1; for example from 20:10000 to 1; such as from beta bonds. 40:10000 to 1; for example from 80:10000 to 1; such as US 2010/0O86647 A1 Apr. 8, 2010 27

from 100:10000 to 1; for example from 100:10000 to 1: such as from 10:10000 to 1; for example from 20:10000 to such as from 200:10000 to 1; for example from 250:10000 1; such as from 40:10000 to 1; for example from 80:10000 to 1; such as from 400:10000 to 1; for example from 500: to 1; such as from 100:10000 to 1; for example from 100: 10000 to 1; such as from 1000:10000 to 1; for example 10000 to 1; such as from 200:10000 to 1; for example from from 2000:10000 to 1; such as from 2500:10000 to 1; for 250:10000 to 1; such as from 400:10000 to 1; for example example from 3000:10000 to 1; such as from 4000:10000 from 500:10000 to 1; such as from 1000:10000 to 1; for to 1; for example from 5000:10000 to 1; such as from example from 2000:10000 to 1; such as from 2500:10000 6000:10000 to 1; for example from 7000:10000 to 1; such to 1; for example from 3000:10000 to 1; such as from as from 7500:10000 to 1; for example from 8000:10000 to 4000:10000 to 1; for example from 5000:10000 to 1; such 1; such as from 9000:10000 to 1; for example from 9500: as from 6000:10000 to 1; for example from 7000:10000 to 10000 to 1, such as from 1:10000 to 5:10000; for example 1; such as from 7500:10000 to 1; for example from 8000: from 5:10000 to 20:10000, such as from 20:10000 to 100: 10000 to 1; such as from 9000:10000 to 1; for example 10000; for example from 100:10000 to 500:10000; such as from 9500:10000 to 1; such as from 1:10000 to 5:10000; from 500:10000 to 1000:10000; for example from 1000: for example from 5:10000 to 20:10000, such as from 10000 to 2000:10000; such as from 2000:10000 to 3000: 20:10000 to 100:10000; for example from 100:10000 to 10000; for example from 3000:10000 to 4000:10000; such 500:10000; such as from 500: 10000 to 1000:10000; for as from 4000:10000 to 5000:10000; for example from example from 1000:10000 to 2000:10000; such as from 5000:10000 to 6000:10000; such as from 6000:10000 to 2000:10000 to 3000:10000; for example from 3000:10000 7000:10000; for example from 7000:10000 to to 4000:10000; such as from 4000:10000 to 5000:10000; 8000:10000; such as from 8000:10000 to 9000:10000. for example from 5000:10000 to 6000:10000; such as from 0444 195. The bioactive agent according to any of items 7, 6000:10000 to 7000:10000; for example from 7000:10000 38 and 69, wherein the ratio R=b/a between a) the number to 8000:10000; such as from 8000:10000 to 9000:10000. of glucose monosaccharides and b) the number of further 0446. 197. The bioactive agent according to any of items 7, monosaccharides is about 0.0001, for example about 38 and 69, wherein the ratio R=b/a between a) the number 0.0005, such as about 0.001, for example about 0.005, such of glucose monosaccharides and b) the number of glucu as about 0.01, for example about 0.05, such as about 0.1, ronic acid monosaccharides is about 0.0001, for example for example about 0.2, such as about 0.3, for example about about 0.0005, such as about 0.001, for example about 0.4, such as about 0.5, for example about 0.6, such as about 0.005, such as about 0.01, for example about 0.05, such as 0.7, for example about 0.8, such as about 0.9, for example about 0.1, for example about 0.2. Such as about 0.3, for about 1; for example from 1:10000 to 1, such as from example about 0.4, such as about 0.5, for example about 2:10000 to 1; for example from 4:10000 to 1; such as from 0.6, such as about 0.7, for example about 0.8, such as about 10:10000 to 1; for example from 20:10000 to 1; such as 0.9, for example about 1; for example from 1:10000 to 1, from 40:10000 to 1; for example from 80:10000 to 1; such such as from 2:10000 to 1; for example from 4:10000 to 1: as from 100:10000 to 1; for example from 100:10000 to 1: such as from 10:10000 to 1; for example from 20:10000 to such as from 200:10000 to 1; for example from 250:10000 1; such as from 40:10000 to 1; for example from 80:10000 to 1; such as from 400:10000 to 1; for example from 500: to 1; such as from 100:10000 to 1; for example from 100: 10000 to 1; such as from 1000:10000 to 1; for example 10000 to 1; such as from 200:10000 to 1; for example from from 2000:10000 to 1; such as from 2500:10000 to 1; for 250:10000 to 1; such as from 400:10000 to 1; for example example from 3000:10000 to 1; such as from 4000:10000 from 500:10000 to 1; such as from 1000:10000 to 1; for to 1; for example from 5000:10000 to 1; such as from example from 2000:10000 to 1; such as from 2500:10000 6000:10000 to 1; for example from 7000:10000 to 1; such to 1; for example from 3000:10000 to 1; such as from as from 7500:10000 to 1; for example from 8000:10000 to 4000:10000 to 1; for example from 5000:10000 to 1; such 1; such as from 9000:10000 to 1; for example from 9500: as from 6000:10000 to 1; for example from 7000:10000 to 10000 to 1; such as from 1:10000 to 5:10000; for example 1; such as from 7500:10000 to 1; for example from 8000: from 5:10000 to 20:10000, such as from 20:10000 to 100: 10000 to 1; such as from 9000:10000 to 1; for example 10000; for example from 100:10000 to 500:10000; such as from 9500:10000 to 1; such as from 1:10000 to 5:10000; from 500:10000 to 1000:10000; for example from 1000: for example from 5:10000 to 20:10000, such as from 10000 to 2000:10000; such as from 2000:10000 to 3000: 20:10000 to 100:10000; for example from 100:10000 to 10000; for example from 3000:10000 to 4000:10000; such 500:10000; such as from 500: 10000 to 1000:10000; for as from 4000:10000 to 5000:10000; for example from example from 1000:10000 to 2000:10000; such as from 5000:10000 to 6000:10000; such as from 6000:10000 to 2000:10000 to 3000:10000; for example from 3000:10000 7000:10000; for example from 7000:10000 to to 4000:10000; such as from 4000:10000 to 5000:10000; 8000:10000; such as from 8000:10000 to 9000:10000. for example from 5000:10000 to 6000:10000; such as from 0445 196. The bioactive agent according to any of items 7, 6000:10000 to 7000:10000; for example from 7000:10000 38 and 69, wherein the ratio R=a/b between a) the number to 8000:10000; such as from 8000:10000 to 9000:10000. of glucose monosaccharides and b) the number of glucu 0447, 198. The bioactive agent according to any of items 7, ronic acid monosaccharides is about 0.0001, for example 38 and 69, wherein the ratio R=a/b between a) the number about 0.0005, such as about 0.001, for example about of glucose monosaccharides and b) the number of galac 0.005, such as about 0.01, for example about 0.05, such as tose monosaccharides is about 0.0001, for example about about 0.1, for example about 0.2, such as about 0.3, for 0.0005, such as about 0.001, for example about 0.005, such example about 0.4, such as about 0.5, for example about as about 0.01, for example about 0.05, such as about 0.1, 0.6, such as about 0.7, for example about 0.8, such as about for example about 0.2, such as about 0.3, for example about 0.9, for example about 1; for example from 1:10000 to 1, 0.4, such as about 0.5, for example about 0.6, such as about such as from 2:10000 to 1; for example from 4:10000 to 1: 0.7, for example about 0.8, such as about 0.9, for example US 2010/0O86647 A1 Apr. 8, 2010 28

about 1; for example from 1:10000 to 1, such as from 0.4, such as about 0.5, for example about 0.6, such as about 2:10000 to 1; for example from 4:10000 to 1; such as from 0.7, for example about 0.8, such as about 0.9, for example 10:10000 to 1; for example from 20:10000 to 1; such as about 1; for example from 1:10000 to 1, such as from from 40:10000 to 1; for example from 80:10000 to 1; such 2:10000 to 1; for example from 4:10000 to 1; such as from as from 100:10000 to 1; for example from 100:10000 to 1: 10:10000 to 1; for example from 20:10000 to 1; such as such as from 200:10000 to 1; for example from 250:10000 from 40:10000 to 1; for example from 80:10000 to 1; such to 1; such as from 400:10000 to 1; for example from 500: as from 100:10000 to 1; for example from 100:10000 to 1: 10000 to 1; such as from 1000:10000 to 1; for example such as from 200:10000 to 1; for example from 250:10000 from 2000:10000 to 1; such as from 2500:10000 to 1; for to 1; such as from 400:10000 to 1; for example from 500: example from 3000:10000 to 1; such as from 4000:10000 10000 to 1; such as from 1000:10000 to 1; for example to 1; for example from 5000:10000 to 1; such as from from 2000:10000 to 1; such as from 2500:10000 to 1; for 6000:10000 to 1; for example from 7000:10000 to 1; such example from 3000:10000 to 1; such as from 4000:10000 as from 7500:10000 to 1; for example from 8000:10000 to to 1; for example from 5000:10000 to 1; such as from 1; such as from 9000:10000 to 1; for example from 9500: 6000:10000 to 1; for example from 7000:10000 to 1; such 10000 to 1; such as from 1:10000 to 5:10000; for example as from 7500:10000 to 1; for example from 8000:10000 to from 5:10000 to 20:10000, such as from 20:10000 to 100: 1; such as from 9000:10000 to 1; for example from 9500: 10000; for example from 100:10000 to 500:10000; such as 10000 to 1; such as from 1:10000 to 5:10000; for example from 500:10000 to 1000:10000; for example from 1000: from 5:10000 to 20:10000, such as from 20:10000 to 100: 10000 to 2000:10000; such as from 2000:10000 to 3000: 10000; for example from 100:10000 to 500:10000; such as 10000; for example from 3000:10000 to 4000:10000; such from 500:10000 to 1000:10000; for example from 1000: as from 4000:10000 to 5000:10000; for example from 10000 to 2000:10000; such as from 2000:10000 to 3000: 5000:10000 to 6000:10000; such as from 6000:10000 to 10000; for example from 3000:10000 to 4000:10000; such 7000:10000; for example from 7000:10000 to as from 4000:10000 to 5000:10000; for example from 8000:10000; such as from 8000:10000 to 9000:10000. 5000:10000 to 6000:10000; such as from 6000:10000 to 0448) 199. The bioactive agent according to any of items 7, 7000:10000; for example from 7000:10000 to 38 and 69, wherein the ratio R=b/a between a) the number 8000:10000; such as from 8000:10000 to 9000:10000. of glucose monosaccharides and b) the number of galac 0450 201. The bioactive agent according to any of items 7, tose monosaccharides is about 0.0001, for example about 38 and 69, wherein the ratio R=b/a between a) the number 0.0005, such as about 0.001, for example about 0.005, such of glucose monosaccharides and b) the number of mannose as about 0.01, for example about 0.05, such as about 0.1, monosaccharides is about 0.0001, for example about for example about 0.2, such as about 0.3, for example about 0.0005, such as about 0.001, for example about 0.005, such 0.4, such as about 0.5, for example about 0.6, such as about as about 0.01, for example about 0.05, such as about 0.1, 0.7, for example about 0.8, such as about 0.9, for example for example about 0.2, such as about 0.3, for example about about 1; for example from 1:10000 to 1, such as from 0.4, such as about 0.5, for example about 0.6, such as about 2:10000 to 1; for example from 4:10000 to 1; such as from 0.7, for example about 0.8, such as about 0.9, for example 10:10000 to 1; for example from 20:10000 to 1; such as about 1; for example from 1:10000 to 1, such as from from 40:10000 to 1; for example from 80:10000 to 1; such 2:10000 to 1; for example from 4:10000 to 1; such as from as from 100:10000 to 1; for example from 100:10000 to 1: 10:10000 to 1; for example from 20:10000 to 1; such as such as from 200:10000 to 1; for example from 250:10000 from 40:10000 to 1; for example from 80:10000 to 1; such to 1; such as from 400:10000 to 1; for example from 500: as from 100:10000 to 1; for example from 100:10000 to 1: 10000 to 1; such as from 1000:10000 to 1; for example such as from 200:10000 to 1; for example from 250:10000 from 2000:10000 to 1; such as from 2500:10000 to 1; for to 1; such as from 400:10000 to 1; for example from 500: example from 3000:10000 to 1; such as from 4000:10000 10000 to 1; such as from 1000:10000 to 1; for example to 1; for example from 5000:10000 to 1; such as from from 2000:10000 to 1; such as from 2500:10000 to 1; for 6000:10000 to 1; for example from 7000:10000 to 1; such example from 3000:10000 to 1; such as from 4000:10000 as from 7500:10000 to 1; for example from 8000:10000 to to 1; for example from 5000:10000 to 1; such as from 1; such as from 9000:10000 to 1; for example from 9500: 6000:10000 to 1; for example from 7000:10000 to 1; such 10000 to 1; such as from 1:10000 to 5:10000; for example as from 7500:10000 to 1; for example from 8000:10000 to from 5:10000 to 20:10000, such as from 20:10000 to 100: 1; such as from 9000:10000 to 1; for example from 9500: 10000; for example from 100:10000 to 500:10000; such as 10000 to 1; such as from 1:10000 to 5:10000; for example from 500:10000 to 1000:10000; for example from 1000: from 5:10000 to 20:10000, such as from 20:10000 to 100: 10000 to 2000:10000; such as from 2000:10000 to 3000: 10000; for example from 100:10000 to 500:10000; such as 10000; for example from 3000:10000 to 4000:10000; such from 500:10000 to 1000:10000; for example from 1000: as from 4000:10000 to 5000:10000; for example from 10000 to 2000:10000; such as from 2000:10000 to 3000: 5000:10000 to 6000:10000; such as from 6000:10000 to 10000; for example from 3000:10000 to 4000:10000; such 7000:10000; for example from 7000:10000 to as from 4000:10000 to 5000:10000; for example from 8000:10000; such as from 8000:10000 to 9000:10000. 5000:10000 to 6000:10000; such as from 6000:10000 to 0449 200. The bioactive agent according to any of items 7, 7000:10000; for example from 7000:10000 to 38 and 69, wherein the ratio R=a/b between a) the number 8000:10000; such as from 8000:10000 to 9000:10000. of glucose monosaccharides and b) the number of mannose 0451 202. The bioactive agent according to any of items 7, monosaccharides is about 0.0001, for example about 38 and 69, wherein the ratio R=a/b between a) the number 0.0005, such as about 0.001, for example about 0.005, such of glucose monosaccharides and b) the number of arabi as about 0.01, for example about 0.05, such as about 0.1, nose monosaccharides is about 0.0001, for example about for example about 0.2, such as about 0.3, for example about 0.0005, such as about 0.001, for example about 0.005, such US 2010/0O86647 A1 Apr. 8, 2010 29

as about 0.01, for example about 0.05, such as about 0.1, monosaccharides is about 0.0001, for example about for example about 0.2, such as about 0.3, for example about 0.0005, such as about 0.001, for example about 0.005, such 0.4, such as about 0.5, for example about 0.6, such as about as about 0.01, for example about 0.05, such as about 0.1, 0.7, for example about 0.8, such as about 0.9, for example for example about 0.2, such as about 0.3, for example about about 1; for example from 1:10000 to 1, such as from 0.4, such as about 0.5, for example about 0.6, such as about 2:10000 to 1; for example from 4:10000 to 1; such as from 0.7, for example about 0.8, such as about 0.9, for example 10:10000 to 1; for example from 20:10000 to 1; such as about 1; for example from 1:10000 to 1, such as from from 40:10000 to 1; for example from 80:10000 to 1; such 2:10000 to 1; for example from 4:10000 to 1; such as from as from 100:10000 to 1; for example from 100:10000 to 1: 10:10000 to 1; for example from 20:10000 to 1; such as such as from 200:10000 to 1; for example from 250:10000 from 40:10000 to 1; for example from 80:10000 to 1; such to 1; such as from 400:10000 to 1; for example from 500: as from 100:10000 to 1; for example from 100:10000 to 1: 10000 to 1; such as from 1000:10000 to 1; for example such as from 200:10000 to 1; for example from 250:10000 from 2000:10000 to 1; such as from 2500:10000 to 1; for example from 3000:10000 to 1; such as from 4000:10000 to 1; such as from 400:10000 to 1; for example from 500: to 1; for example from 5000:10000 to 1; such as from 10000 to 1; such as from 1000:10000 to 1; for example 6000:10000 to 1; for example from 7000:10000 to 1; such from 2000:10000 to 1; such as from 2500:10000 to 1; for as from 7500:10000 to 1; for example from 8000:10000 to example from 3000:10000 to 1; such as from 4000:10000 1; such as from 9000:10000 to 1; for example from 9500: to 1; for example from 5000:10000 to 1; such as from 10000 to 1; such as from 1:10000 to 5:10000; for example 6000:10000 to 1; for example from 7000:10000 to 1; such from 5:10000 to 20:10000, such as from 20:10000 to 100: as from 7500:10000 to 1; for example from 8000:10000 to 10000; for example from 100:10000 to 500:10000; such as 1; such as from 9000:10000 to 1; for example from 9500: from 500:10000 to 1000:10000; for example from 1000: 10000 to 1; such as from 1:10000 to 5:10000; for example 10000 to 2000:10000; such as from 2000:10000 to 3000: from 5:10000 to 20:10000, such as from 20:10000 to 100: 10000; for example from 3000:10000 to 4000:10000; such 10000; for example from 100:10000 to 500:10000; such as as from 4000:10000 to 5000:10000; for example from from 500:10000 to 1000:10000; for example from 1000: 5000:10000 to 6000:10000; such as from 6000:10000 to 10000 to 2000:10000; such as from 2000:10000 to 3000: 7000:10000; for example from 7000:10000 to 10000; for example from 3000:10000 to 4000:10000; such 8000:10000; such as from 8000:10000 to 9000:10000. as from 4000:10000 to 5000:10000; for example from 0452. 203. The bioactive agent according to any of items 7, 5000:10000 to 6000:10000; such as from 6000:10000 to 38 and 69, wherein the ratio R=b/a between a) the number 7000:10000; for example from 7000:10000 to of glucose monosaccharides and b) the number of arabi 8000:10000; such as from 8000:10000 to 9000:10000. nose monosaccharides is about 0.0001, for example about 0454) 205. The bioactive agent according to any of items 7, 0.0005, such as about 0.001, for example about 0.005, such 38 and 69, wherein the ratio R=b/a between a) the number as about 0.01, for example about 0.05, such as about 0.1, of glucose monosaccharides and b) the number of Xylose for example about 0.2, such as about 0.3, for example about monosaccharides is about 0.0001, for example about 0.4, such as about 0.5, for example about 0.6, such as about 0.0005, such as about 0.001, for example about 0.005, such 0.7, for example about 0.8, such as about 0.9, for example as about 0.01, for example about 0.05, such as about 0.1, about 1; for example from 1:10000 to 1, such as from for example about 0.2, such as about 0.3, for example about 2:10000 to 1; for example from 4:10000 to 1; such as from 0.4, such as about 0.5, for example about 0.6, such as about 10:10000 to 1; for example from 20:10000 to 1; such as 0.7, for example about 0.8, such as about 0.9, for example from 40:10000 to 1; for example from 80:10000 to 1; such about 1; for example from 1:10000 to 1, such as from as from 100:10000 to 1; for example from 100:10000 to 1: 2:10000 to 1; for example from 4:10000 to 1; such as from such as from 200:10000 to 1; for example from 250:10000 10:10000 to 1; for example from 20:10000 to 1; such as to 1; such as from 400:10000 to 1; for example from 500: from 40:10000 to 1; for example from 80:10000 to 1; such 10000 to 1; such as from 1000:10000 to 1; for example as from 100:10000 to 1; for example from 100:10000 to 1: from 2000:10000 to 1; such as from 2500:10000 to 1; for such as from 200:10000 to 1; for example from 250:10000 example from 3000:10000 to 1; such as from 4000:10000 to 1; such as from 400:10000 to 1; for example from 500: to 1; for example from 5000:10000 to 1; such as from 10000 to 1; such as from 1000:10000 to 1; for example 6000:10000 to 1; for example from 7000:10000 to 1; such from 2000:10000 to 1; such as from 2500:10000 to 1; for as from 7500:10000 to 1; for example from 8000:10000 to example from 3000:10000 to 1; such as from 4000:10000 1; such as from 9000:10000 to 1; for example from 9500: to 1; for example from 5000:10000 to 1; such as from 10000 to 1; such as from 1:10000 to 5:10000; for example 6000:10000 to 1; for example from 7000:10000 to 1; such from 5:10000 to 20:10000, such as from 20:10000 to 100: as from 7500:10000 to 1; for example from 8000:10000 to 10000; for example from 100:10000 to 500:10000; such as 1; such as from 9000:10000 to 1; for example from 9500: from 500:10000 to 1000:10000; for example from 1000: 10000 to 1; such as from 1:10000 to 5:10000; for example 10000 to 2000:10000; such as from 2000:10000 to 3000: from 5:10000 to 20:10000, such as from 20:10000 to 100: 10000; for example from 3000:10000 to 4000:10000; such 10000; for example from 100:10000 to 500:10000; such as as from 4000:10000 to 5000:10000; for example from from 500:10000 to 1000:10000; for example from 1000: 5000:10000 to 6000:10000; such as from 6000:10000 to 10000 to 2000:10000; such as from 2000:10000 to 3000: 7000:10000; for example from 7000:10000 to 10000; for example from 3000:10000 to 4000:10000; such 8000:10000; such as from 8000:10000 to 9000:10000. as from 4000:10000 to 5000:10000; for example from 0453 204. The bioactive agent according to any of items 7, 5000:10000 to 6000:10000; such as from 6000:10000 to 38 and 69, wherein the ratio R=a/b between a) the number 7000:10000; for example from 7000:10000 to of glucose monosaccharides and b) the number of Xylose 8000:10000; such as from 8000:10000 to 9000:10000. US 2010/0O86647 A1 Apr. 8, 2010 30

0455 206. The bioactive agent according to item 2, 0469 220. The bioactive agent according to item 216, wherein the polysaccharide comprises a structural compo wherein Basidiomycete cell is selected from the family of nent in the backbone comprising beta-1,2-linked D-man Clavariaceae. nopyranosyl residues and a structural component in the 0470 221. The bioactive agent according to item 216, side chains comprising beta-D-glucopyranosyl-3-O-beta wherein Basidiomycete cell is selected from the family of D-glucopyranosyl residues. Coprinaceae. 0456. 207. The bioactive agent according to item 2, 0471) 222. The bioactive agent according to item 216, wherein the polysaccharide is a complex comprising a wherein Basidiomycete cell is selected from the family of (1,4)-alpha-D-glucan and a (1,6)-beta glucan. Cortinariaceae. 0457 208. The bioactive agent according to item 2, 0472. 223. The bioactive agent according to item 216, wherein the polysaccharide is a complex comprising a wherein Basidiomycete cell is selected from the family of (1,4)-alpha-D-glucan and a (1,6)-alpha glucan. Entolomataceae. 0458 209. The bioactive agent according to any of the 0473 224. The bioactive agent according to item 216, above items 1 to 208, wherein said bioactive agent is pro wherein Basidiomycete cell is selected from the family of duced by liquid cultivation of a Basidiomycete cell Fistulinaceae. Selected from the group consisting of cells belonging to the 0474 225. The bioactive agent according to item 216, Subclasses of Agaricomycetidae, Exobasidiomycetidae, wherein Basidiomycete cell is selected from the family of Tremellomycetidae and Ustilaginomycetidae. Gigaspermaceae. 0459 210. The bioactive agent according to item 209, 0475 226. The bioactive agent according to item 216, wherein the Basidiomycete cell is selected form the sub wherein Basidiomycete cell is selected from the family of class of Agaricomycetidae. Hemigasteraceae. 0476 227. The bioactive agent according to item 216, 0460) 211. The bioactive agent according to item 209, wherein Basidiomycete cell is selected from the family of wherein the Basidiomycete cell is selected form the sub Hydnangiaceae. class of Exobasidiomycetidae. 0477 228. The bioactive agent according to item 216, 0461) 212. The bioactive agent according to item 209, wherein Basidiomycete cell is selected from the family of wherein the Basidiomycete cell is selected form the sub Lycoperdaceae. class of Tremellomyceditae. 0478 229. The bioactive agent according to item 216, 0462. 213. The bioactive agent according to item 209, wherein Basidiomycete cell is selected from the family of wherein the Basidiomycete cell is selected form the sub Marasmiaceae. class of Ustilaginomycetidae. 0479. 230. The bioactive agent according to item 216, 0463. 214. The bioactive agent according to item 1 to 208, wherein Basidiomycete cell is selected from the family of wherein said bioactive agent is produced by liquid cultiva Mesopheliaceae. tion of a Basidiomycete cell selected from the group con 0480. 231. The bioactive agent according to item 216, sisting of cells belonging to the orders of Agaricales, Bole wherein Basidiomycete cell is selected from the family of tales, Cantheralles, Ceratobasidiales, Dacrymycetales, Mycenastraceae. Hymenochaetales, Phallales, Polyporales, Poriales, Rus 0481 232. The bioactive agent according to item 216, Sulales, Thelphorales, Auriculariales, Christianseniales, wherein Basidiomycete cell is selected from the family of Cystofilobasidiales, Filobasidiales, Tremellaleles, Niaceae. Tulasenellales and Urocystales. 0482 233. The bioactive agent according to item 216, 0464) 215. The bioactive agent according to item 214, wherein Basidiomycete cell is selected from the family of wherein the Basidiomycete cell is selected from the order Nidulariaceae. of Agaricales. 0483 234. The bioactive agent according to item 216, 0465 216. The bioactive agent according to item 215, wherein Basidiomycete cell is selected from the family of wherein said Basidiomycete cell belongs to a family Phelloriniaceae. Selected from the group consisting of Agaricaceae, Bolbi 0484. 235. The bioactive agent according to item 216, tiaceae, Broomeiaceae, Clavariaceae, Coprinaceae, Corti wherein Basidiomycete cell is selected from the family of nariaceae, Entolomataceae, Fistulinaceae, Gigasper Pleurotaceae. maceae, Hemigasteraceae, Hydnangiaceae, 0485 236. The bioactive agent according to item 216, Lycoperdaceae, Marasmiaceae, Mesopheliaceae, Myce wherein Basidiomycete cell is selected from the family of nastraceae, Niaceae, Nidulariaceae, Phelloriniaceae, Pleu Pluteaceae. rotaceae, Pluteaceae, Pterulaceae, Schizophyllaceae, Stro 0486 237. The bioactive agent according to item 216, matocyphaceae, Strophariaceae, Tricholomataceae, wherein Basidiomycete cell is selected from the family of Tulostomataceae. Typhulaceae and Xerulaceae. Pterulaceae. 0466 217. The bioactive agent according to item 216, 0487. 238. The bioactive agent according to item 216, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Agaricaceae. Schizophyllaceae. 0467 218. The bioactive agent according to item 216, 0488 239. The bioactive agent according to item 216, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Bolbitiaceae. Stromatocyphaceae. 0468. 219. The bioactive agent according to item 216, 0489 240. The bioactive agent according to item 216, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Broomeiaceae. Strophariaceae. US 2010/0O86647 A1 Apr. 8, 2010

0490 241. The bioactive agent according to item 216, 0509. 260. The bioactive agent according to item 246, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Tricholomataceae. Meripilaceae. 0491 242. The bioactive agent according to item 216, 0510 261. The bioactive agent according to item 246, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Tulostomataceae. Meruliaceae. 0492 243. The bioactive agent according to item 216, 0511) 262. The bioactive agent according to item 246, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Typhulaceae. Phanerochaetaceae. 0493 244. The bioactive agent according to item 216, 0512 263. The bioactive agent according to item 246, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Xerulaceae. Podoscyphaceae. 0494. 245. The bioactive agent according to item 214, 0513. 264. The bioactive agent according to item 246, wherein the Basidiomycete cell is selected from the order wherein Basidiomycete cell is selected from the family of of Polyporales. Polyporaceae. 0495 246. The bioactive agent according to item 245, 0514, 265. The bioactive agent according to item 246, wherein said Basidiomycete cell belongs to a family wherein Basidiomycete cell is selected from the family of Selected from the group consisting of Albatrellaceae, Athe Sistotremataceae. liaceae, Boreostereaceae, Corticiaceae, Cyphellaceae, 0515 266. The bioactive agent according to item 246, Cystostereaceae, Epitheliaceae, Fomitopsidaceae, Gano wherein Basidiomycete cell is selected from the family of dermataceae, Gloeophyllaceae, Grammotheleaceae, Sparassidaceae. Hapalopillaceae, Hyphodermataceae, Meripilaceae, Mer uliaceae, Phanerochaetaceae, Podoscyphaceae, Polypora 0516 267. The bioactive agent according to item 246, ceae, Sistotremataceae, Sparassidaceae, Steccherinaceae, wherein Basidiomycete cell is selected from the family of Tubulicrinaceae and Xenasmataceae. Steccherinaceae. 0496 247. The bioactive agent according to item 246, 0517 268. The bioactive agent according to item 246, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Albatrellaceae. Tubulicrinaceae. 0497 248. The bioactive agent according to item 246, 0518 269. The bioactive agent according to item 246, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Atheliaceae. Xenasmataceae. 0498 249. The bioactive agent according to item 246, 0519 270. The bioactive agent according to item 214, wherein Basidiomycete cell is selected from the family of wherein the Basidiomycete cell is selected from the order Boreostereaceae. of Boletales. 0499 250. The bioactive agent according to item 246, 0520 271. The bioactive agent according to item 270, wherein Basidiomycete cell is selected from the family of wherein said Basidiomycete cell belongs to a family Corticiaceae. selected from the group consisting of Boletaceae, Boleti 0500 251. The bioactive agent according to item 246, nellaceae, Coniophoraceae, Diplocystaceae, Gasterel wherein Basidiomycete cell is selected from the family of laceae, Gastrosporiaceae, Gomphidiaceae, Gyroporaceae, Cyphellaceae. Hygrophoropsidaceae, Hymenogasteraceae, Leucogas 0501. 252. The bioactive agent according to item 246, traceae, Melanogastraceae, Octavianiaceae, Octaviani wherein Basidiomycete cell is selected from the family of naceae, Paxillaceae, Protogastraceae, Rhizopogonaceae, Cystostereaceae. Sclerodermataceae and Suillaceae. 0502. 253. The bioactive agent according to item 246, 0521. 272. The bioactive agent according to item 271, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Epitheliaceae. Boletaceae. 0503 254. The bioactive agent according to item 246, 0522) 273. The bioactive agent according to item 271, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Fomitopsidaceae. Boletinellaceae. 0504) 255. The bioactive agent according to item 246, 0523 274. The bioactive agent according to item 271, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Ganodermataceae. Coniophoraceae. 0505 256. The bioactive agent according to item 246, 0524, 275. The bioactive agent according to item 271, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Gloeophyllaceae. Diplocystaceae. 0506. 257. The bioactive agent according to item 246, 0525 276. The bioactive agent according to item 271, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Grammotheleaceae. Gasterellaceae. 0507 258. The bioactive agent according to item 246, 0526 277. The bioactive agent according to item 271, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Hapalopillaceae. Gastrosporiaceae. 0508) 259. The bioactive agent according to item 246, 0527 278. The bioactive agent according to item 271, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Hyphodermataceae. Gomphidiaceae. US 2010/0O86647 A1 Apr. 8, 2010 32

0528 279. The bioactive agent according to item 271, 0548. 299. The bioactive agent according to item 298, wherein Basidiomycete cell is selected from the family of wherein said Basidiomycete cell belongs to a family Gyroporaceae. selected from the group consisting of Ceratobasidiaceae 0529 280. The bioactive agent according to item 271, and Oliveoniaceae. wherein Basidiomycete cell is selected from the family of (0549. 300. The bioactive agent according to item 299, Hygrophoropsidaceae. wherein Basidiomycete cell is selected from the family of 0530 281. The bioactive agent according to item 271, Ceratobasidiaceae. wherein Basidiomycete cell is selected from the family of 0550 301. The bioactive agent according to item 299, Hymenogasteraceae. wherein Basidiomycete cell is selected from the family of 0531 282. The bioactive agent according to item 271, Oliveoniaceae. wherein Basidiomycete cell is selected from the family of 0551 302. The bioactive agent according to item 214, Leucogastraceae. wherein the Basidiomycete cell is selected from the order 0532 283. The bioactive agent according to item 271, of Dacrymycetales. wherein Basidiomycete cell is selected from the family of 0552. 303. The bioactive agent according to item 302, Melanogastraceae. wherein said Basidiomycete cell belongs to a family selected from the group consisting of Cerinomycetaceae 0533. 284. The bioactive agent according to item 271, and Dacrymycetaceae. wherein Basidiomycete cell is selected from the family of 0553 304. The bioactive agent according to item 303, Octavianiaceae. wherein Basidiomycete cell is selected from the family of 0534 285. The bioactive agent according to item 271, Cerinomycetaceae. wherein Basidiomycete cell is selected from the family of 0554) 305. The bioactive agent according to item 303, Octavianinaceae. wherein Basidiomycete cell is selected from the family of 0535 286. The bioactive agent according to item 271, Dacrymycetaceae. wherein Basidiomycete cell is selected from the family of 0555 306. The bioactive agent according to item 214, Paxillaceae. wherein the Basidiomycete cell is selected from the order 0536 287. The bioactive agent according to item 271, of Hymenochaetales. wherein Basidiomycete cell is selected from the family of 0556) 307. The bioactive agent according to item 306, Protogastraceae. wherein said Basidiomycete cell belongs to a family 0537) 288. The bioactive agent according to item 271, selected from the group consisting of Asterostromataceae, wherein Basidiomycete cell is selected from the family of Hymenochaetaceae and Schizoporaceae. Rhizopogonaceae. 0557. 308. The bioactive agent according to item 307, 0538 289. The bioactive agent according to item 271, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Asterostromataceae. Sclerodermataceae. 0558 309. The bioactive agent according to item 307, 0539. 290. The bioactive agent according to item 271, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Hymenochaetaceae. Suillaceae. 0559) 310. The bioactive agent according to item 307, 0540 291. The bioactive agent according to item 214, wherein Basidiomycete cell is selected from the family of wherein the Basidiomycete cell is selected from the order Schizoporaceae. of Cantheralles. 0560 311. The bioactive agent according to item 214, 0541) 292. The bioactive agent according to item 291, wherein the Basidiomycete cell is selected from the order wherein said Basidiomycete cell belongs to a family of Phallales. 0561 312. The bioactive agent according to item 311, Selected from the group consisting of Aphelariaceae, Bot wherein said Basidiomycete cell belongs to a family ryobasidiaceae, Cantharellaceae, Clavulinaceae, and Hyd selected from the group consisting of Geastraceae, Gom aCCaC. phaceae, Hysterangiaceae, Phallaceae and Ramariaceae. 0542 293. The bioactive agent according to item 271, 0562. 313. The bioactive agent according to item 312, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Aphelariaceae. Geastraceae. 0543. 294. The bioactive agent according to item 271, 0563. 314. The bioactive agent according to item 312, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Botryobasidiaceae. Gomphaceae. 0544, 295. The bioactive agent according to item 271, 0564 3.15. The bioactive agent according to item 312, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Cantharellaceae. Hysterangiaceae. 0545 296. The bioactive agent according to item 271, 0565 316. The bioactive agent according to item 312, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Clavulinaceae. Phallaceae. 0546 297. The bioactive agent according to item 271, 0566 317. The bioactive agent according to item 312, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Hydnaceae. Ramariaceae. 0547. 298. The bioactive agent according to item 214, 0567 318. The bioactive agent according to item 214, wherein the Basidiomycete cell is selected from the order wherein the Basidiomycete cell is selected from the order of Ceratobasidiales. of Poriales. US 2010/0O86647 A1 Apr. 8, 2010

0568 319. The bioactive agent according to item 318, 0587 338. The bioactive agent according to item 337, wherein said Basidiomycete cell belongs to a family of wherein Basidiomycete cell is selected from the family of Polyporaceae. Auriculariaceae. 0569. 320. The bioactive agent according to item 214, 0588 339. The bioactive agent according to item 214, wherein the Basidiomycete cell is selected from the order wherein the Basidiomycete cell is selected from the order of Russulales. of Christianseniales. 0570 321. The bioactive agent according to item 320, 0589 340. The bioactive agent according to item 339, wherein said Basidiomycete cell belongs to a family wherein Basidiomycete cell is selected from the family of Selected from the group consisting of Auriscalpiaceae, Christianseniaceae. Bondarzewiaceae, Echinodontiaceae, Hericiaceae, Hybo 0590 341. The bioactive agent according to item 214, gasteraceae, Lachnocladiaceae, Peniophoraceae, Phanero wherein the Basidiomycete cell is selected from the order chaetaceae, Russulaceae, Stephanosporaceae and of Cystofilobasidiales. Stereaceae. 0591 342. The bioactive agent according to item 341, 0571 322. The bioactive agent according to item 321, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Cystofilobasidiaceae. Auriscalpiaceae. 0592 343. The bioactive agent according to item 214, wherein the Basidiomycete cell is selected from the order 0572 323. The bioactive agent according to item 321, of Filobasidiales. wherein Basidiomycete cell is selected from the family of 0593) 344. The bioactive agent according to item 343, Bondarzewiaceae. wherein Basidiomycete cell is selected from the family of 0573 324. The bioactive agent according to item 321, Filobasidiaceae. wherein Basidiomycete cell is selected from the family of 0594 345. The bioactive agent according to item 214, Echinodontiaceae. wherein the Basidiomycete cell is selected from the order 0574 325. The bioactive agent according to item 321, of Tremellales. wherein Basidiomycete cell is selected from the family of 0595 346. The bioactive agent according to item 345, Hericiaceae. wherein said Basidiomycete cell belongs to a family 0575 326. The bioactive agent according to item 321, selected from the group consisting of Aporpiaceae, Cuni wherein Basidiomycete cell is selected from the family of culitremaceae, Exidiaceae, Hyaloriaceae, Phragmoxenidi Hybogasteraceae. aceae, Rhynchogastremataceae, Sirobasidiaceae, Syzy 0576) 327. The bioactive agent according to item 321, gosporaceae, Tetragoniomycetaceae, Tremellaceae and wherein Basidiomycete cell is selected from the family of Tremellodendropsidaceae. Lachnocladiaceae. 0596 347. The bioactive agent according to item 346, 0577 328. The bioactive agent according to item 321, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Aporpiaceae. Peniophoraceae. 0597 348. The bioactive agent according to item 346, 0578 329. The bioactive agent according to item 321, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Cuniculitremaceae. Phanerochaetaceae. 0598. 349. The bioactive agent according to item 346, 0579) 330. The bioactive agent according to item 321, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Exidiaceae. Russulaceae. 0599 350. The bioactive agent according to item 346, 0580 331. The bioactive agent according to item 321, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Hyaloriaceae. Stephanosporaceae. 0600 351. The bioactive agent according to item 346, wherein Basidiomycete cell is selected from the family of 0581 332. The bioactive agent according to item 321, Phragmoxenidiaceae. wherein Basidiomycete cell is selected from the family of 0601 352. The bioactive agent according to item 346, Stereaceae. wherein Basidiomycete cell is selected from the family of 0582 333. The bioactive agent according to item 214, Rhynchogastremataceae. wherein the Basidiomycete cell is selected from the order 0602 353. The bioactive agent according to item 346, of Thelophorales. wherein Basidiomycete cell is selected from the family of 0583. 334. The bioactive agent according to item 333, Sirobasidiaceae. wherein said Basidiomycete cell belongs to a family 0603 354. The bioactive agent according to item 346, Selected from the group consisting of Bankeraceae and wherein Basidiomycete cell is selected from the family of Thelephoraceae. Syzygosporaceae. 0584) 335. The bioactive agent according to item 334, 0604 355. The bioactive agent according to item 346, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Bankeraceae. Tetragoniomycetaceae. 0585 336. The bioactive agent according to item 334, 0605 356. The bioactive agent according to item 346, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the family of Thelephoraceae. Tremellaceae. 0586 337. The bioactive agent according to item 214, 0606 357. The bioactive agent according to item 346, wherein the Basidiomycete cell is selected from the order wherein Basidiomycete cell is selected from the family of of Auriculariales. Tremellodendropsidaceae. US 2010/0O86647 A1 Apr. 8, 2010 34

0607 358. The bioactive agent according to item 214, 0621 372. The bioactive agent according to item 362, wherein the Basidiomycete cell is selected from the order wherein Basidiomycete cell is selected from the genus of of Tulasenellales. Chamaenyces. 0608 359. The bioactive agent according to item 358, 0622 373. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the genus of Tulasnellaceae. Chitonia. 0609 360. The bioactive agent according to item 214, 0623 374. The bioactive agent according to item 362, wherein the Basidiomycete cell is selected from the order wherein Basidiomycete cell is selected from the genus of of Urocystales. Chitoniella. 0610) 361. The bioactive agent according to item 360, 0624 375. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the family of wherein Basidiomycete cell is selected from the genus of Urocystaceae. Chitonis. 0625 376. The bioactive agent according to item 362, 0611 362. The bioactive agent according to item 217, wherein Basidiomycete cell is selected from the genus of wherein said Basidiomycete cell belongs to a genus Chlorolepiota. Selected from the group consisting of Agaricus, Amanita, 0626) 377. The bioactive agent according to item 362, Amylolepiota, Araneosa, Artymenium, Attamyces, Barche wherein Basidiomycete cell is selected from the genus of ria, Cauloglossum, Chainoderma, Chamaenyces, Chito Chlorophyllum. nia, Chitoniella, Chitonis, Chlorolepiota, Chlorophyllum, Chlorosperma, Chlorospora, Clarkeinda, Clavogaster, 0627 378. The bioactive agent according to item 362, Coccobotrys, Crucispora, Cystoagaricus, Cystolepiota, wherein Basidiomycete cell is selected from the genus of Drosella, Endolepiotula, Fungus, Fusispora, Gasterellop Chlorosperma. sis, Glaucospora, Gymnogaster, Gyrophragmium, Heine 0628 379. The bioactive agent according to item 362, mannomyces, Herculea, Hiatulopsis, Holocotylon, wherein Basidiomycete cell is selected from the genus of Horakia, Hymenagaricus, Hypogaea, Hypophyllum, Lepi Chlorospora. dotus, Lepiotella, Lepiotula, Leucoagaricus, Leucobolbi 0629) 380. The bioactive agent according to item 362, tius, Leucocoprinus, Longia, Longula, Macrolepiota, wherein Basidiomycete cell is selected from the genus of Mastocephalus, Melanophyllum, Metraria, Metrodia, Clarkeinda. Micropsalliota, Montagnea, Montagnites, Morobia, 0630 381. The bioactive agent according to item 362, Myces, Neosecotium, Notholepiota, Panaeolopsis, wherein Basidiomycete cell is selected from the genus of Phaeopholiota, Phlebonema, Phyllogaster, Podaxis, Poly Clavogaster. plocium, Pseudoauricularia, Pulverolepiota, Rickella, 0631 382. The bioactive agent according to item 362, Rugosospora, Schinzinia, Schulzeria, Schweinitzia, Seco wherein Basidiomycete cell is selected from the genus of tium, Sericeomyces, Singerina, Smithiogaster; Smithiomy Coccobotrys. ces, Stellifera, Termiticola, Verrucospora, Volvigerum, Vol 0632 383. The bioactive agent according to item 362, volepiota and Xanthagaricus. wherein Basidiomycete cell is selected from the genus of 0612 363. The bioactive agent according to item 362, Crucispora. wherein Basidiomycete cell is selected from the genus of 0633 384. The bioactive agent according to item 362, Agaricus. wherein Basidiomycete cell is selected from the genus of 0613 364. The bioactive agent according to item 362, Cystoagaricus. wherein Basidiomycete cell is selected from the genus of 0634) 385. The bioactive agent according to item 362, Amanita. wherein Basidiomycete cell is selected from the genus of 0614 365. The bioactive agent according to item 362, Cystolepiota. wherein Basidiomycete cell is selected from the genus of 0635 386. The bioactive agent according to item 362, Amylolepiota. wherein Basidiomycete cell is selected from the genus of Drosella. 0615. 366. The bioactive agent according to item 362, 0636) 387. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Araneosa. Endolepiotula. 0616) 367. The bioactive agent according to item 362, 0637 388. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Artymenium. Fungus. 0617 368. The bioactive agent according to item 362, 0638 389. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Attamyces. Fusispora. 0618. 369. The bioactive agent according to item 362, 0639 390. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Barcheria. Gasterellopsis. 0619 370. The bioactive agent according to item 362, 0640 391. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cauloglossum. Glaucospora. 0620 371. The bioactive agent according to item 362, 0641 392. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Chainoderma. Gymnogaster: US 2010/0O86647 A1 Apr. 8, 2010

0642 393. The bioactive agent according to item 362, 0663 414. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Gyrophragmium. Metrodia. 0643) 394. The bioactive agent according to item 362, 0664 415. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Heinemannomyces. Micropsalliota. 0644 395. The bioactive agent according to item 362, 0665 416. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Herculea. Montagnea. 0645 396. The bioactive agent according to item 362, 0.666 417. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hiatulopsis. Montagnites. 0646 397. The bioactive agent according to item 362, 0667 418. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Holocotylon. Morobia. 0647 398. The bioactive agent according to item 362, 0668 419. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Horakia. Myces. 0648 399. The bioactive agent according to item 362, 0669 420. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hymenagaricus. NeoSecotium. 0649 400. The bioactive agent according to item 362, 0670 421. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hypogaea. Notholepiota. 0650 401. The bioactive agent according to item 362, 0671 422. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hypophyllum. Panaeolopsis. 0651 402. The bioactive agent according to item 362, 0672 423. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lepidotus. Phaeopholiota. 0652) 403. The bioactive agent according to item 362, 0673 424. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lepiotella. Phlebonema. 0653. 404. The bioactive agent according to item 362, 0674 425. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lepiotula. Phyllogaster: 0654 405. The bioactive agent according to item 362, 0675 426. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leucoagaricus. Podaxis. 0655 406. The bioactive agent according to item 362, 0676 427. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leucobolbitius. Polyplocium. 0656 407. The bioactive agent according to item 362, 0677 428. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leucocoprinus. Pseudoauricularia. 0657 408. The bioactive agent according to item 362, 0678) 429. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of LOngia. Pulverolepiota. 0658) 409. The bioactive agent according to item 362, 0679 430. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Longula. Rickella. 0659 410. The bioactive agent according to item 362, 0680 431. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Macrolepiota. RugOSOspora. 0660 411. The bioactive agent according to item 362, 0681. 432. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Mastocephalus. Schinzinia. 0661 412. The bioactive agent according to item 362, 0682) 433. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Melanophyllum. Schulzeria. 0662 413. The bioactive agent according to item 362, 0683) 434. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Metraria. Schweinitzia. US 2010/0O86647 A1 Apr. 8, 2010 36

0684 435. The bioactive agent according to item 362, 0701 452. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Secotium. Bolbitius. 0685 436. The bioactive agent according to item 362, 0702) 453. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Sericeomyces. Bulla. 0686 437. The bioactive agent according to item 362, 0703 454. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Singerina. Campanularius. 0687 438. The bioactive agent according to item 362, 0704. 455. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Smithiogaster. Chalymnota. 0688) 439. The bioactive agent according to item 362, 0705 456. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Smithiomyces. Conocybe. 0706 457. The bioactive agent according to item 446, 0689 440. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Copelandia. Stellifera. 0707 458. The bioactive agent according to item 446, 0690 441. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Coprimarius. Termiticola. 0708 459. The bioactive agent according to item 446, 0691 442. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cyclocybe. Verrucospora. 0709 460. The bioactive agent according to item 446, 0692 443. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cyclopus. Volvigerum. 0710 461. The bioactive agent according to item 446, 0693 444. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cyphellopus. Volvolepiota. 07.11 462. The bioactive agent according to item 446, 0694 445. The bioactive agent according to item 362, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cyttarophyllopsis. Xanthagaricus. 0712 463. The bioactive agent according to item 446, 0695 446. The bioactive agent according to item 218, wherein Basidiomycete cell is selected from the genus of wherein said Basidiomycete cell belongs to a genus Cyttarophyllum. Selected from the group consisting of Acetabularia, Agro 0713 464. The bioactive agent according to item 446, cybe, Agrogaster, Alnicola, Anellaria, Bolbitius, Bulla, wherein Basidiomycete cell is selected from the genus of Campanularius, Chalymnota, Conocybe, Copelandia, Galerella. Coprimarius, Cyclocybe, Cyclopus, Cyphellopus, Cyttaro 0714. 465. The bioactive agent according to item 446, phyllopsis, Cyttarophyllum, Galerella, Galeropsis, Gas wherein Basidiomycete cell is selected from the genus of trocybe, Gymnoglossum, Hebelona, Hebelomatis, Hvlo Galeropsis. phila, Myxocybe, Naucoria, Panaeolina, Panaeolus, 0715) 466. The bioactive agent according to item 446, Pholiotella, Pholiotina, Picromyces, Pluteolus, Psammo wherein Basidiomycete cell is selected from the genus of myces, Pseudoconocybe, Pseudodeconica, Ptychella, Gastrocybe. Raddetes, Roumeguerites, Sarcoloma, Setchelliogaster; 0716 467. The bioactive agent according to item 446, Togaria, Tubariella, Tubariopsis, Tvmpanella and wherein Basidiomycete cell is selected from the genus of Wielandomyces. Gymnoglossum. 0696 447. The bioactive agent according to item 446, 0717. 468. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Acetabularia. Hebelona. 0697. 448. The bioactive agent according to item 446, 0718 469. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Agrocybe. Hebelomatis. 0698. 449. The bioactive agent according to item 446, 0719 470. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Agrogaster: Hylophila. 0699 450. The bioactive agent according to item 446, 0720 471. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Alnicola. Myxocybe. 0700 451. The bioactive agent according to item 446, 0721 472. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Anellaria. Naucoria. US 2010/0O86647 A1 Apr. 8, 2010 37

0722 473. The bioactive agent according to item 446, Oryne, Macrotyphula, Manina, Multiclavula, Podostrom wherein Basidiomycete cell is selected from the genus of bium, Ramaria, Ramariopsis, Scytinopogon, Panaeolina. Setigeroclavula and Stichoclavaria. 0723 474. The bioactive agent according to item 446, 0743. 494. The bioactive agent according to item 493, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Panaeolus. Capitoclavaria. 0724. 475. The bioactive agent according to item 446, 0744. 495. The bioactive agent according to item 493, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pholiotella. Clavaria. 0725 476. The bioactive agent according to item 446, 0745. 496. The bioactive agent according to item 493, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pholiotina. Clavulinopsis. 0726 477. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of 0746 497. The bioactive agent according to item 493, Picromyces. wherein Basidiomycete cell is selected from the genus of 0727 478. The bioactive agent according to item 446, Cornicularia. wherein Basidiomycete cell is selected from the genus of 0747 498. The bioactive agent according to item 493, Pluteolus. wherein Basidiomycete cell is selected from the genus of 0728 479. The bioactive agent according to item 446, Donkella. wherein Basidiomycete cell is selected from the genus of 0748 499. The bioactive agent according to item 493, Psammomyces. wherein Basidiomycete cell is selected from the genus of 0729 480. The bioactive agent according to item 446, Holocoryne. wherein Basidiomycete cell is selected from the genus of 0749 500. The bioactive agent according to item 493, Pseudoconocybe. wherein Basidiomycete cell is selected from the genus of 0730 481. The bioactive agent according to item 446, Macrotyphula. wherein Basidiomycete cell is selected from the genus of (0750 501. The bioactive agent according to item 493, Pseudodeconica. wherein Basidiomycete cell is selected from the genus of 0731 482. The bioactive agent according to item 446, Manina. wherein Basidiomycete cell is selected from the genus of (0751 502. The bioactive agent according to item 493, Ptychella. wherein Basidiomycete cell is selected from the genus of 0732 483. The bioactive agent according to item 446, Multiclavula. wherein Basidiomycete cell is selected from the genus of 0752 503. The bioactive agent according to item 493, Raddetes. wherein Basidiomycete cell is selected from the genus of 0733 484. The bioactive agent according to item 446, Podostrombium. wherein Basidiomycete cell is selected from the genus of Roumeguerites. 0753) 504. The bioactive agent according to item 493, 0734 485. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ramaria. Sarcoloma. 0754 505. The bioactive agent according to item 493, 0735 486. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ramariopsis. Setchelliogaster. (0755 506. The bioactive agent according to item 493, 0736. 487. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Scytinopogon. Togaria. (0756) 507. The bioactive agent according to item 493, 0737 488. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Setigeroclavula. Tubariella. (0757. 508. The bioactive agent according to item 493, 0738 489. The bioactive agent according to item 446, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Stichoclavaria. Tubariopsis. 0758 509. The bioactive agent according to item 221, 0739 490. The bioactive agent according to item 446, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of selected from the group consisting of Annularius, Asty Timpanella. lospora, Coprinellus, Coprinopsis, Coprinus, Copri 0740 491. The bioactive agent according to item 446, nusella, Cortiniopsis, Drosophila, Ephemerocybe, Gas wherein Basidiomycete cell is selected from the genus of teroagaricoides, Glyptospora, Gymnochilus, Homophron, Wielandomyces. Hypholomopsis, Lacrymaria, Lentispora, Macrometriula, 0741. 492. The bioactive agent according to item 219, Onchopus, Palaeocybe, Pannucia, Parasola, Pluteopsis, wherein Basidiomycete cell is selected from the genus of Psalliotina, Psammocoparius, Psathyra, Psathyrella, Broomeia. Pselliophora, Pseudocoprinus, Psilocybe, Rhacophyllus, 0742 493. The bioactive agent according to item 220, Xerocoprinus and Zerovaemyces. wherein said Basidiomycete cell belongs to a genus (0759 510. The bioactive agent according to item 509, Selected from the group consisting of Capitoclavaria, Cla wherein Basidiomycete cell is selected from the genus of varia, Clavulinopsis, Cornicularia, Donkella, Holoc Annularius. US 2010/0O86647 A1 Apr. 8, 2010

0760 511. The bioactive agent according to item 509, 0781 532. The bioactive agent according to item 509, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Astylospora. Psalliotina. 0761 512. The bioactive agent according to item 509, 0782 533. The bioactive agent according to item 509, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Coprinellus. Psammocoparius. 0762 513. The bioactive agent according to item 509, 0783 534. The bioactive agent according to item 509, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Coprinopsis. Psathyra. 0763 514. The bioactive agent according to item 509, 0784. 535. The bioactive agent according to item 509, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Coprinus. Psathyrella. 0764) 515. The bioactive agent according to item 509, 0785 536. The bioactive agent according to item 509, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Coprinusella. Pselliophora. 0765 516. The bioactive agent according to item 509, 0786 537. The bioactive agent according to item 509, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cortiniopsis. Pseudocoprinus. 0766 517. The bioactive agent according to item 509, 0787 538. The bioactive agent according to item 509, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Drosophila. Psilocybe. 0767. 518. The bioactive agent according to item 509, 0788 539. The bioactive agent according to item 509, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ephemerocybe. Rhacophyllus. 0768 519. The bioactive agent according to item 509, 0789 540. The bioactive agent according to item 509, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Gasteroagaricoides. Xerocoprinus. 0769 520. The bioactive agent according to item 509, 0790. 541. The bioactive agent according to item 509, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Glyptospora. Zerovaemyces. (0770) 521. The bioactive agent according to item 509, wherein Basidiomycete cell is selected from the genus of 0791 542. The bioactive agent according to item 222, Gymnochilus. wherein said Basidiomycete cell belongs to a genus selected from the group consisting of Agmocybe, Anamika, 0771 522. The bioactive agent according to item 509, Aroramyces, Astrosporina, Bulbopodium, Calathinus, wherein Basidiomycete cell is selected from the genus of Cereicium, Chromocyphella, Clypeus, Cortinarius, Crepi Homophron. dotus, Cribbea, Cuphocybe, Cyanicium, Cymbella, (0772 523. The bioactive agent according to item 509, Cyphellathelia, Cystocybe, Dermocybe, Descolea, Doch wherein Basidiomycete cell is selected from the genus of miopus, Epicorticium, Episphaeria, Flammulaster, Floc Hypholomopsis. culina, Fulvidula, Galera, Galerina, Galerula, Gomphos, (0773) 524. The bioactive agent according to item 509, Gymnopilus, Hebelomina, Horakomyces, Hydrocybe, wherein Basidiomycete cell is selected from the genus of Hydrocybium, Hydrotelamonia, Hygramaricium, Lacrymaria. Hygromyxacium, Inocibium, Inocybe, Inocybella, Ino (0774) 525. The bioactive agent according to item 509, loma, Kjeldsenia, Leucocortinarius, Leucopus, Locellina, wherein Basidiomycete cell is selected from the genus of Mackintoshia, Marasmiopsis, Melanomphalia, Meli Lentispora. derma, Mycolevis, Myxacium, Myxopholis, Nanstelo (0775 526. The bioactive agent according to item 509, cephala, Octojuga, Pellidiscus, Phaeocarpus, Phaeocolly wherein Basidiomycete cell is selected from the genus of bia, Phaeocyphella, Phaeogalera, Phaeoglabrotricha, Macrometrula. Phaeomarasmius, Phaeosolenia, Phialocybe, Phleg (0776 527. The bioactive agent according to item 509, macium, Pholidotopsis, Pleurotellus, PseudodesCollea, wherein Basidiomycete cell is selected from the genus of Pseudogymnopilus, Pyrrhoglossum, Quercella, Ramicola, Onchopus. Rapacea, Raphanozon, Rozites, Sericeocybe, Simocybe, (0777 528. The bioactive agent according to item 509, Sphaerotrachys, Squamaphlegma, Stagnicola, Stephano wherein Basidiomycete cell is selected from the genus of pus, Telamonia, Thaxterogaster; Tremellastrum, Tremel Palaeocybe. lopsis, Tubaria, Velomycena and Weinzettlia. (0778) 529. The bioactive agent according to item 509, 0792 543. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pannucia. Agmocybe. (0779 530. The bioactive agent according to item 509, 0793 544. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Parasola. Anamika. 0780. 531. The bioactive agent according to item 509, 0794 545. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pluteopsis. Aroramyces. US 2010/0O86647 A1 Apr. 8, 2010 39

0795 546. The bioactive agent according to item 542, 0816. 567. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Astrosporina. Fulvidula. 0796 547. The bioactive agent according to item 542, 0817 568. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bulbopodium. Galera. 0797 548. The bioactive agent according to item 542, 0818 569. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Calathinus. Galerina. 0798 549. The bioactive agent according to item 542, 0819 570. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cereicium. Galerula. 0799 550. The bioactive agent according to item 542, 0820) 571. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Chromocyphella. Gomphos. 0800 551. The bioactive agent according to item 542, 0821 572. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Clypeus. Gymnopilus. 0801) 552. The bioactive agent according to item 542, 0822. 573. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cortinarius. Hebelomina. 0802 553. The bioactive agent according to item 542, 0823 574. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Crepidotus. Horakomyces. 0803 554. The bioactive agent according to item 542, 0824 575. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cribbea. Hydrocybe. 0804 555. The bioactive agent according to item 542, 0825 576. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cuphocybe. Hydrocybium. 0805 556. The bioactive agent according to item 542, 0826 577. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cyanicium. Hydrotelamonia. 0806 557. The bioactive agent according to item 542, 0827. 578. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cymbella. Hygramaricium. 0807 558. The bioactive agent according to item 542, 0828 579. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cyphellathelia. Hygromyxacium. 0808 559. The bioactive agent according to item 542, 0829. 580. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cystocybe. Inocibium. 0809 560. The bioactive agent according to item 542, 0830) 581. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dermocybe. Inocybe. 0810) 561. The bioactive agent according to item 542, 0831 582. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Descolea. Inocybella. 0811 562. The bioactive agent according to item 542, 0832 583. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dochimiopus. Inoloma. 0812 563. The bioactive agent according to item 542, 0833 584. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Epicorticium. Kjeldsenia. 0813 564. The bioactive agent according to item 542, 0834 585. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Episphaeria. Leucocortinarius. 0814 565. The bioactive agent according to item 542, 0835 586. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Flammulaster: Leucopus. 0815 566. The bioactive agent according to item 542, 0836 587. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Flocculina. Locellina. US 2010/0O86647 A1 Apr. 8, 2010 40

0837) 588. The bioactive agent according to item 542, 0858 609. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Mackintoshia. PseudodesCollea. 0838 589. The bioactive agent according to item 542, 0859 610. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Marasmiopsis. Pseudogymnopilus. 0839 590. The bioactive agent according to item 542, 0860 611. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Melanomphalia. Pyrrhoglossum. 0840 591. The bioactive agent according to item 542, 0861 612. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Meliderma. Quercella. 0841 592. The bioactive agent according to item 542, 0862 613. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Mycolevis. Ramicola. 0842. 593. The bioactive agent according to item 542, 0863 614. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Myxacium. Rapacea. 0843 594. The bioactive agent according to item 542, 0864 615. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Myxopholis. Raphanozon. 0844 595. The bioactive agent according to item 542, 0865 616. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Nanstelocephala. Rozites. 0845 596. The bioactive agent according to item 542, 0866 617. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Octojuga. Sericeocybe. 0846 597. The bioactive agent according to item 542, 0867 618. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pellidiscus. Simocybe. 0847 598. The bioactive agent according to item 542, 0868 619. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phaeocarpus. Sphaerotrachys. 0848 599. The bioactive agent according to item 542, 0869. 620. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phaeocollybia. Squamaphlegma. 0849 600. The bioactive agent according to item 542, 0870) 621. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phaeocyphella. Stagnicola. 0850 601. The bioactive agent according to item 542, 0871 622. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phaeogalera. Stephanopus. 0851 602. The bioactive agent according to item 542, 0872 623. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phaeoglabrotricha. Telamonia. 0852 603. The bioactive agent according to item 542, 0873. 624. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phaeomarasmius. Thaxterogaster. 0853. 604. The bioactive agent according to item 542, 0874 625. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phaeosolenia. Tremellastrum. 0854 605. The bioactive agent according to item 542, 0875 626. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phialocybe. Tremellopsis. 0855 606. The bioactive agent according to item 542, 0876 627. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phlegmacium. Tubaria. 0856 607. The bioactive agent according to item 542, 0877. 628. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pholidotopsis. Velomycena. 0857 608. The bioactive agent according to item 542, 0878 629. The bioactive agent according to item 542, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pleurotellus. Weinzettlia. US 2010/0O86647 A1 Apr. 8, 2010

0879 630. The bioactive agent according to item 223, 0897 648. The bioactive agent according to item 630, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of Selected from the group consisting of Alboleptonia, Areni Leptoniella. Cola, Calliderma, Claudopus, Clitopiloidea, Clitopilopsis, 0898 649. The bioactive agent according to item 630, Clitopilus, Eccilia, Entoloma, Fibropilus, Hexaiuga, Hir wherein Basidiomycete cell is selected from the genus of neola, Inocephalus, Inopilus, Lanolea, Latzinaea, Lepto Nigropogon. nia, Leptoniella, Nigropogon, Nolanea, Omphaliopsis, (0899 650. The bioactive agent according to item 630, Orcella, Paraeccilia, Paraleptonia, Paxillopsis, Pouza wherein Basidiomycete cell is selected from the genus of rella, Pouzaromyces, Rhodocybe, Rhodocybella, Rhodo Nolanea. gaster, Rhodophana, Rhodophyllus, Richoniella and Tri 0900 651. The bioactive agent according to item 630, chopilus. wherein Basidiomycete cell is selected from the genus of 0880 631. The bioactive agent according to item 630, Omphaliopsis. wherein Basidiomycete cell is selected from the genus of 0901 652. The bioactive agent according to item 630, Alboleptonia. wherein Basidiomycete cell is selected from the genus of 0881 632. The bioactive agent according to item 630, Orcella. wherein Basidiomycete cell is selected from the genus of 0902 653. The bioactive agent according to item 630, Arenicola. wherein Basidiomycete cell is selected from the genus of 0882 633. The bioactive agent according to item 630, Paraeccilia. wherein Basidiomycete cell is selected from the genus of 0903 654. The bioactive agent according to item 630, Calliderma. wherein Basidiomycete cell is selected from the genus of 0883 634. The bioactive agent according to item 630, Paraleptonia. wherein Basidiomycete cell is selected from the genus of 0904. 655. The bioactive agent according to item 630, Claudopus. wherein Basidiomycete cell is selected from the genus of 0884 635. The bioactive agent according to item 630, Paxillopsis. wherein Basidiomycete cell is selected from the genus of (0905 656. The bioactive agent according to item 630, Clitopiloidea. wherein Basidiomycete cell is selected from the genus of 0885. 636. The bioactive agent according to item 630, Pouzarella. wherein Basidiomycete cell is selected from the genus of (0906 657. The bioactive agent according to item 630, Clitopilopsis. wherein Basidiomycete cell is selected from the genus of 0886 637. The bioactive agent according to item 630, Pouzaromyces. wherein Basidiomycete cell is selected from the genus of (0907 658. The bioactive agent according to item 630, Clitopilus. wherein Basidiomycete cell is selected from the genus of 0887. 638. The bioactive agent according to item 630, Rhodocybe. wherein Basidiomycete cell is selected from the genus of (0908 659. The bioactive agent according to item 630, Eccilia. wherein Basidiomycete cell is selected from the genus of 0888 639. The bioactive agent according to item 630, Rhodocybella. wherein Basidiomycete cell is selected from the genus of (0909 660. The bioactive agent according to item 630, Entoloma. wherein Basidiomycete cell is selected from the genus of 0889 640. The bioactive agent according to item 630, Rhodogaster: wherein Basidiomycete cell is selected from the genus of 0910 661. The bioactive agent according to item 630, Fibropilus. wherein Basidiomycete cell is selected from the genus of 0890) 641. The bioactive agent according to item 630, Rhodophana. wherein Basidiomycete cell is selected from the genus of 0911) 662. The bioactive agent according to item 630, Hexajuga. wherein Basidiomycete cell is selected from the genus of 0891) 642. The bioactive agent according to item 630, Rhodophyllus. wherein Basidiomycete cell is selected from the genus of 0912) 663. The bioactive agent according to item 630, Hirneola. wherein Basidiomycete cell is selected from the genus of 0892) 643. The bioactive agent according to item 630, Richoniella. wherein Basidiomycete cell is selected from the genus of 0913) 664. The bioactive agent according to item 630, Inocephalus. wherein Basidiomycete cell is selected from the genus of 0893 644. The bioactive agent according to item 630, Trichopilus. wherein Basidiomycete cell is selected from the genus of 0914 665. The bioactive agent according to item 224, Inopilus. wherein said Basidiomycete cell belongs to a genus 0894 645. The bioactive agent according to item 630, selected from the group consisting of Agarico-carnis, wherein Basidiomycete cell is selected from the genus of Buglossus, Confistulina, Fistulina, Hypodrys and Pseud Lanolea. ofistulina. 0895 646. The bioactive agent according to item 630, 0915 666. The bioactive agent according to item 665, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Latzinaea. Agarico-carnis. 0896 647. The bioactive agent according to item 630, 0916 667. The bioactive agent according to item 665, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leptonia. Buglossus. US 2010/0O86647 A1 Apr. 8, 2010 42

0917 668. The bioactive agent according to item 665, 0934 685. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Confistulina. Bovista. 0918, 669. The bioactive agent according to item 665, 0935 686. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Fistulina. Bovistaria. (0919 670. The bioactive agent according to item 665, 0936 687. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hypodrys. Bovistella. 0920 671. The bioactive agent according to item 665, 0937 688. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudofistulina. Bovistina. 0921 672. The bioactive agent according to item 225, 0938 689. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Gigasperma. Calbovista. 0922 673. The bioactive agent according to item 226, 0939 690. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hemigaster: Calvatia. 0940 691. The bioactive agent according to item 680, 0923 674. The bioactive agent according to item 227, wherein Basidiomycete cell is selected from the genus of wherein said Basidiomycete cell belongs to a genus Calvatiella. Selected from the group consisting of Hydmangium, Lac 0941 692. The bioactive agent according to item 680, caria, Maccagnia, Podohydmangium and Russuliopsis. wherein Basidiomycete cell is selected from the genus of 0924 675. The bioactive agent according to item 674, Calvatiopsis. wherein Basidiomycete cell is selected from the genus of 0942 693. The bioactive agent according to item 680, Hydnangium. wherein Basidiomycete cell is selected from the genus of 0925 676. The bioactive agent according to item 674, Capillaria. wherein Basidiomycete cell is selected from the genus of 0943 694. The bioactive agent according to item 680, Laccaria. wherein Basidiomycete cell is selected from the genus of 0926 677. The bioactive agent according to item 674, Catastoma. wherein Basidiomycete cell is selected from the genus of 0944 695. The bioactive agent according to item 680, Maccagnia. wherein Basidiomycete cell is selected from the genus of 0927. 678. The bioactive agent according to item 674, Cerophora. wherein Basidiomycete cell is selected from the genus of 0945 696. The bioactive agent according to item 680, Podohydmangium. wherein Basidiomycete cell is selected from the genus of 0928 679. The bioactive agent according to item 674, Disciseda. wherein Basidiomycete cell is selected from the genus of 0946 697. The bioactive agent according to item 680, Russuliopsis. wherein Basidiomycete cell is selected from the genus of 0929 680. The bioactive agent according to item 228, Enteromyxa. wherein said Basidiomycete cell belongs to a genus 0947 698. The bioactive agent according to item 680, Selected from the group consisting of Abstoma, Acuto wherein Basidiomycete cell is selected from the genus of capilitium, Arachnion, Arachniopsis, Bovista, Bovistaria, Eriosphaera. Bovistella, Bovistina, Calbovista, Calvatia, Calvatiella, 0948 699. The bioactive agent according to item 680, Calvatiopsis, Capillaria, Catastoma, Cerophora, Dis wherein Basidiomycete cell is selected from the genus of ciseda, Enteromyxa, Eriosphaera, Gastropilla, Globaria, Gastropilla. Glyptoderma, Handkea, Hippoperdon, Hypoblema, Japo (0949 700. The bioactive agent according to item 680, nogaster; Langermannia, Lanopila, Lasiosphaera, wherein Basidiomycete cell is selected from the genus of Lycogalopsis, Lycoperdon, Lycoperdopsis, Morganella, Globaria. Omallycus, Piemycus, Piesmycus, Pila, Priapus, Pseudoly 0950 701. The bioactive agent according to item 680, Coperdon, Sackea, Scoleciocarpus, Sufa, Utraria and Vas wherein Basidiomycete cell is selected from the genus of cellum. Glyptoderma. 0930 681. The bioactive agent according to item 680, 0951 702. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Abstoma. Handkea. 0931 682. The bioactive agent according to item 680, 0952 703. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Acutocapillitium. Hippoperdon. 0932 683. The bioactive agent according to item 680, 0953. 704. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Arachnion. Hypoblema. 0933 684. The bioactive agent according to item 680, 0954. 705. The bioactive agent according to item 680, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Arachniopsis. Japonogaster: US 2010/0O86647 A1 Apr. 8, 2010

0955. 706. The bioactive agent according to item 680, Flagelloscypha, Flammulina, Galeromycena, Gerronema, wherein Basidiomycete cell is selected from the genus of Glabrocyphella, Gloiocephala, Heliomyces, Hispidoca Langermannia. lyptella, Hologloea, Hormonitaria, Hymenoconidium, 0956 707. The bioactive agent according to item 680, Hymenogloea, Hymenomarasmius, Lachnella, Laschia, wherein Basidiomycete cell is selected from the genus of Lecanocybe, Lentinula, Libellus, Macrocystidia, Macro Lanopila. cystis, Manuripia, Marasmiellus, Marasmius, Meris 0957 708. The bioactive agent according to item 680, modes, Micromphale, Monodelphus, Mucidula, Mycetinis, wherein Basidiomycete cell is selected from the genus of Mycomedusa, Myxocollybia, Nochascypha, Omphalotus, Lasiosphaera. Oudemansia, Oudemansiella, Phaeocyphellopsis, Phae 0958 709. The bioactive agent according to item 680, Odepas, Phaeolimacium, Physalacria, Plagiotus, Poly wherein Basidiomycete cell is selected from the genus of marasmius, Polymyces, Poroauricula, Porolaschia, Proto Lycogalopsis. marasinius, Pseudodasyscypha, Pseudotyphula, 0959 710. The bioactive agent according to item 680, Pterospora, Rhizomorpha, Rhodocolybia, Scorteus, Setu wherein Basidiomycete cell is selected from the genus of lipes, Shitaker, Skepperiella, Stipitocyphella, Strobilurus, Lycoperdon. Stromatocyphella, Sympodia, Tephrophana, Tetrapyrgos, 0960 711. The bioactive agent according to item 680, Vanromburghia, Xerula and Xerulina. wherein Basidiomycete cell is selected from the genus of 0974. 725. The bioactive agent according to item 724, Lycoperaopsis. wherein Basidiomycete cell is selected from the genus of 0961 712. The bioactive agent according to item 680, Amyloflagellula. wherein Basidiomycete cell is selected from the genus of 0975 726. The bioactive agent according to item 724, Morganella. wherein Basidiomycete cell is selected from the genus of 0962 713. The bioactive agent according to item 680, Anastrophella. wherein Basidiomycete cell is selected from the genus of 0976 727. The bioactive agent according to item 724, Omallycus. wherein Basidiomycete cell is selected from the genus of 0963 714. The bioactive agent according to item 680, Androsaceus. wherein Basidiomycete cell is selected from the genus of 0977) 728. The bioactive agent according to item 724, Piemycus. wherein Basidiomycete cell is selected from the genus of 0964 715. The bioactive agent according to item 680, Anthracophyllum. wherein Basidiomycete cell is selected from the genus of 0978 729. The bioactive agent according to item 724, Pies mycus. wherein Basidiomycete cell is selected from the genus of 0965 716. The bioactive agent according to item 680, Aphotistus. wherein Basidiomycete cell is selected from the genus of 0979 730. The bioactive agent according to item 724, Pila. wherein Basidiomycete cell is selected from the genus of 0966 717. The bioactive agent according to item 680, Aphyllotus. wherein Basidiomycete cell is selected from the genus of 0980) 731. The bioactive agent according to item 724, Priapus. wherein Basidiomycete cell is selected from the genus of 0967 718. The bioactive agent according to item 680, Armillaria. wherein Basidiomycete cell is selected from the genus of 0981 732. The bioactive agent according to item 724, Pseudolycoperdon. wherein Basidiomycete cell is selected from the genus of 0968 719. The bioactive agent according to item 680, Armillariella. wherein Basidiomycete cell is selected from the genus of 0982) 733. The bioactive agent according to item 724, Sackea. wherein Basidiomycete cell is selected from the genus of 0969 720. The bioactive agent according to item 680, Baeospora. wherein Basidiomycete cell is selected from the genus of 0983. 734. The bioactive agent according to item 724, Scoleciocarpus. wherein Basidiomycete cell is selected from the genus of 0970) 721. The bioactive agent according to item 680, Baumanniella. wherein Basidiomycete cell is selected from the genus of 0984) 735. The bioactive agent according to item 724, Sufa. wherein Basidiomycete cell is selected from the genus of 0971) 722. The bioactive agent according to item 680, Calathella. wherein Basidiomycete cell is selected from the genus of 0985 736. The bioactive agent according to item 724, Utraria. wherein Basidiomycete cell is selected from the genus of 0972 723. The bioactive agent according to item 680, Campanella. wherein Basidiomycete cell is selected from the genus of 0986 737. The bioactive agent according to item 724, Vascellum. wherein Basidiomycete cell is selected from the genus of 0973 724. The bioactive agent according to item 229, Cephaloscypha. wherein said Basidiomycete cell belongs to a genus 0987) 738. The bioactive agent according to item 724, Selected from the group consisting of Amyloflagellula, wherein Basidiomycete cell is selected from the genus of Anastrophella, Androsaceus, Anthracophyllum, Aphotis Chaetocalathus. tus, Aphyllotus, Armillaria, Armilariella, Baeospora, 0988 739. The bioactive agent according to item 724, Baumanniella, Calathella, Campanella, Cephaloscypha, wherein Basidiomycete cell is selected from the genus of Chaetocalathus, Chamaeceras, Collybidium, Colly biop Chamaeceras. sis, Coprinopsis, Cymatella, Cymatellopsis, Cyphellopsis, 0989 740. The bioactive agent according to item 724, Cyptotrama, Dactylosporina, Deigloria, Discocyphella, wherein Basidiomycete cell is selected from the genus of Eoagaricus, Epicnaphus, Favolaschia, Fissolimbus, Collybidium. US 2010/0O86647 A1 Apr. 8, 2010 44

0990) 741. The bioactive agent according to item 724, 1011 762. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Colly biopsis. Hologloea. 0991) 742. The bioactive agent according to item 724, 1012 763. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Coprinopsis. Hormonitaria. 0992 743. The bioactive agent according to item 724, 1013 764. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cymatella. Hymenoconidium. 0993 744. The bioactive agent according to item 724, 1014 765. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cymatellopsis. Hymenogloea. 0994) 745. The bioactive agent according to item 724, 1015 766. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cyphellopsis. Hymenomarasmius. 0995 746. The bioactive agent according to item 724, 1016 767. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cyptotrama. Lachnella. 0996 747. The bioactive agent according to item 724, 1017 768. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dactylosporina. Laschia. 0997. 748. The bioactive agent according to item 724, 1018 769. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Deigloria. Lecanocybe. 0998 749. The bioactive agent according to item 724, 1019 770. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Discocyphella. Lentinula. 0999 750. The bioactive agent according to item 724, 1020 771. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Eoagaricus. Libellus. 1000 751. The bioactive agent according to item 724, 1021 772. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Epicnaphus. Macrocystidia. 1001 752. The bioactive agent according to item 724, 1022 773. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Favolaschia. Macrocystis. 1002 753. The bioactive agent according to item 724, 1023 774. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Fissolimbus. Manuripia. 1003 754. The bioactive agent according to item 724, 1024 775. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Flagelloscypha. Marasmiellus. 1004 755. The bioactive agent according to item 724, 1025 776. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Flammulina. Marasmius. 1005 756. The bioactive agent according to item 724, 1026 777. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Galeromycena. Merismodes. 1006 757. The bioactive agent according to item 724, 1027 778. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Gerronema. Micromphale. 1007 758. The bioactive agent according to item 724, 1028 779. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Glabrocyphella. Monodelphus. 1008 759. The bioactive agent according to item 724, 1029 780. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Gloiocephala. Mucidula. 1009 760. The bioactive agent according to item 724, 1030 781. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Heliomyces. Mycetinis. 1010 761. The bioactive agent according to item 724, 1031 782. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hispidocalyptella. Mycomedusa. US 2010/0O86647 A1 Apr. 8, 2010

1032 783. The bioactive agent according to item 724, 1053 804. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Myxocolybia. Setulipes. 1033 784. The bioactive agent according to item 724, 1054 805. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Nochascypha. Shitaker. 1034 785. The bioactive agent according to item 724, 1055) 806. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Omphalotus. Skepperiella. 1035 786. The bioactive agent according to item 724, 1056 807. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Oudemansia. Stipitocyphella. 1036 787. The bioactive agent according to item 724, 1057 808. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Oudemansiella. Strobilurus. 1037 788. The bioactive agent according to item 724, 1058. 809. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phaeocyphellopsis. Stromatocyphella. 1038 789. The bioactive agent according to item 724, 1059 810. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phaeodepas. Sympodia. 1039 790. The bioactive agent according to item 724, 1060 811. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phaeolimacium. Tephrophana. 1040 791. The bioactive agent according to item 724, 1061 812. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Physalacria. Tetrapyrgos. 1041 792. The bioactive agent according to item 724, 1062 813. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Plagiotus. Vanromburghia. 1042 793. The bioactive agent according to item 724, wherein Basidiomycete cell is selected from the genus of 1063 814. The bioactive agent according to item 724, Polymarasmius. wherein Basidiomycete cell is selected from the genus of 1043 794. The bioactive agent according to item 724, Xerula. wherein Basidiomycete cell is selected from the genus of 1064 815. The bioactive agent according to item 724, Polymyces. wherein Basidiomycete cell is selected from the genus of 1044 795. The bioactive agent according to item 724, Xerulina. wherein Basidiomycete cell is selected from the genus of 1065 816. The bioactive agent according to item 230, Poroauricula. wherein said Basidiomycete cell belongs to a genus 1045 796. The bioactive agent according to item 724, selected from the group consisting of Andebbia, Cas wherein Basidiomycete cell is selected from the genus of toreum, Gummiglobus, Gummivena, Inoderma, Malaic Porolaschia. zukia, Mesophelia, Nothocastoreum and Potoromyces. 1046 797. The bioactive agent according to item 724, 1066 817. The bioactive agent according to item 816, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Protomarasmius. Andebbia. 1047 798. The bioactive agent according to item 724, 1067 818. The bioactive agent according to item 816, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudodasyscypha. Castoreum. 1048 799. The bioactive agent according to item 724, 1068 819. The bioactive agent according to item 816, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudotyphula. Gummiglobus. 1049 800. The bioactive agent according to item 724, 1069 820. The bioactive agent according to item 816, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pterospora. Gummivena. 1050 801. The bioactive agent according to item 724, 1070 821. The bioactive agent according to item 816, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Rhizomorpha. Inoderma. 1051 802. The bioactive agent according to item 724, 1071 822. The bioactive agent according to item 816, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Rhodocollybia. Malajczukia. 1052 803. The bioactive agent according to item 724, 1072 823. The bioactive agent according to item 816, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Scorteus. Mesophelia. US 2010/0O86647 A1 Apr. 8, 2010 46

1073 824. The bioactive agent according to item 816, 1092 843. The bioactive agent according to item 841, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Nothocastoreum. Battarreopsis. 1074 825. The bioactive agent according to item 816, 1093 844. The bioactive agent according to item 841, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Potoromyces. Cyphelomyces. 1075 826. The bioactive agent according to item 231, 1094 845. The bioactive agent according to item 841, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of Selected from the group consisting of Endonevrum, Myce Dictyocephalos. nastrum and Pachyderma. 1095 846. The bioactive agent according to item 841, 1076 827. The bioactive agent according to item 826, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phelorinia. Endonevrum. 1096 847. The bioactive agent according to item 841, wherein Basidiomycete cell is selected from the genus of 1077 828. The bioactive agent according to item 826, Whetstonia. wherein Basidiomycete cell is selected from the genus of 1097 848. The bioactive agent according to item 841, Mycenastrum. wherein Basidiomycete cell is selected from the genus of 1078. 829. The bioactive agent according to item 826, Xylopodium. wherein Basidiomycete cell is selected from the genus of 1098 849. The bioactive agent according to item 235, Pachyderma. wherein said Basidiomycete cell belongs to a genus 1079. 830. The bioactive agent according to item 232, selected from the group consisting of Acanthocystis, wherein Basidiomycete cell is selected from the genus of Agaricochaete, Crepidopus, Cyclopleurotus, Gelona, Nia. Geopetalum, Hohenbuehelia, Lentodiopsis, Pleurotus, 1080 831. The bioactive agent according to item 233, Pterophyllus and Scleroma. wherein said Basidiomycete cell belongs to a genus 1099 850. The bioactive agent according to item 849, Selected from the group consisting of Crucibulum, wherein Basidiomycete cell is selected from the genus of Cyathia, Cyathodes, Cyathus, Granularia, Mycocalia, Acanthocystis. Nidula, Nidularia and Peziza. 1100 851. The bioactive agent according to item 849, 1081 832. The bioactive agent according to item 831, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Agaricochaete. Crucibulum. 1101 852. The bioactive agent according to item 849, 1082) 833. The bioactive agent according to item 831, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Crepidopus. Cyathia. 1102 853. The bioactive agent according to item 849, 1083 834. The bioactive agent according to item 831, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cyclopleurotus. Cyathodes. 1103 854. The bioactive agent according to item 849, 1084 835. The bioactive agent according to item 831, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Gelona. Cyathus. 1104 855. The bioactive agent according to item 849, 1085 836. The bioactive agent according to item 831, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Geopetalum. Granularia. 1105 856. The bioactive agent according to item 849, 1086 837. The bioactive agent according to item 831, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hohenbuehelia. Mycocalia. 1106 857. The bioactive agent according to item 849, wherein Basidiomycete cell is selected from the genus of 1087 838. The bioactive agent according to item 831, Lentodiopsis. wherein Basidiomycete cell is selected from the genus of 1107 858. The bioactive agent according to item 849, Nidula. wherein Basidiomycete cell is selected from the genus of 1088) 839. The bioactive agent according to item 831, Pleurotus. wherein Basidiomycete cell is selected from the genus of 1108 859. The bioactive agent according to item 849, Nidularia. wherein Basidiomycete cell is selected from the genus of 1089 840. The bioactive agent according to item 831, Pterophyllus. wherein Basidiomycete cell is selected from the genus of 1109 860. The bioactive agent according to item 849, Peziza. wherein Basidiomycete cell is selected from the genus of 1090 841. The bioactive agent according to item 234, Scleroma. wherein said Basidiomycete cell belongs to a genus 1110 861. The bioactive agent according to item 236, Selected from the group consisting of Areolaria, Battarre wherein said Basidiomycete cell belongs to a genus Opsis, Cyphelomyces, Dictyocephalos, Phellorinia, Whet selected from the group consisting of Agaricus, Amanita, stonia and Xylopodium. Amanitaria, Amanitella, Amanitina, Amanitopsis, Amar 1091 842. The bioactive agent according to item 841, rendia, Amidella, Amplariella, Annularia, Ariella, Aspi wherein Basidiomycete cell is selected from the genus of della, Boletium, Chamaeota, Gilbertia, Hyporrhodius, Areolaria. Lepidella, Leucomyces, Limacella, Myxoderma, Pluteus, US 2010/0O86647 A1 Apr. 8, 2010 47

Pseudofarinaceus, Rhodosporus, Termitosphaera, Torren 1131 882. The bioactive agent according to item 861, dia, Vaginaria, Vaginarius, Vaginata, Venenarius, Volva, wherein Basidiomycete cell is selected from the genus of Volvaria, Volvariella, Volvariopsis, Volvarius, Volvella, Pluteus. Volvoamanita and Volvoboletus. 1132) 883. The bioactive agent according to item 861, 1111 862. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudofarinaceus. Agaricus. 1133 884. The bioactive agent according to item 861, 1112 863. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Rhodosporus. Amanita. 1134 885. The bioactive agent according to item 861, 1113 864. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Termitosphaera. Amanitaria. 1135 886. The bioactive agent according to item 861, 1114 865. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Torrendia. Amanitella. 1115 866. The bioactive agent according to item 861, 1136 887. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amanitina. Vaginaria. 1116 867. The bioactive agent according to item 861, 1137 888. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amanitopsis. Vaginarius. 1117 868. The bioactive agent according to item 861, 1138 889. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amarrendia. Vaginata. 1118 869. The bioactive agent according to item 861, 1139 890. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amidella. Venenarius. 1119 870. The bioactive agent according to item 861, 1140 891. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amplariella. Volva. 1120) 871. The bioactive agent according to item 861, 1141 892. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Annularia. Volvaria. 1121 872. The bioactive agent according to item 861, 1142 893. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ariella. Volvariella. 1122 873. The bioactive agent according to item 861, 1143 894. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Aspidella. Volvariopsis. 1123. 874. The bioactive agent according to item 861, 1144 895. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Boletiuni. Volvarius. 1124 875. The bioactive agent according to item 861, wherein Basidiomycete cell is selected from the genus of 1145 896. The bioactive agent according to item 861, Chamaeota. wherein Basidiomycete cell is selected from the genus of 1125 876. The bioactive agent according to item 861, Wolvella. wherein Basidiomycete cell is selected from the genus of 1146 897. The bioactive agent according to item 861, Gilbertia. wherein Basidiomycete cell is selected from the genus of 1126 877. The bioactive agent according to item 861, Volvoamanita. wherein Basidiomycete cell is selected from the genus of 1147 898. The bioactive agent according to item 861, Hyporrhodius. wherein Basidiomycete cell is selected from the genus of 1127 878. The bioactive agent according to item 861, Volvoboletus. wherein Basidiomycete cell is selected from the genus of 1148 899. The bioactive agent according to item 237, Lepidella. wherein said Basidiomycete cell belongs to a genus 1128 879. The bioactive agent according to item 861, selected from the group consisting of Actiniceps, Allan wherein Basidiomycete cell is selected from the genus of tula, Ceratella, Deflexula, Dimorphocystis, Parapteruli Leucomyces. cium, Penicillaria, Phaeopterula, Pterula and Pterulicium. 1129 880. The bioactive agent according to item 861, 1149 900. The bioactive agent according to item 899, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Limacella. Actiniceps. 1130 881. The bioactive agent according to item 861, 1150 901. The bioactive agent according to item 899, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Myxoderma. Allantula. US 2010/0O86647 A1 Apr. 8, 2010 48

1151 902. The bioactive agent according to item 899, 1171 922. The bioactive agent according to item 910, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ceratella. Rhipidium. 1152 903. The bioactive agent according to item 899, 1172 923. The bioactive agent according to item 910, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Deflexula. Scaphophoeun. 1153 904. The bioactive agent according to item 899, 1173 924. The bioactive agent according to item 910, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dimorphocystis. Schizonia. 1154. 905. The bioactive agent according to item 899, 1174 925. The bioactive agent according to item 910, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Parapterulicium. Schizophyllum. 1155 906. The bioactive agent according to item 899, wherein Basidiomycete cell is selected from the genus of 1175 926. The bioactive agent according to item 910, Penicillaria. wherein Basidiomycete cell is selected from the genus of 1156 907. The bioactive agent according to item 899, Solenia. wherein Basidiomycete cell is selected from the genus of 1176) 927. The bioactive agent according to item 239, Phaeopterula. wherein Basidiomycete cell is selected from the genus of 1157. 908. The bioactive agent according to item 899, Stromatoscypha. wherein Basidiomycete cell is selected from the genus of 1177 928. The bioactive agent according to item 240, Pterula. wherein said Basidiomycete cell belongs to a genus 1158 909. The bioactive agent according to item 899, selected from the group consisting of Cytophyllopsis, wherein Basidiomycete cell is selected from the genus of Deconica, Delitescor; Derminus, Dryophila, Flammopsis, Pterulicium. Flammula, Galeropsina, Geophila, Gymnocybe, Hemi 1159 910. The bioactive agent according to item 238, pholiota, Hypholoma, Hypodendrum, Kuehneromyces, Le wherein said Basidiomycete cell belongs to a genus Ratia, Lerationyces, Melanotus, Mythicomyces, Nemato Selected from the group consisting of Apus, Auriculariop loma, Nemecomyces, Nivatogastrium, Pachylepyrium, sis, Cytidiella, Ditiola, Flabellaria, Henningsomyces, Phaeonematoloma, Pholiota, Pleuroflammula, Psilocybe, Hyponevris, Petrona, Phaeoschizophyllum, Porotheleum, Ryssospora, Stropharia, Stropholoma, Visculus and Wer Rectipilus, Rhipidium, Scaphophoeum, Schizonia, Schizo COC. phyllum and Solenia. 1178 929. The bioactive agent according to item 928, 1160 911. The bioactive agent according to item 910, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cytophyllopsis. Apus. 1179 930. The bioactive agent according to item 928, 1161 912. The bioactive agent according to item 910, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Deconica. Auriculariopsis. 1180 931. The bioactive agent according to item 928, 1162. 913. The bioactive agent according to item 910, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Delitescor: Cytidiella. 1181 932. The bioactive agent according to item 928, 1163) 914. The bioactive agent according to item 910, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Derminus. Ditiola. 1182 933. The bioactive agent according to item 928, 1164 915. The bioactive agent according to item 910, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dryophila. Flabellaria. 1165 916. The bioactive agent according to item 910, 1183 934. The bioactive agent according to item 928, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Henningsomyces. Flammopsis. 1166 917. The bioactive agent according to item 910, 1184 935. The bioactive agent according to item 928, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hyponevris. Flammula. 1167 918. The bioactive agent according to item 910, 1185 936. The bioactive agent according to item 928, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Petrona. Galeropsina. 1168 919. The bioactive agent according to item 910, 1186 937. The bioactive agent according to item 928, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phaeoschizophyllum. Geophila. 1169 920. The bioactive agent according to item 910, 1187 938. The bioactive agent according to item 928, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Porotheleum. Gymnocybe. 1170 921. The bioactive agent according to item 910, 1188 939. The bioactive agent according to item 928, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Rectipilus. Hemipholiota. US 2010/0O86647 A1 Apr. 8, 2010 49

1189 940. The bioactive agent according to item 928, Asproinocybe, Aspropaxillus, Asterophora, Asterotrichum, wherein Basidiomycete cell is selected from the genus of Asterotus, Austroclitocybe, Austroomphaliaster, Bactrobo Hypholoma. letus, Basidopus, Bertrandia, Bertrandiella, Biannularia, 1190 941. The bioactive agent according to item 928, Boehmia, Botrydina, Caesposus, Callistodermatium, Cal wherein Basidiomycete cell is selected from the genus of listosporium, Calocybe, Calyptella, Camarophyllopsis, Hypodendrum. Camarophyllus, Campanophyllum, Cantharellopsis, 1191 942. The bioactive agent according to item 928, Cantharellula, Cantharocybe, Catathelasma, Catatrama, wherein Basidiomycete cell is selected from the genus of Caulorhiza, Cellypha, Chemonophyllum, Chromosera, Kuehneromyces. Chrysobostrychodes, Chrysomphalina, Clavicybe, 1192 943. The bioactive agent according to item 928, ClavOmphalia, Clitocybe, Clitocybula, Collopus, Colly wherein Basidiomycete cell is selected from the genus of bia, Conchomyces, Coolia, Coriscium, Corniola, Corru Le-Ratia. garia, Cortinellus, Crinipellis, Cuphophyllus, Cynema, 1193 944. The bioactive agent according to item 928, Cyphellocalathus, Cystoderma, Cystodermella, Decapita wherein Basidiomycete cell is selected from the genus of tus, Delicatula, Dendrocollybia, Dennisionyces, Dermo Lerationnyces. loma, Dictyolus, Dictyopanus, Dictyoploca, Dissoderma, 1194. 945. The bioactive agent according to item 928, Echinosporella, Eomycenella, Fayodia, Filoboletus, Fla wherein Basidiomycete cell is selected from the genus of bellimycena, Floccularia, Galactopus, Gamundia, Geo Melanotus. tus, Gerhardtia, Gliophorus, Glutinaster, Godfrinia, Gym 1195 946. The bioactive agent according to item 928, nopus, Gyroflexus, Gyrophila, Haasiella, Heimiomyces, wherein Basidiomycete cell is selected from the genus of Helotium, Hemimycena, Heterosporula, Hiatula, Hodo Mythicomyces. philus, Humidicultis, Hydrophorus, Hydropus, Hygroaster, 1196 947. The bioactive agent according to item 928, Hygrocybe, Hygrophorus, Hygrotrama, Hypsizygus, wherein Basidiomycete cell is selected from the genus of Infundibulicybe, Insiticia, Jacobia, Lactocolybia, Nematoloma. Lampteromyces, Leiopoda, Lepista, Leptoglossum, Lepto 1197 948. The bioactive agent according to item 928, myces, Leptotus, Leucoinocybe, Leucopaxillus, Leucopho wherein Basidiomycete cell is selected from the genus of liota, Lichenomphalia, Limacinus, Linacium, Linopo Nemecomyces. dium, Lulesia, Lyophyllopsis, Lyophyllum, Macrocybe, 1198 949. The bioactive agent according to item 928, Maireina, Mastoleucomyces, Megacolybia, Megatricho wherein Basidiomycete cell is selected from the genus of loma, Melaleuca, Melanoleuca, Metulocyphella, Micro Nivatogastrium. collybia, Microcollybia, Mniopetalum, Moniliophthora, 1199 950. The bioactive agent according to item 928, Monomyces, Mycena, Mycenella, Mycenoporella, wherein Basidiomycete cell is selected from the genus of Mycenopsis, Mycenula, Mycoalvinia, Myxomphalia, Pachylepyrium. Nematoctonus, Neoclitocybe, Neohygrocybe, Neohygro 1200 951. The bioactive agent according to item 928, phorus, Neonothopanus, Nothoclavulina, Nothopanus, wherein Basidiomycete cell is selected from the genus of Nyctalis, Omphalia, Omphalia, Omphaliaster, Ompha Phaeonematoloma. lina, Omphalius, Omphalopsis, Ossicaulis, Palaeo 1201 952. The bioactive agent according to item 928, cephala, Panellus, Paralepista, Peglerochaete, Pegleromy wherein Basidiomycete cell is selected from the genus of ces, Perona, Phaeolepiota, Phaeomycena, Phaeotellus, Pholiota. Phalomia, Phlebomarasmius, Phlebomycena, Phlebo 1202 953. The bioactive agent according to item 928, phora, Phyllotopsis, Phyllotremella, Phyllotus, Physocys wherein Basidiomycete cell is selected from the genus of tidium, Phytoconis, Pleurella, Pleurocollybia, Pleurocy Pleuroflammula. bella, Pleuromycenula, Pleurotopsis, Podabrella, 1203) 954. The bioactive agent according to item 928, Poromycena, Porpoloma, Prunulus, Psammospora, wherein Basidiomycete cell is selected from the genus of Pseudoarmillariella, Pseudobaeospora, Pseudoclitocybe, Psilocybe. Pseudohiatula, Pseudohygrocybe, Pseudohygrophorus, 1204. 955. The bioactive agent according to item 928, Pseudolyophyllum, Pseudomycena, Pseudoomphalina, wherein Basidiomycete cell is selected from the genus of Rajapa, Resinomycena, Resupinatus, Retocybe, Ryssospora. Rhodocyphella, Rhodopaxillus, Rhodotus, Rickenella, 1205 956. The bioactive agent according to item 928, Rimbachia, Ripartitella, Ripartites, Roridomyces, wherein Basidiomycete cell is selected from the genus of Rubeolarius, Rugosomyces, Sarcomyxa, Sclerostilbum, Stropharia. Scytinotopsis, Scytinotus, Semiomphalina, Singerella, 1206 957. The bioactive agent according to item 928, Singerocybe, Sinotermitomyces, Sphaerocephalus, Squa wherein Basidiomycete cell is selected from the genus of manita, Stachyomphalina, Stanglomyces, Stereopodium, Stropholoma. Stigmatolemma, Tectella, Tephrocybe, Termitomyces, 1207 958. The bioactive agent according to item 928, Tilachlidiopsis, Tilotus, Tomentifolium, Tricholoma, Tri wherein Basidiomycete cell is selected from the genus of cholomella, Tricholomopsis, Tricholosporum, Trigonipes, Visculus. Trogia, Ugola, Urceolus, Urospora, Urosporellina, Valen 1208 959. The bioactive agent according to item 928, tinia, Xeromphalina and Zephirea. wherein Basidiomycete cell is selected from the genus of 1210 961. The bioactive agent according to item 960, Weraroa. wherein Basidiomycete cell is selected from the genus of 1209 960. The bioactive agent according to item 241, Aeruginospora. wherein said Basidiomycete cell belongs to a genus 1211 962. The bioactive agent according to item 960, Selected from the group consisting of Aeruginospora, wherein Basidiomycete cell is selected from the genus of Amparolina, Ampulloclitocybe, Arrhenia, Arthrosporella, Amparolina. US 2010/0O86647 A1 Apr. 8, 2010 50

1212 963. The bioactive agent according to item 960, 1233 984. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ampulloclitocybe. Calocybe. 1213 964. The bioactive agent according to item 960, 1234. 985. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ampulloclitocybe. Calyptella. 1214 965. The bioactive agent according to item 960, 1235 986. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Arrhenia. Camarophyllopsis. 1215 966. The bioactive agent according to item 960, 1236 987. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Arthrosporella. Camarophyllus. 1216) 967. The bioactive agent according to item 960, 1237 988. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Asproinocybe. Campanophyllum. 1217. 968. The bioactive agent according to item 960, 1238 989. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Aspropaxillus. Cantharellopsis. 1218 969. The bioactive agent according to item 960, 1239 990. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Asterophora. Cantharellula. 1219 970. The bioactive agent according to item 960, 1240 991. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Asterotrichum. Cantharocybe. 1220. 971. The bioactive agent according to item 960, 1241 992. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Asterotus. Catathelasma. 1221 972. The bioactive agent according to item 960, 1242 993. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Austroclitocybe. Catatrama. 1222 973. The bioactive agent according to item 960, 1243 994. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Austroomphaliaster: Caulorhiza. 1223 974. The bioactive agent according to item 960, 1244. 995. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bactroboletus. Cellypha. 1224 975. The bioactive agent according to item 960, 1245 996. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Basidopus. Chemonophyllum. 1225 976. The bioactive agent according to item 960, 1246 997. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bertrandia. Chromosera. 1226 977. The bioactive agent according to item 960, 1247 998. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bertrandiella. Chrysobostrychodes. 1227 978. The bioactive agent according to item 960, 1248 999. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus wherein Basidiomycete cell is selected from the genus of Biannularia. Chrysomphalina. 1228 979. The bioactive agent according to item 960, 1249 1000. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Boehmia. Clavicybe. 1229 980. The bioactive agent according to item 960, 1250 1001. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Botrydina. ClavOmphalia. 1230 981. The bioactive agent according to item 960, 1251 1002. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of CaespOsus. Clitocybe. 1231 982. The bioactive agent according to item 960, 1252 1003. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Callistodermatium. Clitocybula. 1232 983. The bioactive agent according to item 960, 1253 1004. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Callistosporium. Collopus. US 2010/0O86647 A1 Apr. 8, 2010

1254 1005. The bioactive agent according to item 960, 1275 1026. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Collybia. Dissoderma. 1255 1006. The bioactive agent according to item 960, 1276. 1027. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Conchomyces. Echinosporella. 1256 1007. The bioactive agent according to item 960, 1277 1028. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Coolia. Eomycenella. 1257 1008. The bioactive agent according to item 960, 1278 1029. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Coriscium. Fayodia. 1258 1009. The bioactive agent according to item 960, 1279 1030. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Corniola. Filoboletus. 1259 1010. The bioactive agent according to item 960, 1280 1031. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Corrugaria. Flabellimycena. 1260 1011. The bioactive agent according to item 960, 1281 1032. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cortinellus. Floccularia. 1261) 1012. The bioactive agent according to item 960, 1282) 1033. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Crinipellis. Galactopus. 1262 1013. The bioactive agent according to item 960, 1283) 1034. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cuphophyllus. Gamundia. 1263. 1014. The bioactive agent according to item 960, 1284 1035. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cynema. Geotus. 1264 1015. The bioactive agent according to item 960, 1285 1036. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cyphellocalathus. Gerhardtia. 1265 1016. The bioactive agent according to item 960, 1286 1037. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cystoderma. Gliophorus. 1266 1017. The bioactive agent according to item 960, 1287 1038. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cystodermella. Glutinaster. 1267 1018. The bioactive agent according to item 960, 1288) 1039. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Decapitatus. Godfrinia. 1268) 1019. The bioactive agent according to item 960, 1289 1040. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Delicatula. Gymnopus. 1269 1020. The bioactive agent according to item 960, 1290 1041. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dendrocollybia. Gyroflexus. 1270 1021. The bioactive agent according to item 960, 1291 1042. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dennisionyces. Gyrophila. 1271 1022. The bioactive agent according to item 960, 1292 1043. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dermoloma. Haasiella. 1272 1023. The bioactive agent according to item 960, 1293. 1044. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dictyolus. Heimiomyces. 1273 1024. The bioactive agent according to item 960, 1294 1045. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dictyopanus. Helotium. 1274 1025. The bioactive agent according to item 960, 1295 1046. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dictyoploca. Hemimycena. US 2010/0O86647 A1 Apr. 8, 2010 52

1296) 1047. The bioactive agent according to item 960, 1317 1068. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Heterosporula. Leucopaxillus. 1297 1048. The bioactive agent according to item 960, 1318 1069. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hiatula. Leucopholiota. 1298) 1049. The bioactive agent according to item 960, 1319 1070. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hodophilus. Lichenomphalia. 1299) 1050. The bioactive agent according to item 960, 1320 1071. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Humidicultis. Limacinus. 1300 1051. The bioactive agent according to item 960, 1321 1072. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hydrophorus. Linacium. 1301 1052. The bioactive agent according to item 960, 1322 1073. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hydropus. Linopodium. 1302 1053. The bioactive agent according to item 960, 1323 1074. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of H'groaster: Lulesia. 1303 1054. The bioactive agent according to item 960, 1324 1075. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hygrocybe. Lyophyllopsis. 1304 1055. The bioactive agent according to item 960, 1325 1076. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hygrophorus. Lyophyllum. 1305 1056. The bioactive agent according to item 960, 1326 1077. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hygrotrama. Macrocybe. 1306 1057. The bioactive agent according to item 960, 1327 1078. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hypsizygus. Maireina. 1307 1058. The bioactive agent according to item 960, 1328. 1079. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Infindibulicybe. Mastoleucomyces. 1308 1059. The bioactive agent according to item 960, 1329 1080. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Insiticia. Megacolybia. 1309 1060. The bioactive agent according to item 960, 1330 1081. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Jacobia. Megatricholoma. 1310 1061. The bioactive agent according to item 960, 1331 1082. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lactocolybia. Melaleuca. 1311 1062. The bioactive agent according to item 960, 1332 1083. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lampteromyces. Melanoleuca. 1312 1063. The bioactive agent according to item 960, 1333 1084. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leiopoda. Metulocyphella. 1313 1064. The bioactive agent according to item 960, 1334 1085. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lepista. Microcollybia. 1314 1065. The bioactive agent according to item 960, 1335 1086. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leptoglossum. Mniopetalum. 1315. 1066. The bioactive agent according to item 960, 1336 1087. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leptotus. Moniliophthora. 1316 1067. The bioactive agent according to item 960, 1337 1088. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leucoinocybe. Monomyces. US 2010/0O86647 A1 Apr. 8, 2010

1338 1089. The bioactive agent according to item 960, 1359 1110. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Mycena. Palaeocephala. 1339) 1090. The bioactive agent according to item 960, 1360 1111. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Mycenella. Panellus. 1340 1091. The bioactive agent according to item 960, 1361) 1112. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Mycenoporella. Paralepista. 1341 1092. The bioactive agent according to item 960, 1362 1113. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Mycenopsis. Peglerochaete. 1342 1093. The bioactive agent according to item 960, 1363 1114. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Mycenula. Pegleromyces. 1343. 1094. The bioactive agent according to item 960, 1364. 1115. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Mycoalvinia. Perona. 1344 1095. The bioactive agent according to item 960, 1365. 1116. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Myxomphalia. Phaeolepiota. 1345 1096. The bioactive agent according to item 960, 1366 1117. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Nematoctonus. Phaeomycena. 1346 1097. The bioactive agent according to item 960, 1367. 1118. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Neoclitocybe. Phaeotellus. 1347 1098. The bioactive agent according to item 960, 1368 1119. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Neohygrocybe. Phalomia. 1348 1099. The bioactive agent according to item 960, 1369 1120. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Neohygrophorus. Phlebomarasmius. 1349 1100. The bioactive agent according to item 960, 1370) 1121. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Neonothopanus. Phlebomycena. 1350 1101. The bioactive agent according to item 960, 1371) 1122. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Nothoclavulina. Phlebophora. 1351 1102. The bioactive agent according to item 960, 1372) 1123. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Nothopanus. Phyllotopsis. 1352 1103. The bioactive agent according to item 960, 1373) 1124. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Nyctalis. Phyllotremella. 1353 1104. The bioactive agent according to item 960, 1374 1125. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Omphalia. Phyllotus. 1354 1105. The bioactive agent according to item 960, 1375) 1126. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Omphaliaster: Physocystidium. 1355 1106. The bioactive agent according to item 960, 1376) 1127. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Omphalina. Phytoconis. 1356 1107. The bioactive agent according to item 960, 1377 1128. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Omphalius. Pleurella. 1357 1108. The bioactive agent according to item 960, 1378 1129. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Omphalopsis. Pleurocolybia. 1358) 1109. The bioactive agent according to item 960, 1379 1130. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ossicaulis. Pleurocybella. US 2010/0O86647 A1 Apr. 8, 2010 54

1380 1131. The bioactive agent according to item 960, 1401 1152. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pleuromycenula. Rhodopaxillus. 1381) 1132. The bioactive agent according to item 960, 1402 1153. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pleurotopsis. Rhodotus. 1382) 1133. The bioactive agent according to item 960, 1403 1154. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Podabrella. Rickenella. 1383 1134. The bioactive agent according to item 960, 1404 1155. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Poromycena. Rimbachia. 1384 1135. The bioactive agent according to item 960, 1405 1156. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of PorpOloma. Ripartitella. 1385) 1136. The bioactive agent according to item 960, 1406 1157. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Prunulus. Ripartites. 1386 1137. The bioactive agent according to item 960, 1407 1158. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Psammospora. Roridomyces. 1387 1138. The bioactive agent according to item 960, 1408 1159. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudoarmillariella. Rubeolarius. 1388 1139. The bioactive agent according to item 960, 1409 1160. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudobaeospora. Rugosomyces. 1389 1140. The bioactive agent according to item 960, 1410) 1161. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudoclitocybe. Sarcomyxa. 1390 1141. The bioactive agent according to item 960, 1411) 1162. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudohiatula. Sclerostilbum. 1391) 1142. The bioactive agent according to item 960, 1412 1163. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudohygrocybe. Scytinotopsis. 1392 1143. The bioactive agent according to item 960, 1413 1164. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudohygrophorus. Scytinotus. 1393 1144. The bioactive agent according to item 960, 1414) 1165. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudolyophyllum. Semiomphalina. 1394) 1145. The bioactive agent according to item 960, 1415 1166. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudomycena. Singerella. 1395) 1146. The bioactive agent according to item 960, 1416 1167. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pseudoomphalina. Singerocybe. 1396 1147. The bioactive agent according to item 960, 1417 1168. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Rajapa. Sinotermitomyces. 1397 1148. The bioactive agent according to item 960, 1418 1169. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Resinomycena. Sphaerocephalus. 1398. 1149. The bioactive agent according to item 960, 1419 1170. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Resupinatus. Squamanita. 1399) 1150. The bioactive agent according to item 960, 1420 1171. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Retocybe. StachyOmphalina. 1400 1151. The bioactive agent according to item 960, 1421 1172. The bioactive agent according to item 960, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Rhodocyphella. Stanglomyces. US 2010/0O86647 A1 Apr. 8, 2010

1422 1173. The bioactive agent according to item 960, 1443) 1194. The bioactive agent according to item 242, wherein Basidiomycete cell is selected from the genus of wherein said Basidiomycete cell belongs to a genus Stereopodium. selected from the group consisting of Battarraeastrum, 1423) 1174. The bioactive agent according to item 960, Battarrea, Battarreoides, Chlamydopus, Dendromyces, wherein Basidiomycete cell is selected from the genus of Oueletia, Schizostoma, Sphaericeps, Tulasnodea and Stigmatolemma. Tulostoma. 1424. 1175. The bioactive agent according to item 960, 1444. 1195. The bioactive agent according to item 1195, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tectella. Battarraeastrum. 1425) 1176. The bioactive agent according to item 960, 1445 1196. The bioactive agent according to item 1195, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tephrocybe. Battarrea. 1426 1177. The bioactive agent according to item 960, 1446 1197. The bioactive agent according to item 1195, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Termitomyces. Battarreoides. 1427 1178. The bioactive agent according to item 960, 1447 1198. The bioactive agent according to item 1195, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tilachlidiopsis. Chlamydopus. 1428. 1179. The bioactive agent according to item 960, 1448) 1199. The bioactive agent according to item 1195, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tilotus. Dendromyces. 1429 1180. The bioactive agent according to item 960, 1449 1200. The bioactive agent according to item 1195, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tomentifolium. Oueletia. 1430. 1181. The bioactive agent according to item 960, 1450 1201. The bioactive agent according to item 1195, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tricholoma. Schizostoma. 1431 1182. The bioactive agent according to item 960, 1451 1202. The bioactive agent according to item 1195, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tricholomella. Sphaericeps. 1432) 1183. The bioactive agent according to item 960, 1452 1203. The bioactive agent according to item 1195, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tricholomopsis. Tulasnodea. 1433 1184. The bioactive agent according to item 960, 1453) 1204. The bioactive agent according to item 1195, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tricholosporum. Tulostoma. 1454 1205. The bioactive agent according to item 243, 1434 1185. The bioactive agent according to item 960, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of selected from the group consisting of Apiosporium, Trigonipes. Astoma, Bronicola, Cnazonaria, Coccopleum, Dacry 1435 1186. The bioactive agent according to item 960, opsella, Gliocoryne, Lutypha, Phacorhiza, Pistillaria, Pis wherein Basidiomycete cell is selected from the genus of tillina, Scleromitra, Sclerotiomyces, Sclerotium, Trogia. Sphaerula, Tiphula and Xylochoeras. 1436 1187. The bioactive agent according to item 960, 1455 1206. The bioactive agent according to item 1205, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ugola. Apiosporium. 1437 1188. The bioactive agent according to item 960, 1456 1207. The bioactive agent according to item 1205, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Urceolus. Astoma. 1438 1189. The bioactive agent according to item 960, 1457 1208. The bioactive agent according to item 1205, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Urospora. Bromicolla. 1439 1190. The bioactive agent according to item 960, 1458) 1209. The bioactive agent according to item 1205, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Urosporellina. Cnazonaria. 1440 1191. The bioactive agent according to item 960, 1459 1210. The bioactive agent according to item 1205, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Valentinia. Coccopleum. 1441 1192. The bioactive agent according to item 960, 1460 1211. The bioactive agent according to item 1205, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Xeromphalina. Dacryopsella. 1442) 1193. The bioactive agent according to item 960, 1461 1212. The bioactive agent according to item 1205, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Zephirea. Gliocoryne. US 2010/0O86647 A1 Apr. 8, 2010 56

1462. 1213. The bioactive agent according to item 1205, Fibulomyces, Fibulorhizoctonia, Gyrolophium, Hypoch wherein Basidiomycete cell is selected from the genus of nella, Hypochniciellum, Irpicodon, Laudatea, Leptosporo Lutypha. myces, Lobulicium, Luellia, Melzericium, Mycostigma, 1463) 1214. The bioactive agent according to item 1205, Piloderma, Plicatura, Plicaturopsis, Rhipidonema, Rhipi wherein Basidiomycete cell is selected from the genus of donematomyces, Rhizomena, Taeniospora, Tomentellop Phacorhiza. sis, Tvlosperma, Tvlospora and Wainiocora. 1464. 1215. The bioactive agent according to item 1205, 1481 1232. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pistillaria. Amphinema. 1465 1216. The bioactive agent according to item 1205, 1482 1233. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pistillina. Amyloathelia. 1466 1217. The bioactive agent according to item 1205, 1483) 1234. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Scleromitra. Amylocorticium. 1467. 1218. The bioactive agent according to item 1205, 1484 1235. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Sclerotiomyces. Athelia. 1468 1219. The bioactive agent according to item 1205, 1485 1236. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Sclerotium. Athelicium. 1469 1220. The bioactive agent according to item 1205, 1486 1237. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Sphaerula. Athelidium. 1470 1221. The bioactive agent according to item 1205, 1487. 1238. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tiphula. Atheliopsis. 1471) 1222. The bioactive agent according to item 1205, 1488 1239. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Xylochoeras. Butlerelfia. 1472 1223. The bioactive agent according to item 244, 1489 1240. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Rhizomarasmius. ByssocOrticium. 1473) 1224. The bioactive agent according to item 247, 1490 1241. The bioactive agent according to item 1231, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of Selected from the group consisting of Albatrellopsis, Byssocristella. Albatrellus, Jahnoporus, Ovinus, Polyporoletus and Scuti ger. 1491 1242. The bioactive agent according to item 1231, 1474 1225. The bioactive agent according to item 1225, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Byssoporia. Albatrellopsis. 1492 1243. The bioactive agent according to item 1231, 1475) 1226. The bioactive agent according to item 1225, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Caerulicium. Albatrellus. 1493) 1244. The bioactive agent according to item 1231, 1476) 1227. The bioactive agent according to item 1225, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cora. Jahnoporus. 1494. 1245. The bioactive agent according to item 1231, 1477 1228. The bioactive agent according to item 1225, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Coraemyces. Ovinus. 1495 1246. The bioactive agent according to item 1231, 1478 1229. The bioactive agent according to item 1225, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Corella. Polyporoletus. 1496 1247. The bioactive agent according to item 1231, 1479 1230. The bioactive agent according to item 1225, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cristinia. Scutiger. 1497 1248. The bioactive agent according to item 1231, 1480 1231. The bioactive agent according to item 248, wherein Basidiomycete cell is selected from the genus of wherein said Basidiomycete cell belongs to a genus Dacryobasidium. Selected from the group consisting of Amphinema, Amy 1498 1249. The bioactive agent according to item 1231, loathelia, Amylocorticium, Athelia, Athelicium, Athe wherein Basidiomycete cell is selected from the genus of lidium, Atheliopsis, Butlerelfia, ByssocOrticium, Byssocris Dichonema. tella, Byssoporia, Caerulicium, Cora, Coraemyces, 1499 1250. The bioactive agent according to item 1231, Corella, Cristinia, Dacryobasidium, Dichonema, Dicty wherein Basidiomycete cell is selected from the genus of onema, Dictyonematomyces, Digitatispora, Diplonema, Dictyonema. US 2010/0O86647 A1 Apr. 8, 2010 57

1500 1251. The bioactive agent according to item 1231, 1521) 1272. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dictyonematomyces. Taeniospora. 1501 1252. The bioactive agent according to item 1231, 1522 1273. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Digitatispora. Tomentellopsis. 1502 1253. The bioactive agent according to item 1231, 1523) 1274. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Diplonema. Tvlosperma. 1503) 1254. The bioactive agent according to item 1231, 1524 1275. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Fibulomyces. Tvlospora. 1504 1255. The bioactive agent according to item 1231, 1525 1276. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Fibulorhizoctonia. Wainiocora. 1505 1256. The bioactive agent according to item 1231, 1526 1277. The bioactive agent according to item 249, wherein Basidiomycete cell is selected from the genus of wherein said Basidiomycete cell belongs to a genus Gyrolophium. selected from the group consisting Boreostereum, Chaeto 1506 1257. The bioactive agent according to item 1231, carpus, Chaetodermella, Columnocystis, Grandinioides, wherein Basidiomycete cell is selected from the genus of Hirneola, Mycobonia, Mycothele and Veluticeps. Hypochnella. 1527. 1278. The bioactive agent according to item 1277, 1507 1258. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Boreostereum. Hypochniciellum. 1528 1279. The bioactive agent according to item 1277, 1508 1259. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Chaetocarpus. Irpicodon. 1529 1280. The bioactive agent according to item 1277, 1509 1260. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Chaetodermella. Laudatea. 1530 1281. The bioactive agent according to item 1277, 1510 1261. The bioactive agent according to item 1231, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Columnocystis. Amphinema, Amyloathelia, Amylocorticium, Athelia, Lep 1531) 1282. The bioactive agent according to item 1277, tosporomyces. wherein Basidiomycete cell is selected from the genus of 1511 1262. The bioactive agent according to item 1231, Grandinioides. wherein Basidiomycete cell is selected from the genus of 1532 1283. The bioactive agent according to item 1277, Lobulicium. wherein Basidiomycete cell is selected from the genus of 1512 1263. The bioactive agent according to item 1231, Hirneola. wherein Basidiomycete cell is selected from the genus of 1533 1284. The bioactive agent according to item 1277, Luellia. wherein Basidiomycete cell is selected from the genus of 1513 1264. The bioactive agent according to item 1231, Mycobonia. wherein Basidiomycete cell is selected from the genus of 1534 1285. The bioactive agent according to item 1277, Melzericium. wherein Basidiomycete cell is selected from the genus 1514 1265. The bioactive agent according to item 1231, Mycothele. wherein Basidiomycete cell is selected from the genus of 1535 1286. The bioactive agent according to item 1277, Mycostigma. wherein Basidiomycete cell is selected from the genus of 1515 1266. The bioactive agent according to item 1231, Veluticeps. wherein Basidiomycete cell is selected from the genus of 1536 1287. The bioactive agent according to item 250, Piloderma. wherein said Basidiomycete cell belongs to a genus 1516 1267. The bioactive agent according to item 1231, selected from the group consisting Acantholichen, Aleuro wherein Basidiomycete cell is selected from the genus of corticium, Allosphaerium, Ambivina, Amylobasidium, Plicatura. Auricula, Bryochysium, Corticirama, Corticium, 1517. 1268. The bioactive agent according to item 1231, Cyanobasidium, Cytidia, Dendrocorticium, Dendrodon wherein Basidiomycete cell is selected from the genus of tia, Dendrophysellum, Dendrothele, Dextrinodontia, Hem Plicaturopsis. mesomyces, Laeticorticium, Laetisaria, Leptocorticium, 1518 1269. The bioactive agent according to item 1231, Licrostroma, Limonomyces, Lindtneria, Lomatia, Loma wherein Basidiomycete cell is selected from the genus of tina, Lyomyces, Matula, Melzerodontia, Merulicium, Rhipidonema. Moniliopsis, Mutatoderma, Mycinema, Mycolindtneria, 1519 1270. The bioactive agent according to item 1231, Necator, Nothocorticium, Papyrodiscus, Phaeophlebia, wherein Basidiomycete cell is selected from the genus of Pulcherricium, Punctularia, Rhizoctonia, Ripexicium, Rhipidonematomyces. Thanatophytum and Vuilleminia. 1520 1271. The bioactive agent according to item 1231, 1537 1288. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Rhizonema. Acantholichen. US 2010/0O86647 A1 Apr. 8, 2010

1538 1289. The bioactive agent according to item 1287, 1559 1310. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Aleurocorticium. Lindtneria. 1539 1290. The bioactive agent according to item 1287, 1560. 1311. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Allosphaerium. Lomatia. 1540 1291. The bioactive agent according to item 1287, 1561) 1312. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ambivina. Lomatina. 1541) 1292. The bioactive agent according to item 1287, 1562. 1313. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amylobasidium. LyOmyces. 1542 1293. The bioactive agent according to item 1287, 1563 1314. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Auricula. Matula. 1543) 1294. The bioactive agent according to item 1287, 1564 1315. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bryochysium. Melzerodontia. 1544 1295. The bioactive agent according to item 1287, 1565. 1316. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Corticirama. Merulicium. 1545 1296. The bioactive agent according to item 1287, 1566 1317. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Corticium. Moniliopsis. 1546 1297. The bioactive agent according to item 1287, 1567 1318. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cyanobasidium. Mutatoderma. 1547 1298. The bioactive agent according to item 1287, 1568 1319. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cytidia. Mycinema. 1548 1299. The bioactive agent according to item 1287, 1569 1320. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dendrocorticium. Mycolindtneria. 1549 1300. The bioactive agent according to item 1287, 1570 1321. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dendrodontia. Necator. 1550 1301. The bioactive agent according to item 1287, 1571 1322. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dendrophysellum. Nothocorticium. 1551) 1302. The bioactive agent according to item 1287, 1572. 1323. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dendrothele. Papyrodiscus. 1552 1303. The bioactive agent according to item 1287, 1573) 1324. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Dextrinodontia. Phaeophlebia. 1553) 1304. The bioactive agent according to item 1287, 1574 1325. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hemmesomyces. Pulcherricium. 1554 1305. The bioactive agent according to item 1287, 1575) 1326. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Laeticorticium. Punctularia. 1555 1306. The bioactive agent according to item 1287, 1576. 1327. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Laetisaria. Rhizoctonia. 1556) 1307. The bioactive agent according to item 1287, 1577 1328. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leptocorticium. Ripexicium. 1557 1308. The bioactive agent according to item 1287, 1578 1329. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Licrostroma. Thanatophytum. 1558 1309. The bioactive agent according to item 1287, 1579 1330. The bioactive agent according to item 1287, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Limonomyces. Vuilleminia. US 2010/0O86647 A1 Apr. 8, 2010 59

1580 1331. The bioactive agent according to item 251, 1599. 1350. The bioactive agent according to item 1331, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of Selected from the group consisting of Adustomyces, Sarcodontia. Asterocyphella, Catilla, Cyphella, Dendrocyphella, Fla 1600 1351. The bioactive agent according to item 1331, vophlebia, Globulicium, Gloeocorticium, Halocyphina, wherein Basidiomycete cell is selected from the genus of Hyphoradulum, Incrustocalyptella, Limnoperdon, Oxy Seticyphella. dontia, Phaeoporotheleum, Pseudolagarobasidium, Radu 1601 1352. The bioactive agent according to item 1331, lodon, Radulomyces, Rhodoarrhenia, Sarcodontia, Seti wherein Basidiomycete cell is selected from the genus of cyphella, Sphaerobasidioscypha, Thujacorticium, Sphaerobasidioscypha. Wiesnerina, and Woldmaria. 1602 1353. The bioactive agent according to item 1331, 1581. 1332. The bioactive agent according to item 1331, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Thujacorticium. Adustomyces. 1603) 1354. The bioactive agent according to item 1331, 1582. 1333. The bioactive agent according to item 1331, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Wiesnerina. Asterocyphella. 1604 1355. The bioactive agent according to item 1331, 1583) 1334. The bioactive agent according to item 1331, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Woldmaria. Catilla. 1605 1356. The bioactive agent according to item 252, 1584 1335. The bioactive agent according to item 1331, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of selected from the group consisting of Cericium, Crustomy Cyphella. ces, Cystidiodontia, Cystostereum, Dentocorticium, Par 1585 1336. The bioactive agent according to item 1331, vobasidium, Physodontia and Pteridomyces. wherein Basidiomycete cell is selected from the genus of 1606 1357. The bioactive agent according to item 1356, Dendrocyphella. wherein Basidiomycete cell is selected from the genus of 1586 1337. The bioactive agent according to item 1331, Cericium. wherein Basidiomycete cell is selected from the genus of 1607 1358. The bioactive agent according to item 1356, Flavophlebia. wherein Basidiomycete cell is selected from the genus of 1587. 1338. The bioactive agent according to item 1331, Crustomyces. wherein Basidiomycete cell is selected from the genus of 1608 1359. The bioactive agent according to item 1356, Globulicium. wherein Basidiomycete cell is selected from the genus of 1588 1339. The bioactive agent according to item 1331, Cystidiodontia. wherein Basidiomycete cell is selected from the genus of 1609 1360. The bioactive agent according to item 1356, Gloeocorticium. wherein Basidiomycete cell is selected from the genus of 1589 1340. The bioactive agent according to item 1331, Cystostereum. wherein Basidiomycete cell is selected from the genus of 1610 1361. The bioactive agent according to item 1356, Halocyphina. wherein Basidiomycete cell is selected from the genus of 1590 1341. The bioactive agent according to item 1331, Dentocorticium. wherein Basidiomycete cell is selected from the genus of 1611 1362. The bioactive agent according to item 1356, Hyphoradulum. wherein Basidiomycete cell is selected from the genus of 1591. 1342. The bioactive agent according to item 1331, Parvobasidium. wherein Basidiomycete cell is selected from the genus of 1612 1363. The bioactive agent according to item 1356, Incrustocalyptella. wherein Basidiomycete cell is selected from the genus of 1592) 1343. The bioactive agent according to item 1331, Physodontia. wherein Basidiomycete cell is selected from the genus of 1613 1364. The bioactive agent according to item 1356, Limnoperdon. wherein Basidiomycete cell is selected from the genus of 1593 1344. The bioactive agent according to item 1331, Pteridomyces. wherein Basidiomycete cell is selected from the genus of 1614 1365. The bioactive agent according to item 253, Oxydontia. wherein said Basidiomycete cell belongs to a genus 1594 1345. The bioactive agent according to item 1331, selected from the group consisting of Epithele, Epithellop wherein Basidiomycete cell is selected from the genus of sis and Skeletohydmum. Phaeoporotheleum. 1615 1366. The bioactive agent according to item 1365, 1595. 1346. The bioactive agent according to item 1331, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Epithele. Pseudolagarobasidium. 1616 1367. The bioactive agent according to item 1365, 1596 1347. The bioactive agent according to item 1331, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Epitheliopsis. Radulodon. 1617 1368. The bioactive agent according to item 1365, 1597 1348. The bioactive agent according to item 1331, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Skeletohydnum. Radulomyces. 1618 1369. The bioactive agent according to item 254, 1598 1349. The bioactive agent according to item 1331, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of selected from the group consisting of Agaricon, Agarico Rhodoarrhenia. pulpa, Agarico-suber, Agaricum, Agaricus, Amylocystis, US 2010/0O86647 A1 Apr. 8, 2010 60

Anomoporia, Auriporia, Buglossoporus, Daedalea, Donk 1638 1389. The bioactive agent according to item 1369, ioporia, Fomitopsis, Gilbertsonia, Hemidiscia, Laricifo wherein Basidiomycete cell is selected from the genus of mes, Osteina, Parmastomyces, Phaeodaedalea, Pilato Piptoporus. porus, Piptoporus, Placoderma, Podoporia, Postia, 1639 1390. The bioactive agent according to item 1369, Rhodofomes, Spelaeomyces, Spongiporus, Strangulidium, wherein Basidiomycete cell is selected from the genus of Striglia, Ungularia, Wolfiporia and Xvlostroma. Placoderma. 1619 1370. The bioactive agent according to item 1369, 1640. 1391. The bioactive agent according to item 1369, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Agaricon. Podoporia. 1620. 1371. The bioactive agent according to item 1369, 1641 1392. The bioactive agent according to item 1369, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Agarico-pulpa. Postia. 1621 1372. The bioactive agent according to item 1369, 1642) 1393. The bioactive agent according to item 1369, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Agarico-suber. Rhodofomes. 1622. 1373. The bioactive agent according to item 1369, 1643) 1394. The bioactive agent according to item 1369, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Agaricum. Spelaeomyces. 1623 1374. The bioactive agent according to item 1369, 1644 1395. The bioactive agent according to item 1369, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Agaricus. Spongiporus. 1624 1375. The bioactive agent according to item 1369, 1645 1396. The bioactive agent according to item 1369, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amylocystis. Strangulidium. 1625 1376. The bioactive agent according to item 1369, 1646 1397. The bioactive agent according to item 1369, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Anomoporia. Striglia. 1626 1377. The bioactive agent according to item 1369, 1647 1398. The bioactive agent according to item 1369, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Auriporia. Ungularia. 1627 1378. The bioactive agent according to item 1369, 1648 1399. The bioactive agent according to item 1369, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Buglossoporus. Wolfporia. 1628 1379. The bioactive agent according to item 1369, 1649. 1400. The bioactive agent according to item 1369, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Daedalea. Xylostroma. 1629 1380. The bioactive agent according to item 1369, 1650 1401. The bioactive agent according to item 255, wherein Basidiomycete cell is selected from the genus of wherein said Basidiomycete cell belongs to a genus Donkioporia. selected from the group consisting of Amauroderma, Den 1630 1381. The bioactive agent according to item 1369, drophagus, Elfvingia, Friesia, Ganoderma, Haddowia, wherein Basidiomycete cell is selected from the genus of Humphreya, Lazulinospora, Magoderna, Thermophy Fomitopsis. matospora, Tomophagus, Trachyderma and Whitfordia. 1631) 1382. The bioactive agent according to item 1369, 1651. 1402. The bioactive agent according to item 1401, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Gilbertsonia. Amauroderma. 1632) 1383. The bioactive agent according to item 1369, 1652) 1403. The bioactive agent according to item 1401, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hemidiscia. Dendrophagus. 1633 1384. The bioactive agent according to item 1369, 1653) 1404. The bioactive agent according to item 1401, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Laricifomes. Elfvingia. 1634 1385. The bioactive agent according to item 1369, 1654) 1405. The bioactive agent according to item 1401, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Osteina. Friesia. 1635. 1386. The bioactive agent according to item 1369, 1655 1406. The bioactive agent according to item 1401, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Parmastomyces. Ganoderma. 1636. 1387. The bioactive agent according to item 1369, 1656) 1407. The bioactive agent according to item 1401, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phaeodaedalea. Haddowia. 1637 1388. The bioactive agent according to item 1369, 1657 1408. The bioactive agent according to item 1401, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pilatoporus. Humphreya. US 2010/0O86647 A1 Apr. 8, 2010

1658. 1409. The bioactive agent according to item 1401, 1678. 1429. The bioactive agent according to item 1425, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lazulinospora. Theleporus. 1659 1410. The bioactive agent according to item 1401, 1679. 1430. The bioactive agent according to item 1425, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Magoderna. Tinctoporia. 1660. 1411. The bioactive agent according to item 1401, 1680 1431. The bioactive agent according to item 258, wherein Basidiomycete cell is selected from the genus of wherein said Basidiomycete cell belongs to a genus Thermophymatospora. selected from the group consisting of Aurantiporus, Bjer 1661 1412. The bioactive agent according to item 1401, kandera, Ceraporus, Ceriporia, CeripOriopsis, Climaco wherein Basidiomycete cell is selected from the genus of cystis, Gelatoporia, Hapalopilus, Irpiciporus, Ischno Tomophagus. derma, Leptoporus, Myriadoporus, Porpomyces, 1662. 1413. The bioactive agent according to item 1401, Pouzaroporia, Sarcoporia, Sonion and Spongipellis. wherein Basidiomycete cell is selected from the genus of 1681 1432. The bioactive agent according to item 1431, Trachyderma. wherein Basidiomycete cell is selected from the genus of 1663. 1414. The bioactive agent according to item 1401, Aurantiporus. wherein Basidiomycete cell is selected from the genus of 1682. 1433. The bioactive agent according to item 1431, Whitfordia. wherein Basidiomycete cell is selected from the genus of 1664. 1415. The bioactive agent according to item 256, Bjerkandera. wherein said Basidiomycete cell belongs to a genus 1683. 1434. The bioactive agent according to item 1431, Selected from the group consisting of Anisomyces, Cerato wherein Basidiomycete cell is selected from the genus of phora, Gloeophyllum, Griseoporia, Lenzitina, Phaeocori Ceraporus. Olellus, Reisneria, Serda and Sesia. 1684. 1435. The bioactive agent according to item 1431, 1665. 1416. The bioactive agent according to item 1415, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ceriporia. Anisomyces. 1685 1436. The bioactive agent according to item 1431, 1666) 1417. The bioactive agent according to item 1415, wherein Basidiomycete cell is selected from the genus wherein Basidiomycete cell is selected from the genus of CeripOriopsis. Ceratophora. 1686) 1437. The bioactive agent according to item 1431, 1667 1418. The bioactive agent according to item 1415, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Climacocystis. Gloeophyllum. 1687 1438. The bioactive agent according to item 1431, 1668. 1419. The bioactive agent according to item 1415, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Gelatoporia. Griseoporia. 1688 1439. The bioactive agent according to item 1431, 1669. 1420. The bioactive agent according to item 1415, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hapalopilus. Lenzitina. 1689. 1440. The bioactive agent according to item 1431, 1670 1421. The bioactive agent according to item 1415, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Irpiciporus. Phaeocoriolellus. 1690 1441. The bioactive agent according to item 1431, 1671. 1422. The bioactive agent according to item 1415, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ischnoderma. Reisneria. 1691. 1442. The bioactive agent according to item 1431, 1672 1423. The bioactive agent according to item 1415, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leptoporus. Serda. 1692) 1443. The bioactive agent according to item 1431, 1673 1424. The bioactive agent according to item 1415, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Myriadoporus. Sesia. 1693. 1444. The bioactive agent according to item 1431, 1674. 1425. The bioactive agent according to item 257, wherein Basidiomycete cell is selected from the genus of wherein said Basidiomycete cell belongs to a genus Porpomyces. Selected from the group consisting of Grammothele, 1694) 1445. The bioactive agent according to item 1431, Hymenogramme, Porogramme, Theleporus and Tinctopo wherein Basidiomycete cell is selected from the genus of C. Pouzaroporia. 1675) 1426. The bioactive agent according to item 1425, 1695) 1446. The bioactive agent according to item 1431, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Grammothele. Sarcoporia. 1676) 1427. The bioactive agent according to item 1425, 1696) 1447. The bioactive agent according to item 1431, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hymenogramme. Sonion. 1677 1428. The bioactive agent according to item 1425, 1697 1448. The bioactive agent according to item 1431, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Porogramme. Spongipellis. US 2010/0O86647 A1 Apr. 8, 2010 62

1698. 1449. The bioactive agent according to item 259, 1716) 1467. The bioactive agent according to item 1449, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of Selected from the group consisting of Aegerita, Aegeritina, Gloeohypochnicium. Aegeritopsis, Amaurohydnum, Amauromyces, Athelo 1717 1468. The bioactive agent according to item 1449, derma, Brevicellicium, Bulbillomyces, Cerocorticium, wherein Basidiomycete cell is selected from the genus of Chrysoderma, Conohypha, Coronicium, Crocysporium, Hydnellum. Cyanodontia, Dermosporium, Elaphocephala, Galzinia, 1718 1469. The bioactive agent according to item 1449, Gloeohypochnicium, Hydnellum, Hyphoderma, Hyph wherein Basidiomycete cell is selected from the genus of Odontiastra, Hyphodontiella, Hypochnicium, Intextomy Hyphoderma. ces, Kneifia, Kneifiella, Lyomyces, Metulodontia, Neok 1719. 1470. The bioactive agent according to item 1449, neifia, Nodotia, Odontiopsis, Pirex, Pycnodon, wherein Basidiomycete cell is selected from the genus of Subulicium, Subulicystidium, Uncobasidium and Xvlodon. Hyphodontiastra. 1699. 1450. The bioactive agent according to item 1449, 1720 1471. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Aegerita. Hyphodontiella. 1700 1451. The bioactive agent according to item 1449, 1721 1472. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Aegeritina. Hypochnicium. 1701 1452. The bioactive agent according to item 1449, 1722) 1473. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Aegeritopsis. Intextomyces. 1702) 1453. The bioactive agent according to item 1449, 1723. 1474. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amaurohydmum. Kneifia. 1703) 1454. The bioactive agent according to item 1449, 1724 1475. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amauromyces. Kneifiella. 1704 1455. The bioactive agent according to item 1449, 1725 1476. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Atheloderma. LyOmyces. 1726 1477. The bioactive agent according to item 1449, 1705 1456. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Metulodontia. Brevicellicium. 1706 1457. The bioactive agent according to item 1449, 1727 1478. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bulbillomyces. Neokneifia. 1728. 1479. The bioactive agent according to item 1449, 1707 1458. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Nodotia. Cerocorticium. 1729. 1480. The bioactive agent according to item 1449, 1708. 1459. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Odontiopsis. Chrysoderma. 1730. 1481. The bioactive agent according to item 1449, 1709. 1460. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pirex. Conohypha. 1731 1482. The bioactive agent according to item 1449, 1710 1461. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pycnodon. Coronicium. 1732) 1483. The bioactive agent according to item 1449, 1711) 1462. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Subulicium. Crocysporium. 1733 1484. The bioactive agent according to item 1449, 1712 1463. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Subulicystidium. Cyanodontia. 1734 1485. The bioactive agent according to item 1449, 1713. 1464. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Uncobasidium. Dermosporium. 1735. 1486. The bioactive agent according to item 1449, 1714 1465. The bioactive agent according to item 1449, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Xylodon. Elaphocephala. 1736) 1487. The bioactive agent according to item 260, 1715 1466. The bioactive agent according to item 1449, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of selected from the group consisting of Abortiporus, Galzinia. Antrodia, Bornetina, Cartilosoma, Cautinia, Cladoden US 2010/0O86647 A1 Apr. 8, 2010

dron, Cladomeris, Coriolellus, Diacanthodes, Flabellopi 1757 1508. The bioactive agent according to item 1487, lus, Grifola, Henningsia, Heteroporus, Hydnopolyporus, wherein Basidiomycete cell is selected from the genus of Irpicium, Leucofomes, Loweomyces, Meripilus, Merisma, Polypilus. Physisporinus, Polypilus and Rigidoporus. 1758 1509. The bioactive agent according to item 1487, 1737 1488. The bioactive agent according to item 1487, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Rigidoporus. Abortiporus. 1759 1510. The bioactive agent according to item 261, 1738 1489. The bioactive agent according to item 1487, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of selected from the group consisting of Acia, Byssomerulius, Antrodia. Caloporia, Caloporus, Castanoporus, Ceraceohydmum, 1739 1490. The bioactive agent according to item 1487, Ceraceomerulius, Chondrostereum, Climacodon, Colum wherein Basidiomycete cell is selected from the genus of nodontia, Crustoderma, Cylindrobasidium, Dacryobolus, Bornetina. Donkia, Gloeocystidium, Gloeoporus, Gloeostereum, 1740 1491. The bioactive agent according to item 1487, Himantia, Jacksonomyces, Meruliopsis, Merulius, Mycoa wherein Basidiomycete cell is selected from the genus of cia, Mycoaciella, Phlebia, Resinicium, Ricnophora, Cartilosoma. Scopuloides, Skvortzovia and Trabecularia. 1741 1492. The bioactive agent according to item 1487, 1760 1511. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cautinia. Acia. 1742) 1493. The bioactive agent according to item 1487, 1761) 1512. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cladodendron. Byssomerulius. 1743 1494. The bioactive agent according to item 1487, 1762. 1513. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cladomeris. Caloporia. 1744. 1495. The bioactive agent according to item 1487, 1763. 1514. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Coriolellus. Caloporus. 1745 1496. The bioactive agent according to item 1487, 1764) 1515. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Diacanthodes. Castanoporus. 1746) 1497. The bioactive agent according to item 1487, 1765. 1516. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Flabellopilus. Ceraceohydmum. 1747 1498. The bioactive agent according to item 1487, 1766 1517. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Grifola. Ceraceomerulius. 1748. 1499. The bioactive agent according to item 1487, 1767. 1518. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Henningsia. Chondrostereum. 1749 1500. The bioactive agent according to item 1487, 1768. 1519. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Heteroporus. Climacodon. 1750 1501. The bioactive agent according to item 1487, 1769. 1520. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hydnopolyporus. Columnodontia. 1751 1502. The bioactive agent according to item 1487, 1770 1521. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Irpicium. Crustoderma. 1752 1503. The bioactive agent according to item 1487, 1771 1522. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Leucofomes. Cylindrobasidium. 1753 1504. The bioactive agent according to item 1487, 1772 1523. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Loweomyces. Dacryobolus. 1754 1505. The bioactive agent according to item 1487, 1773 1524. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Meripilus. Donkia. 1755 1506. The bioactive agent according to item 1487, 1774 1525. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Merisma. Gloeocystidium. 1756) 1507. The bioactive agent according to item 1487, 1775) 1526. The bioactive agent according to item 1510, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Physisporinus. Gloeoporus. US 2010/0O86647 A1 Apr. 8, 2010 64

1776) 1527. The bioactive agent according to item 1510, 1795) 1546. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Gloeostereum. Efibula. 1777 1528. The bioactive agent according to item 1510, 1796 1547. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Himantia. Erythricium. 1778. 1529. The bioactive agent according to item 1510, 1797 1548. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Jacksonomyces. Grandiniella. 1779. 1530. The bioactive agent according to item 1510, 1798. 1549. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Meruliopsis. Gyrophanopsis. 1780 1531. The bioactive agent according to item 1510, 1799 1550. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Merulius. Hjortstamia. 1781 1532. The bioactive agent according to item 1510, 1800 1551. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Mycoacia. Hydnophlebia. 1782 1533. The bioactive agent according to item 1510, 1801) 1552. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Mycoaciella. Hyphodermella. 1783. 1534. The bioactive agent according to item 1510, 1802 1553. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phlebia. Hyphodermopsis. 1784 1535. The bioactive agent according to item 1510, 1803 1554. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Resinicium. Licentia. 1785 1536. The bioactive agent according to item 1510, 1804 1555. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ricnophora. Lloydella. 1786 1537. The bioactive agent according to item 1510, 1805 1556. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Scopuloides. Lopharia. 1787] 1538. The bioactive agent according to item 1510, 1806 1557. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Skvortzovia. Membranicium. 1788 1539. The bioactive agent according to item 1510, 1807 1558. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Trabecularia. Odonticium. 1789 1540. The bioactive agent according to item 262, 1808 1559. The bioactive agent according to item 1540, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of Selected from the group consisting of Australicium, Bot Phanerochaete. rvodontia, Candelabrochaete, Ceraceomyces, Corticium, 1809 1560. The bioactive agent according to item 1540, Efibula, Erythricium, Grandiniella, Gyrophanopsis, wherein Basidiomycete cell is selected from the genus of Hjortstamia, Hydnophlebia, Hyphodermella, Hyphoder Phlebiopsis. mopsis, Licentia, Lloydella, Lopharia, Membranicium, 1810 1561. The bioactive agent according to item 1540, Odonticium, Phanerochaete, Phlebiopsis, Porostereum, wherein Basidiomycete cell is selected from the genus of Terana, Thwaitesiella and Xerocarpus. Porostereun. 1790 1541. The bioactive agent according to item 1540, 1811 1562. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Australicium. Terana. 1791. 1542. The bioactive agent according to item 1540, 1812 1563. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Botryodontia. Thwaitesiella. 1792 1543. The bioactive agent according to item 1540, 1813 1564. The bioactive agent according to item 1540, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Candelabrochaete. Xerocarpus. 1793. 1544. The bioactive agent according to item 1540, 1814 1565. The bioactive agent according to item 263, wherein Basidiomycete cell is selected from the genus of wherein said Basidiomycete cell belongs to a genus Ceraceomyces. selected from the group consisting of Actinostroma, 1794) 1545. The bioactive agent according to item 1540, Aquascypha, Beccaria, Beccariella, Bresadolina, Caripia, wherein Basidiomycete cell is selected from the genus of Cladoderris, Coralloderma, Cotylidia, Craterella, Cyma Corticium. toderma, Cyphellostereum, Granulobasidium, Infla US 2010/0O86647 A1 Apr. 8, 2010

tostereum, Podoscypha, Pseudolasiobolus, Stereogloeo Atroporus, Aurantiporellus, Australoporus, Austrolenti cystidium, Stereophyllum and Stereopsis. nus, Bresadolia, Bridgeoporus, Bulliardia, Burgoa, 1815 1566. The bioactive agent according to item 1565, Caloporus, Cellularia, Ceriomyces, Cerioporus, Cerrena, wherein Basidiomycete cell is selected from the genus of Choriphyllum, Cladoporus, Coriolopsis, Coriolus, Cryp Actinostroma. tomphalina, Cryptoporus, Cubamyces, Cyanosporus, Cys 1816) 1567. The bioactive agent according to item 1565, tidiophorus, Cystostiptoporus, Daedaleopsis, Datronia, wherein Basidiomycete cell is selected from the genus of Dendrochaete, Dendropolyporus, Dextrinosporium, Aquascypha. Dichomitus, Digitellus, Earliella, Echinochaete, Elf 1817. 1568. The bioactive agent according to item 1565, wherein Basidiomycete cell is selected from the genus of ingiella, Enslinia, Fabisporus, Faerberia, Favolus, Beccaria. Fibroporia, Flabellophora, Fomes, Fomitella, Funalia, 1818 1569. The bioactive agent according to item 1565, Fuscocerrena, Gemmularia, Geopetalum, Globifomes, wherein Basidiomycete cell is selected from the genus of Grammotheliopsis, Hansenia, Haploporus, Heliocybe, Beccariella. Hexagonia, Hirschioporus, Hornodermoporus, Incrusto 1819. 1570. The bioactive agent according to item 1565, poria, Laccocephalum, Laetifomes, Laetiporus, Lasio wherein Basidiomycete cell is selected from the genus of chlaena, Lentinopanus, Lentinus, Lentodiellum, Lento Bresadolina. dium, Lentus, Lenzites, Leptopora, Leptoporellus, 1820 1571. The bioactive agent according to item 1565, Leptotrimitus, Leucolenzites, Leucoporus, Lignosus, wherein Basidiomycete cell is selected from the genus of Lithopolyporales, Loweporus, Macrohyporia, Macropo Caripia. ria, Megasporoporia, Melanoporella, Melanoporia, Mel 1821. 1572. The bioactive agent according to item 1565, anopus, Merulioporia, Microporellus, Microporus, Molli wherein Basidiomycete cell is selected from the genus of Carpus, Mycelithe, Navisporus, Neolentinus, Cladoderris. Neolentiporus, Nigrofomes, Nigroporus, Oligoporus, 1822 1573. The bioactive agent according to item 1565, Osmoporus, Pachykytospora, Pachyma, Panus, Paramy wherein Basidiomycete cell is selected from the genus of ces, Perenniporia, PerennipOriella, Persooniana, Peta Coralloderma. loides, Phaeolus, Phaeotrametes, Pherina, Phorima, 1823 1574. The bioactive agent according to item 1565, Phyllodontia, Physisporus, Piloporia, Placodes, Pleuro wherein Basidiomycete cell is selected from the genus of pus, Pocillaria, Podofomes, Pogonomyces, Polyporellus, Cotylidia. Polyporus, Polyporus, Polyporus, Poria, Porodisculus, 1824, 1575. The bioactive agent according to item 1565, Porodiscus, Poronidulus, Poroptyche, Pseudofavoilus, wherein Basidiomycete cell is selected from the genus of Pseudophaeolus, Pseudopiptoporus, Pseudotrametes, Craterella. Ptychogaster, Pycnoporellus, Pycnoporus, Pyrofomes, 1825 1576. The bioactive agent according to item 1565, Riopa, Romelia, Royoporus, Rubroporus, Ryvardenia, wherein Basidiomycete cell is selected from the genus of Scenidium, Sclerodepsis, Sistotrema, Skeletocutis, Spar Cymatoderma. situbus, Spongiosus, Stiptophyllum, Tinctoporellus, 1826 1577. The bioactive agent according to item 1565, Tomentoporus, Trametella, Trametes, Trichaptum, Trun wherein Basidiomycete cell is selected from the genus of cospora, Tuberaster, Tvromyces, Ungulina, Vanderbylia, Cyphellostereum. Velolentinus, Xerotinus, Xerotus, Xvlometron and Xvlopi 1827 1578. The bioactive agent according to item 1565, lus. wherein Basidiomycete cell is selected from the genus of 1835 1586. The bioactive agent according to item 1585, Granulobasidium. wherein Basidiomycete cell is selected from the genus of 1828 1579. The bioactive agent according to item 1565, Abundisporus. wherein Basidiomycete cell is selected from the genus of 1836) 1587. The bioactive agent according to item 1585, Inflatostereum. wherein Basidiomycete cell is selected from the genus of 1829. 1580. The bioactive agent according to item 1565, Agarico-igniarium. wherein Basidiomycete cell is selected from the genus 1837) 1588. The bioactive agent according to item 1585, Podoscypha. wherein Basidiomycete cell is selected from the genus of 1830, 1581. The bioactive agent according to item 1565, Agaricum. wherein Basidiomycete cell is selected from the genus of 1838 1589. The bioactive agent according to item 1585, Pseudolasiobolus. wherein Basidiomycete cell is selected from the genus of 1831. 1582. The bioactive agent according to item 1565, Amyloporia. wherein Basidiomycete cell is selected from the genus of Stereogloeocystidium. 1839. 1590. The bioactive agent according to item 1585, 1832 1583. The bioactive agent according to item 1565, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amyloporiella. Stereophyllum. 1840 1591. The bioactive agent according to item 1585, 1833 1584. The bioactive agent according to item 1565, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Antromycopsis. Stereopsis. 1841) 1592. The bioactive agent according to item 1585, 1834 1585. The bioactive agent according to item 264, wherein Basidiomycete cell is selected from the genus of wherein said Basidiomycete cell belongs to a genus ApOXOna. Selected from the group consisting of Abundisporus, 1842) 1593. The bioactive agent according to item 1585, Agarico-igniarium, Agaricum, Amyloporia, Amylopori wherein Basidiomycete cell is selected from the genus of ella, Antromycopsis, Apoxona, Artolenzites, Asterochaete, Artolenzites. US 2010/0O86647 A1 Apr. 8, 2010 66

1843 1594. The bioactive agent according to item 1585, 1864. 1615. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Asterochaete. Cyanosporus. 1844 1595. The bioactive agent according to item 1585, 1865 1616. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Atroporus. Cystidiophorus. 1845 1596. The bioactive agent according to item 1585, 1866. 1617. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Aurantiporellus. Cystostiptoporus. 1846 1597. The bioactive agent according to item 1585, 1867. 1618. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Australoporus. Daedaleopsis. 1847 1598. The bioactive agent according to item 1585, 1868 1619. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Austrolentinus. Datronia. 1848. 1599. The bioactive agent according to item 1585, 1869 1620. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bresadolia. Dendrochaete. 1849 1600. The bioactive agent according to item 1585, 1870 1621. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bridgeoporus. Dendropolyporus. 1850 1601. The bioactive agent according to item 1585, 1871. 1622. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bulliardia. Dextrinosporium. 1851 1602. The bioactive agent according to item 1585, 1872 1623. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Burgoa. Dichomitus. 1852 1603. The bioactive agent according to item 1585, 1873) 1624. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Caloporus. Digitellus. 1853 1604. The bioactive agent according to item 1585, 1874 1625. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cellularia. Earliella. 1854. 1605. The bioactive agent according to item 1585, 1875 1626. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus Ceriomyces. Echinochaete. 1855 1606. The bioactive agent according to item 1585, 1876 1627. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus Cerioporus. Elfvingiella. 1856. 1607. The bioactive agent according to item 1585, 1877 1628. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cerrena. Enslinia. 1857. 1608. The bioactive agent according to item 1585, 1878 1629. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Choriphyllum. Fabisporus. 1858 1609. The bioactive agent according to item 1585, 1879 1630. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cladoporus. Faerberia. 1859 1610. The bioactive agent according to item 1585, 1880 1631. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Coriolopsis. Favolus. 1860) 1611. The bioactive agent according to item 1585, 1881 1632. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Coriolus. Fibroporia. 1861) 1612. The bioactive agent according to item 1585, 1882) 1633. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus Cryptomphalina. Flabellophora. 1862. 1613. The bioactive agent according to item 1585, 1883) 1634. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cryptoporus. Fones. 1863. 1614. The bioactive agent according to item 1585, 1884 1635. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Cubamyces. Fomitella. US 2010/0O86647 A1 Apr. 8, 2010 67

1885 1636. The bioactive agent according to item 1585, 1906 1657. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Funalia. Lentus. 1886 1637. The bioactive agent according to item 1585, 1907 1658. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Fuscocerrena. Lenzites. 1887. 1638. The bioactive agent according to item 1585, 1908 1659. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Gemmularia. Leptopora. 1888 1639. The bioactive agent according to item 1585, 1909 1660. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Geopetalum. Leptoporellus. 1889 1640. The bioactive agent according to item 1585, 1910 1661. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus wherein Basidiomycete cell is selected from the genus of Globifomes. Leptotrimitus. 1890 1641. The bioactive agent according to item 1585, 1911 1662. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Grammotheliopsis. Leucolenzites. 1891. 1642. The bioactive agent according to item 1585, 1912 1663. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hansenia. Leucoporus. 1892 1643. The bioactive agent according to item 1585, 1913 1664. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus Haploporus. Lignosus. 1893 1644. The bioactive agent according to item 1585, 1914 1665. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Heliocybe. Lithopolyporales. 1894) 1645. The bioactive agent according to item 1585, 1915. 1666. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus wherein Basidiomycete cell is selected from the genus of Hexagonia. Loweporus. 1895. 1646. The bioactive agent according to item 1585, 1916. 1667. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hirschioporus. Macrohyporia. 1896 1647. The bioactive agent according to item 1585, 1917. 1668. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Hornodermoporus. Macroporia. 1897 1648. The bioactive agent according to item 1585, 1918 1669. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Incrustoporia. Megasporoporia. 1898 1649. The bioactive agent according to item 1585, 1919 1670. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Laccocephalum. Melanoporella. 1899) 1650. The bioactive agent according to item 1585, 1920) 1671. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Laetifomes. Melanoporia. 1900 1651. The bioactive agent according to item 1585, 1921 1672. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Laetiporus. Melanopus. 1901 1652. The bioactive agent according to item 1585, 1922 1673. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lasiochlaena. Merulioporia. 1902 1653. The bioactive agent according to item 1585, 1923) 1674. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus wherein Basidiomycete cell is selected from the genus of Lentinopanus. Meruliporia. 1903) 1654. The bioactive agent according to item 1585, 1924, 1675. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus wherein Basidiomycete cell is selected from the genus of Lentinus. Microporellus. 1904) 1655. The bioactive agent according to item 1585, 1925 1676. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lentodiellum. Microporus. 1905 1656. The bioactive agent according to item 1585, 1926 1677. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Lentodium. Mollicarpus. US 2010/0O86647 A1 Apr. 8, 2010

1927. 1678. The bioactive agent according to item 1585, 1948 1699. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Mycelithe. Physisporus. 1928 1679. The bioactive agent according to item 1585, 1949 1700. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Navisporus. Piloporia. 1929 1680. The bioactive agent according to item 1585, 1950) 1701. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Neolentinus. Piloporia. 1930 1681. The bioactive agent according to item 1585, 1951 1702. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Neolentiporus. Placodes. 1931 1682. The bioactive agent according to item 1585, 1952) 1703. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Nigrofomes. Pleuropus. 1932) 1683. The bioactive agent according to item 1585, 1953) 1704. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Nigroporus. Pocillaria. 1933 1684. The bioactive agent according to item 1585, 1954) 1705. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus wherein Basidiomycete cell is selected from the genus of Oligoporus. Podofomes. 1934 1685. The bioactive agent according to item 1585, 1955 1706. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus Osmoporus. Pogonomyces. 1935. 1686. The bioactive agent according to item 1585, 1956) 1707. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pachykytospora. Polyporellus. 1936. 1687. The bioactive agent according to item 1585, 1957 1708. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pachyma. Polyporus. 1937 1688. The bioactive agent according to item 1585, 1958 1709. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Panus. Poria. 1938 1689. The bioactive agent according to item 1585, 1959 1710. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus Paramyces. Porodisculus. 1939) 1690. The bioactive agent according to item 1585, 1960 1711. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Perenniporia. Porodiscus. 1940) 1691. The bioactive agent according to item 1585, 1961) 1712. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of PerennipOriella. Poronidulus. 1941 1692. The bioactive agent according to item 1585, 1962. 1713. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Persooniana. Poroptyche. 1942) 1693. The bioactive agent according to item 1585, 1963. 1714. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Petaloides. Pseudofavoilus. 1943 1694. The bioactive agent according to item 1585, 1964. 1715. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phaeolus. Pseudophaeolus. 1944 1695. The bioactive agent according to item 1585, 1965. 1716. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phaeotrametes. Pseudopiptoporus. 1945 1696. The bioactive agent according to item 1585, 1966 1717. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus Pherina. Pseudotrametes. 1946 1697. The bioactive agent according to item 1585, 1967. 1718. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phorima. Ptychogaster. 1947. 1698. The bioactive agent according to item 1585, 1968. 1719. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Phyllodontia. Pycnoporellus. US 2010/0O86647 A1 Apr. 8, 2010 69

1969] 1720. The bioactive agent according to item 1585, 1990) 1741. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pycnoporus. Tvromyces. 1970) 1721. The bioactive agent according to item 1585, 1991. 1742. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Pyrofomes. Ungulina. 1971 1722. The bioactive agent according to item 1585, 1992) 1743. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus wherein Basidiomycete cell is selected from the genus of Riopa. Vanderbylia. 1972) 1723. The bioactive agent according to item 1585, 1993) 1744. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Romelia. Velolentinus. 1973) 1724. The bioactive agent according to item 1585, 1994) 1745. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Royoporus. Xerotinus. 1974 1725. The bioactive agent according to item 1585, 1995) 1746. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Rubroporus. Xerotus. 1975) 1726. The bioactive agent according to item 1585, 1996) 1747. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Ryvardenia. Xylometron. 1976) 1727. The bioactive agent according to item 1585, 1997 1748. The bioactive agent according to item 1585, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Scenidium. Xylopilus. 1977 1728. The bioactive agent according to item 1585, 1998 1749. The bioactive agent according to item 265, wherein Basidiomycete cell is selected from the genus of wherein said Basidiomycete cell belongs to a genus Sclerodepsis. selected from the group consisting of Cristelloporia, Echi 1978 1729. The bioactive agent according to item 1585, notrema, Fibriciellum, Fibuloporia, Galziniella, Hep wherein Basidiomycete cell is selected from the genus of tasporium, Hydnotrema, Ingoldiella, Minimedusa, Osteo Sistotrema. morpha, Paulicorticium, Repetobasidiellurn, 1979 1730. The bioactive agent according to item 1585, Repetobasidium, Sistotrema, Sistotremastrum, Sisto wherein Basidiomycete cell is selected from the genus of tremella, Sphaerobasidium, Tomentella, Trechispora and Skeletocutis. Urnobasidium. 1980) 1731. The bioactive agent according to item 1585, 1999. 1750. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Sparsitubus. Cristelloporia. 1981 1732. The bioactive agent according to item 1585, 2000 1751. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Spongiosus. Echinotrema. 1982 1733. The bioactive agent according to item 1585, 2001 1752. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Stiptophyllum. Fibriciellum. 1983) 1734. The bioactive agent according to item 1585, 2002 1753. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tinctoporellus. Fibuloporia. 1984 1735. The bioactive agent according to item 1585, 2003) 1754. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus wherein Basidiomycete cell is selected from the genus of Tomentoporus. Gaiziniella. 1985 1736. The bioactive agent according to item 1585, 2004 1755. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Trametella. Heptasporium. 1986 1737. The bioactive agent according to item 1585, 2005 1756. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Trametes. Hydnotrema. 1987. 1738. The bioactive agent according to item 1585, 2006 1757. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus Trichaptum. Ingoldiella. 1988 1739. The bioactive agent according to item 1585, 2007 1758. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Truncospora. Minimedusa. 1989 1740. The bioactive agent according to item 1585, 2008 1759. The bioactive agent according to item 1749, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tuberaster: Osteomorpha. US 2010/0O86647 A1 Apr. 8, 2010 70

2009 1760. The bioactive agent according to item 1749, 2028. 1779. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Paulicorticium. Australohydnum. 2010, 1761. The bioactive agent according to item 1749, 2029 1780. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Repetobasidiellum. Baeostratoporus. 2011 1762. The bioactive agent according to item 1749, 2030, 1781. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Repetobasidium. Chaetoporus. 2012 1763. The bioactive agent according to item 1749, 2031) 1782. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Sistotrema. Cinereomyces. 2013, 1764. The bioactive agent according to item 1749, 2032 1783. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Sistotremastrum. Diplomitoporus. 2014 1765. The bioactive agent according to item 1749, 2033 1784. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Sistotremella. Etheirodon. 2015 1766. The bioactive agent according to item 1749, 2034 1785. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Sphaerobasidium. Fibricium. 2016 1767. The bioactive agent according to item 1749, 2035 1786. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Tomentella. Flaviporus. 2017. 1768. The bioactive agent according to item 1749, 2036) 1787. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Trechispora. Flavodon. 2018 1769. The bioactive agent according to item 1749, 2037 1788. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Urnobasidium. Irpex. 2019 1770. The bioactive agent according to item 266, 2038 1789. The bioactive agent according to item 1775, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of Selected from the group consisting of Bondarcevomyces, Junghuhnia. Masseeola, Sparassiella and Sparassis. 2020, 1771. The bioactive agent according to item 1770, 2039 1790. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Bondarcevomyces. Lamelloporus. 2021. 1772. The bioactive agent according to item 1770, 2040 1791. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Masseeola. Laschia. 2022 1773. The bioactive agent according to item 1770, 2041 1792. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Sparassiella. Leptodon. 2023, 1774. The bioactive agent according to item 1770, 2042 1793. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Sparassis. Metuloidea. 2024, 1775. The bioactive agent according to item 267, 2043 1794. The bioactive agent according to item 1775, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is selected from the genus of Selected from the group consisting of Amethicium, Antro Mycoleptodon. diella, Aschersonia, Australohydnum, Baeostratoporus, 2044 1795. The bioactive agent according to item 1775, Chaetoporus, Cinereomyces, Diplomitoporus, Etheiro wherein Basidiomycete cell is selected from the genus of don, Fibricium, Flaviporus, Flavodon, Irpex, Junghuhnia, Mycoleptodonoides. Lamelloporus, Laschia, Leptodon, Metuloidea, Mycolept 2045 1796. The bioactive agent according to item 1775, Odon, Mycoleptodonoides, Mycorrhaphium, Odontia, wherein Basidiomycete cell is selected from the genus of Odontina, Spathulina, Steccherinum and Stegiacantha. Mycorrhaphium. 2025 1776. The bioactive agent according to item 1775, 2046 1797. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Amethicium. Odontia. 2026 1777. The bioactive agent according to item 1775, 2047 1798. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Antrodiella. Odontina. 2027 1778. The bioactive agent according to item 1775, 2048 1799. The bioactive agent according to item 1775, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is selected from the genus of Aschersonia. Spathulina. US 2010/0O86647 A1 Apr. 8, 2010

2049 1800. The bioactive agent according to item 1775, cupreo-brunneus, Agaricus diminutivus, Agaricus fiasco wherein Basidiomycete cell is selected from the genus fibrillosus, Agaricus fiscovelatus, Agaricus hondensis, Steccherinum. Agaricus lilaceps, Agaricus micromegathus, Agaricus 2050 1801. The bioactive agent according to item 1775, praeclaresquamosus, Agaricus pattersonae, Agaricus per wherein Basidiomycete cell is selected from the genus of obscurus, Agaricus semotus, Agaricus Silvicola, Agaricus Stegiacantha. subrutilescens and Agaricus xanthodermus. 2051 1802. The bioactive agent according to item 268, 2068 1819. The bioactive agent according to item 1819, wherein said Basidiomycete cell belongs to a genus wherein Basidiomycete cell is Agaricus arorae. Selected from the group consisting of Granulocystis, Lei 2069. 1820. The bioactive agent according to item 1819, fia, Litschauerella, Tubulicium, Tubulicrinis and Tubulix wherein Basidiomycete cell is Agaricus arvensis. aCSF.C. 2070 1821. The bioactive agent according to item 1819, 2052 1803. The bioactive agent according to item 1802, wherein Basidiomycete cell is Agaricus augustus. wherein Basidiomycete cell is selected from the genus of 2071 1822. The bioactive agent according to item 1819, Granulocystis. wherein Basidiomycete cell is Agaricus benesi. 2053 1804. The bioactive agent according to item 1802, 2072, 1823. The bioactive agent according to item 1819, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is Agaricus bernardii. Leifia. 2073 1824. The bioactive agent according to item 1819, 2054 1805. The bioactive agent according to item 1802, wherein Basidiomycete cell is Agaricus bitorquis. wherein Basidiomycete cell is selected from the genus of 2074, 1825. The bioactive agent according to item 1819, Litschauerella. wherein Basidiomycete cell is Agaricus californicus. 2055 1806. The bioactive agent according to item 1802, 2075, 1826. The bioactive agent according to item 1819, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is Agaricus campestris. Tubulicium. 2076 1827. The bioactive agent according to item 1819, 2056 1807. The bioactive agent according to item 1802, wherein Basidiomycete cell is Agaricus comptulus. wherein Basidiomycete cell is selected from the genus of 2077 1828. The bioactive agent according to item 1819, Tubulicrinis. wherein Basidiomycete cell is Agaricus cupreo-brunneus. 2057 1808. The bioactive agent according to item 1802, 2078. 1829. The bioactive agent according to item 1819, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is Agaricus diminutivus. Tubulixenasma. (2079 1830. The bioactive agent according to item 1819, 2058. 1809. The bioactive agent according to item 268, wherein Basidiomycete cell is Agaricus fuscofibrillosus. wherein said Basidiomycete cell belongs to a genus 2080 1831. The bioactive agent according to item 1819, Selected from the group consisting of Aphanobasidium, wherein Basidiomycete cell is Agaricus fuscovelatus. Clitopilina, Cunninghammyces, Lepidomyces, Phlebiella, 2081 1832. The bioactive agent according to item 1819, Xenasma, Xenasmatella and Xenosperma. wherein Basidiomycete cell is Agaricus hondensis. 2059 1810. The bioactive agent according to item 1809, 2082, 1833. The bioactive agent according to item 1819, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is Agaricus lilaceps. Aphanobasidium. 2083 1834. The bioactive agent according to item 1819, 2060 1811. The bioactive agent according to item 1809, wherein Basidiomycete cell is Agaricus micromegathus. wherein Basidiomycete cell is selected from the genus of 2084 1835. The bioactive agent according to item 1819, Clitopilina. wherein Basidiomycete cell is Agaricus praeclaresquamo 2061 1812. The bioactive agent according to item 1809, SS. wherein Basidiomycete cell is selected from the genus of 2085 1836. The bioactive agent according to item 1819, Cunninghammyces. wherein Basidiomycete cell is Agaricus pattersonae. 2062 1813. The bioactive agent according to item 1809, 2086 1837. The bioactive agent according to item 1819, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is Agaricus perobscurus. Lepidomyces. 2087 1838. The bioactive agent according to item 1819, 2063. 1814. The bioactive agent according to item 1809, wherein Basidiomycete cell is Agaricus Semotus. wherein Basidiomycete cell is selected from the genus of 2088 1839. The bioactive agent according to item 1819, Phlebiella. wherein Basidiomycete cell is Agaricus Silvicola. 2064. 1815. The bioactive agent according to item 1809, 2089. 1840. The bioactive agent according to item 1819, wherein Basidiomycete cell is selected from the genus of wherein Basidiomycete cell is Agaricus Subrutilescens. Xenasma. 2090 1841. The bioactive agent according to item 1819, 2065, 1816. The bioactive agent according to item 1809, wherein Basidiomycete cell is Agaricus xanthodermus. wherein Basidiomycete cell is selected from the genus of 2091 1842. The bioactive agent according to item 925, Xenasmatella. wherein said Basidiomycete cell belongs to a species 2066 1817. The bioactive agent according to item 1809, selected from the group consisting of Schizophyllum wherein Basidiomycete cell is selected from the genus of album, Schizophyllum alneum, Schizophyllum alneum, Xenosperma. Schizophyllum amplum, Schizophyllum brasiliense, 2067 1818. The bioactive agent according to item 363, Schizophyllum brevillamellatum, Schizophyllum commune, wherein said Basidiomycete cell belongs to a species Schizophyllum egelingianum, Schizophyllum exiguum, Selected from the group consisting of Agaricus arorae, Schizophyllum fasciatum, Schizophyllum flabellare, Agaricus arvensis, Agaricus augustus, Agaricus benesi, Schizophyllum leprieurii, Schizophyllum lobatum, Schizo Agaricus bernardii, Agaricus bitorquis, Agaricus Califor phyllum mexicanum, Schizophyllum multifidum, Schizo nicus, Agaricus Campestris, Agaricus Comptulus, Agaricus phyllum murrayi, Schizophyllum mya, Schizophyllum pal US 2010/0O86647 A1 Apr. 8, 2010 72

matum, Schizophyllum radiatum, Schizophyllum cupreolaccatum, Ganoderma cupreum, Ganoderma cupu umbrinum and Schizophyllum variabile. latiprocerum, Ganoderma curranii, Ganoderma curtisii, 2092 1843. The bioactive agent according to item 1842, Ganoderma dahli, Ganoderma daiqingshanense, Gano wherein Basidiomycete cell is Schizophyllum album. derma dejongii, Ganoderma densizonatum, Ganoderma 2093 1844. The bioactive agent according to item 1842, diaoluoshanense, Ganoderma donki, Ganoderma dor wherein Basidiomycete cell is Schizophyllum alneum. sale, Ganoderma dubio-cochlear; Ganoderma dussi, 2094 1845. The bioactive agent according to item 1842, Ganoderma elmeri, Ganoderma elmerianum, Ganoderma wherein Basidiomycete cell is Schizophyllum alneum. eminii, Ganoderma endochrum, Ganoderma europaeum, 2095, 1846. The bioactive agent according to item 1842, wherein Basidiomycete cell is Schizophyllum amplum. Ganoderma exile, Ganoderma expallens, Ganoderma fas 2096 1847. The bioactive agent according to item 1842, ciatum, Ganoderma fasciculatum, Ganoderma fassii, wherein Basidiomycete cell is Schizophyllum brasiliense. Ganodermafassioides, Ganodermafici, Ganodermafia 2097 1848. The bioactive agent according to item 1842, belliforme, Ganoderma flaviporum, Ganoderma flexipes, wherein Basidiomycete cell is Schizophyllum brevilamel Ganoderma formosanum, Ganoderma formosissimum, latum. Ganoderma formicatum, Ganoderma frondosum, Gano 2098. 1849. The bioactive agent according to item 1842, derma fulvellum, Ganoderma fuscum, Ganoderma gale wherein Basidiomycete cell is Schizophyllum commune. gense, Ganoderma gelsicola, Ganoderma ghesquierei, 2099 1850. The bioactive agent according to item 1842, Ganoderma gibbosum, Ganoderma gilletii, Ganoderma wherein Basidiomycete cell is Schizophyllum egeling guadelupense, Ganoderma guinanense, Ganoderma ianum. guizhouense, Ganoderma hainanense, Ganoderma hen 2100 1851. The bioactive agent according to item 1842, ningsii, Ganoderma hildebrandii, Ganoderma hinnuleum, wherein Basidiomycete cell is Schizophyllum exiguum. Ganoderma hoehnelianum, Ganoderma holidayi, Gano 2101 1852. The bioactive agent according to item 1842, derma hoploides, Ganoderma hypoxanthum, Ganoderma wherein Basidiomycete cell is Schizophyllum fasciatum. impolitum, Ganoderma incrassatum, Ganoderma incrustatum, Ganoderma infilgens, Ganoderma 2102 1853. The bioactive agent according to item 1842, infundibuliforme, Ganoderma insulare, Ganoderma inter wherein Basidiomycete cell is Schizophyllum flabellare. medium, Ganoderma japonicum, Ganoderma jianfenglin 2103 1854. The bioactive agent according to item 1842, gense, Ganoderma koningsbergii, Ganoderma kosteri, wherein Basidiomycete cell is Schizophyllum leprieurii. Ganoderma kunmingense, Ganoderma laccatum, Gano 2104) 1855. The bioactive agent according to item 1842, derma lamaoense, Ganoderma leptopum, Ganoderma leu wherein Basidiomycete cell is Schizophyllum lobatum. cocreas, Ganoderma leucophaeum, Ganoderma leytense, 2105 1856. The bioactive agent according to item 1842, Ganoderma lignosum, Ganoderma limushanense, Gano wherein Basidiomycete cell is Schizophyllum mexicanum. derma lingua, Ganoderma linhartii, Ganoderma lioninetii, 2106 1857. The bioactive agent according to item 1842, Ganoderma lipsiense, Ganoderma lovdii, Ganoderma wherein Basidiomycete cell is Schizophyllum multifidum. lobatoideum, Ganoderma lobatum, Ganoderma longipes, 2107 1858. The bioactive agent according to item 1842, Ganoderma longistipatum, Ganoderma longistipitatum, wherein Basidiomycete cell is Schizophyllum murrayi. Ganoderma lorenzianum, Ganoderma lucidum, Gano 2108 1859. The bioactive agent according to item 1842, derma lusambilaense, Ganoderma luteicinctum, Gano wherein Basidiomycete cell is Schizophyllum mya. derma luteomarginiatum, Ganoderma luteum, Ganoderma 2109 1860. The bioactive agent according to item 1842, macer, Ganoderma magniporum, Ganoderma maitlandil, wherein Basidiomycete cell is Schizophyllum palmatum. Ganoderma malayanum, Ganoderma malosporum, Gano 2110 1861. The bioactive agent according to item 1842, derma mangiferae, Ganoderma manoutchehrii, Gano wherein Basidiomycete cell is Schizophyllum radiatum. derma mastoporum, Ganoderma mediosimense, Gano 2111 1862. The bioactive agent according to item 1842, derma megaloma, Ganoderma megalosporum, wherein Basidiomycete cell is Schizophyllum umbrinum. Ganoderma meijiangense, Ganoderma melanophaeum, 2112 1863. The bioactive agent according to item 1842, Ganoderma meredithiae, Ganoderma microsporum, wherein Basidiomycete cell is Schizophyllum variabile. Ganoderma miniatocinctum, Ganoderma mirabile, Gano 2113 1864. The bioactive agent according to item 1406, derma mirivelutinum, Ganoderma mongolicum, Gano wherein said Basidiomycete cell belongs to a species derma multicornum, Ganoderma multipileum, Gano Selected from the group consisting of Ganoderma adsper derma multiplicatum, Ganoderma namutambalaense, sum, Ganoderma africanum, Ganoderma applanatum, Ganoderma neglectus, Ganoderma neojaponicum, Gano Ganoderma arcuatum, Ganoderma areolatum, Gano derma neurosporum, Ganoderma nevadense, Ganoderma derma bakeri, Ganoderma balabacense, Ganoderma nigrolucidum, Ganoderma nitens, Ganoderma initidum, cacainum, Ganoderma calcigenum, Ganoderma calido Ganoderma noukahivense, Ganoderma mutans, Gano philum, Ganoderma camphoratum, Ganoderma derma Obockense, Ganoderma obokensis, Ganoderma cantharelloideum, Ganoderma capense, Ganoderma car ochrolaccatum, Ganoderma Oerstedii, Ganoderma nosum, Ganoderma cehengense, Ganoderma cervinum, Omphalodes, Ganoderma opacum, Ganoderma orbiforme, Ganoderma chafangeonii, Ganoderma chalceum, Gano Ganoderma Oregonense, Ganoderma oroflavum, Gano derma chaperi, Ganoderma chenhaiense, Ganoderma derma Oroleucum, Ganoderma Ostracodes, Ganoderma chilense, Ganoderma chiungchungense, Ganoderma Ostreatum, Ganoderma papillatum, Ganoderma parviun chonoides, Ganoderma cochlear, Ganoderma coffeatum, gulatum, Ganoderma parvulum, Ganoderma pernanum, Ganoderma colossus, Ganoderma comorense, Gano Ganoderma personatum, Ganoderma perturbatum, Gano derma comphoratum, Ganoderma concinnum, Gano derma petchi, Ganoderma pfeifferi, Ganoderma philippi, derma conicus, Ganoderma corrugatum, Ganoderma cos Ganoderma piatense, Ganoderma plicatum, Ganoderma tattiS, Ganoderma crebrostriatum, Ganoderma polychromum, Ganoderma polymorphum, Ganoderma US 2010/0O86647 A1 Apr. 8, 2010

praelongum Murrill, Ganoderma praetervisum, Giano 2124 1875. The bioactive agent according to item 1864, derma preussi, Ganoderma pseudoboletus, Ganoderma wherein Basidiomycete cell is Ganoderma calidophilum. pseudoferreum, Ganoderma puberulum, Ganoderma 2125 1876. The bioactive agent according to item 1864, pugilisii, Ganoderma pulchella, Ganoderma pullatum, wherein Basidiomycete cell is Ganoderma camphoratum. Ganoderma pulverulentum, Ganoderma pygmoideum, 2126, 1877. The bioactive agent according to item 1864, Ganoderma ramosissimum, Ganoderma ravenelii, Gano wherein Basidiomycete cell is Ganoderma cantharelloi derma renidens, Ganoderma renii, Ganoderma resina deum. ceum, Ganoderma reticulatosporum, Ganoderma rha 2127 1878. The bioactive agent according to item 1864, codes, Ganoderma rivulosum, Ganoderma rothwelli, wherein Basidiomycete cell is Ganoderma Capense. Ganoderma rotundatum, Ganoderma rubeolum, Gano 2128 1879. The bioactive agent according to item 1864, derma rude, Ganoderma rufoalbum, Ganoderma rufoba wherein Basidiomycete cell is Ganoderma carnosum. dium, Ganoderma rugosissimus, Ganoderma rugosum, 2129, 1880. The bioactive agent according to item 1864, Ganoderma Sanmingense, Ganoderma Sarasinii, Gano wherein Basidiomycete cell is Ganoderma cehengense. derma Schomburgkii, Ganoderma scuipturatum, Gano 2130 1881. The bioactive agent according to item 1864, derma septatum, Ganoderma sequoiae, Ganoderma wherein Basidiomycete cell is Ganoderma cervinum. sessile, Ganoderma sessiliforme, Ganoderma Shandon 2131, 1882. The bioactive agent according to item 1864, gense, Ganoderma Shangsiens, Ganoderma Sichuanense, wherein Basidiomycete cell is Ganoderma chafangeonii. Ganoderma Sikorae, Ganoderma silveirae, Ganoderma 2132) 1883. The bioactive agent according to item 1864, Simaoense, Ganoderma simulans, Ganoderma sinense, wherein Basidiomycete cell is Ganoderma chalceum. Ganoderma Soniense, Ganoderma soveri, Ganoderma 2133 1884. The bioactive agent according to item 1864, Sprucei, Ganoderma Staneri, Ganoderma Stevaertanum, wherein Basidiomycete cell is Ganoderma chaperi. Ganoderma stipitatum, Ganoderma Stratoideum, Gano 2134 1885. The bioactive agent according to item 1864, derma subamboinense, Ganoderma subfornicatum, wherein Basidiomycete cell is Ganoderma chenhaiense. Ganoderma subfilvum, Ganoderma subincrustatum, 2135 1886. The bioactive agent according to item 1864, Ganoderma sublucidum, Ganoderma subperforatum, wherein Basidiomycete cell is Ganoderma chilense. Ganoderma subrenatum, Ganoderma subresinosum, 2136 1887. The bioactive agent according to item 1864, Ganoderma subrugosus, Ganoderma substipitata, Gano wherein Basidiomycete cell is Ganoderma chiungchun derma subtornatum, Ganoderma subtuberculosum, Gano gense. derma subumbraculum, Ganoderma sulcatum, Gano 2137 1888. The bioactive agent according to item 1864, derma tenue, Ganoderma testaceum, Ganoderma wherein Basidiomycete cell is Ganoderma chonoides. theaecolumn, Ganoderma tibetanum, Ganoderma torna 2138 1889. The bioactive agent according to item 1864, tum, Ganoderma torosum, Ganoderma torrendii, Gano wherein Basidiomycete cell is Ganoderma cochlear: derma trengganuense, Ganoderma triangulum, Gano 2139 1890. The bioactive agent according to item 1864, derma triviale, Ganoderma tropicum, Ganoderma trulla, wherein Basidiomycete cell is Ganoderma coffeatum. Ganoderma trulliforme, Ganoderma tsugae, Ganoderma 2140 1891. The bioactive agent according to item 1864, tsunodae, Ganoderma tuberculosum, Ganoderma tumi wherein Basidiomycete cell is Ganoderma colossus. dum, Ganoderma umbraculum, Ganoderma umbrinum, 2141 1892. The bioactive agent according to item 1864, Ganoderma ungulatum, Ganoderma valesiacum, Gano wherein Basidiomycete cell is Ganoderma Comorense. derma vanheurnii, Ganoderma vanmeelii, Ganoderma 2142) 1893. The bioactive agent according to item 1864, variabile, Ganoderma weberianum, Ganoderma william wherein Basidiomycete cell is Ganoderma comphoratum. sianum, Ganoderma wuhuense, Ganoderma wynaadense, 2143 1894. The bioactive agent according to item 1864, Ganoderma xanthocreas, Ganoderma xingviense, Gano wherein Basidiomycete cell is Ganoderma concinnum. derma xylodes, Ganoderma xylonoides, Ganoderma Zhen 2144 1895. The bioactive agent according to item 1864, ningense and Ganoderma Zonatum. wherein Basidiomycete cell is Ganoderma conicus. 2114 1865. The bioactive agent according to item 1864, 2145 1896. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma adspersum. wherein Basidiomycete cell is Ganoderma corrugatum. 2115 1866. The bioactive agent according to item 1864, 2146 1897. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma africanum. wherein Basidiomycete cell is Ganoderma costatus. 2116 1867. The bioactive agent according to item 1864, 2147 1898. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma applanatum. wherein Basidiomycete cell is Ganoderma crebrostriatum. 2117, 1868. The bioactive agent according to item 1864, 2148, 1899. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma arcuatum. wherein Basidiomycete cell is Ganoderma cupreolacca 2118 1869. The bioactive agent according to item 1864, titlin. wherein Basidiomycete cell is Ganoderma areolatum. 2149) 1900. The bioactive agent according to item 1864, 2119 1870. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma curranii. wherein Basidiomycete cell is Ganoderma bakeri. 2150 1901. The bioactive agent according to item 1864, 2120 1871. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma curtisii. wherein Basidiomycete cell is Ganoderma balabacense. 2151 1902. The bioactive agent according to item 1864, 2121 1872. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma dahlii. wherein Basidiomycete cell is Ganoderma cacainum. 2152 1903. The bioactive agent according to item 1864, 2122 1873. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma daiqingshan wherein Basidiomycete cell is Ganoderma cacainum. aSé. 2123 1874. The bioactive agent according to item 1864, 2153. 1904. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma calcigenum. wherein Basidiomycete cell is Ganoderma dejongi. US 2010/0O86647 A1 Apr. 8, 2010 74

2154 1905. The bioactive agent according to item 1864, 2184 1935. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma densizonatum. wherein Basidiomycete cell is Ganoderma gilletii. 2155 1906. The bioactive agent according to item 1864, 2185 1936. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma diaoluoshan wherein Basidiomycete cell is Ganoderma guadelupense. aSé. 2186 1937. The bioactive agent according to item 1864, 2156) 1907. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma guinanense. wherein Basidiomycete cell is Ganoderma donki. 2187. 1938. The bioactive agent according to item 1864, 2157) 1908. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma guizhouense. wherein Basidiomycete cell is Ganoderma dorsale. 2188) 1939. The bioactive agent according to item 1864, 2158) 1909. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma hainanense. wherein Basidiomycete cell is Ganoderma dubio-co 2189 1940. The bioactive agent according to item 1864, chlear: wherein Basidiomycete cell is Ganoderma henningsii. 2159 1910. The bioactive agent according to item 1864, 2190 1941. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma dussii. wherein Basidiomycete cell is Ganoderma hildebrandii. 2160 1911. The bioactive agent according to item 1864, 2191 1942. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma elmeri. wherein Basidiomycete cell is Ganoderma hinnuleum. 2161 1912. The bioactive agent according to item 1864, 2192 1943. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma elmerianum. wherein Basidiomycete cell is Ganoderma hoehnelianum. 2193 1944. The bioactive agent according to item 1864, 2162, 1913. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma hollidayi. wherein Basidiomycete cell is Ganoderma eminii. 2194) 1945. The bioactive agent according to item 1864, 2163 1914. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma hoploides. wherein Basidiomycete cell is Ganoderma endochrum. 2195 1946. The bioactive agent according to item 1864, 2164) 1915. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma hypoxanthum. wherein Basidiomycete cell is Ganoderma europaeum. 2196. 1947. The bioactive agent according to item 1864, 2165 1916. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma impolitum. wherein Basidiomycete cell is Ganoderma exile. 2197 1948. The bioactive agent according to item 1864, 2166 1917. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma incrassatum. wherein Basidiomycete cell is Ganoderma expallens. 2198) 1949. The bioactive agent according to item 1864, 2167 1918. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma incrustatum. wherein Basidiomycete cell is Ganoderma fasciatum. 2199) 1950. The bioactive agent according to item 1864, 2168) 1919. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma infiulgens. wherein Basidiomycete cell is Ganodermafassii. 2200 1951. The bioactive agent according to item 1864, 2169 1920. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma infundibuli wherein Basidiomycete cell is Ganodermafassioides. forme. 2170 1921. The bioactive agent according to item 1864, 2201 1952. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganodermafici. wherein Basidiomycete cell is Ganoderma insulare. 2171) 1922. The bioactive agent according to item 1864, 2202 1953. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma flabelliforme. wherein Basidiomycete cell is Ganoderma intermedium. 2172 1923. The bioactive agent according to item 1864, 2203) 1954. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma flaviporum. wherein Basidiomycete cell is Ganoderma japonicum. 2173) 1924. The bioactive agent according to item 1864, 2204 1955. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma flexipes. wherein Basidiomycete cell is Ganoderma jianfenglin 2174 1925. The bioactive agent according to item 1864, gense. wherein Basidiomycete cell is Ganoderma formosanum. 2205 1956. The bioactive agent according to item 1864, 2175) 1926. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma koningsbergii. wherein Basidiomycete cell is Ganoderma formosissi 2206 1957. The bioactive agent according to item 1864, FiFi. wherein Basidiomycete cell is Ganoderma kosteri. 2176 1927. The bioactive agent according to item 1864, 2207 1958. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma formicatum. wherein Basidiomycete cell is Ganoderma kunmingense. 2177 1928. The bioactive agent according to item 1864, 2208 1959. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganodermafrondosum. wherein Basidiomycete cell is Ganoderma laccatum. 2178 1929. The bioactive agent according to item 1864, 2209 1960. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganodermafiulvellum. wherein Basidiomycete cell is Ganoderma lamaoense. 2179 1930. The bioactive agent according to item 1864, 2210 1961. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma fiscum. wherein Basidiomycete cell is Ganoderma leptopum. 2180 1931. The bioactive agent according to item 1864, 2211 1962. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma gallegense. wherein Basidiomycete cell is Ganoderma leucocreas. 2181 1932. The bioactive agent according to item 1864, 2212 1963. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma gelsicola. wherein Basidiomycete cell is Ganoderma leucophaeum. 2182 1933. The bioactive agent according to item 1864, 2213 1964. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma ghesquierei. wherein Basidiomycete cell is Ganoderma leytense. 2183. 1934. The bioactive agent according to item 1864, 2214 1965. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma gibbosum. wherein Basidiomycete cell is Ganoderma lignosum. US 2010/0O86647 A1 Apr. 8, 2010 75

2215 1966. The bioactive agent according to item 1864, 2246) 1997. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma limushanense. wherein Basidiomycete cell is Ganoderma miniatocinc 221 6 1967. The bioactive agent according to item 1864, titlin. wherein Basidiomycete cell is Ganoderma lingua. 2247 1998. The bioactive agent according to item 1864, 2217 1968. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma mirabile. wherein Basidiomycete cell is Ganoderma linhartii. 2248) 1999. The bioactive agent according to item 1864, 2218 1969. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma mirivelutinum. wherein Basidiomycete cell is Ganoderma lionnetii. 2249 2000. The bioactive agent according to item 1864, 2219 1970. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma mongolicum. wherein Basidiomycete cell is Ganoderma lipsiense. 2250 2001. The bioactive agent according to item 1864, 2220 1971. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma multicornum. wherein Basidiomycete cell is Ganoderma lovdii. 2251 2002. The bioactive agent according to item 1864, 2221 1972. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma multipileum. wherein Basidiomycete cell is Ganoderma lobatoideum. 2252 2003. The bioactive agent according to item 1864, 2222 1973. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma multiplicatum. wherein Basidiomycete cell is Ganoderma lobatum. 2223 1974. The bioactive agent according to item 1864, 2253 2004. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma longipes. wherein Basidiomycete cell is Ganoderma namutambal 2224, 1975. The bioactive agent according to item 1864, CéSé. wherein Basidiomycete cell is Ganoderma longistipatum. 2254 2005. The bioactive agent according to item 1864, 2225 1976. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma neglectus. wherein Basidiomycete cell is Ganoderma lorenzianum. 2255 2006. The bioactive agent according to item 1864, 2226, 1977. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma neojaponicum. wherein Basidiomycete cell is Ganoderma lucidum. 2256 2007. The bioactive agent according to item 1864, 2227 1978. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma neurosporum. wherein Basidiomycete cell is Ganoderma lusambilaense. 2257 2008. The bioactive agent according to item 1864, 2228 1979. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma nevadense. wherein Basidiomycete cell is Ganoderma luteicinctum. 2258 2009. The bioactive agent according to item 1864, 2229 1980. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma nigrolucidum. wherein Basidiomycete cell is Ganoderma luteomar 2259 2010. The bioactive agent according to item 1864, ginatum. wherein Basidiomycete cell is Ganodermanitens. 2230 1981. The bioactive agent according to item 1864, 2260 2011. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma luteum. wherein Basidiomycete cell is Ganodermanitidum. 2231, 1982. The bioactive agent according to item 1864, 2261 2012. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma macer. wherein Basidiomycete cell Ganoderma noukahivense. 2232) 1983. The bioactive agent according to item 1864, 2262 2013. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma magniporum. wherein Basidiomycete cell is Ganoderma mutans. 2233 1984. The bioactive agent according to item 1864, 2263 2014. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma maitlandii. wherein Basidiomycete cell is Ganoderma Obockense. 2234 1985. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma malayanum. 2264 2015. The bioactive agent according to item 1864, 2235. 1986. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma obokensis. wherein Basidiomycete cell is Ganoderma malosporum. 2265 2016. The bioactive agent according to item 1864, 2236 1987. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma ochrolaccatum. wherein Basidiomycete cell is Ganoderma mangiferae. 2266 2017. The bioactive agent according to item 1864, 2237) 1988. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma Oerstedii. wherein Basidiomycete cell is Ganoderma manoutchehrii. 2267 2018. The bioactive agent according to item 1864, 2238 1989. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma Omphalodes. wherein Basidiomycete cell is Ganoderma mastoporum. 2268 2019. The bioactive agent according to item 1864, 2239 1990. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma opacum. wherein Basidiomycete cell is Ganoderma mediosimense. 2269 2020. The bioactive agent according to item 1864, 2240 1991. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma orbiforme. wherein Basidiomycete cell is Ganoderma megaloma. 2270 2021. The bioactive agent according to item 1864, 2241) 1992. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma Oregonense. wherein Basidiomycete cell is Ganoderma megalosporum. 2271 2022. The bioactive agent according to item 1864, 2242) 1993. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma oroflavum. wherein Basidiomycete cell is Ganoderma meijiangense. 2272 2023. The bioactive agent according to item 1864, 2243) 1994. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma Oroleucum. wherein Basidiomycete cell is Ganoderma mel 2273 2024. The bioactive agent according to item 1864, anophaeum. wherein Basidiomycete cell is Ganoderma Ostracodes. 2244) 1995. The bioactive agent according to item 1864, 2274) 2025. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma meredithiae. wherein Basidiomycete cell is ostreatum. 22.45 1996. The bioactive agent according to item 1864, 2275 2026. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma microsporum. wherein Basidiomycete cell is Ganoderma papillatum. US 2010/0O86647 A1 Apr. 8, 2010 76

2276 2027. The bioactive agent according to item 1864, 2306. 2057. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma parviungula wherein Basidiomycete cell is Ganoderma rivulosum. titlin. 23.07 2058. The bioactive agent according to item 1864, 2277 2028. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma rothwellii. wherein Basidiomycete cell is Ganoderma parvulum. 2308. 2059. The bioactive agent according to item 1864, 2278 2029. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma rotundatum. wherein Basidiomycete cell is Ganoderma pernanum. 2309. 2060. The bioactive agent according to item 1864, 2279 2030. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma rubeolum. wherein Basidiomycete cell is Ganoderma personatum. 2310 2061. The bioactive agent according to item 1864, 228.0 2031. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma rude. wherein Basidiomycete cell is Ganoderma perturbatum. 2311 2062. The bioactive agent according to item 1864, 2281. 2032. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma rufoalbum. wherein Basidiomycete cell is Ganoderma petchii. 2312 2063. The bioactive agent according to item 1864, 2282 2033. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma rufobadium. wherein Basidiomycete cell is Ganoderma pfeifferi. 2313 2064. The bioactive agent according to item 1864, 2283 2034. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma rugosissimus. wherein Basidiomycete cell is Ganoderma philippi. 2314 2065. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma rugosum. 2284 2035. The bioactive agent according to item 1864, 2315 2066. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma platense. wherein Basidiomycete cell is Ganoderma Sanmingense. 2285 2036. The bioactive agent according to item 1864, 2316 2067. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma plicatum. wherein Basidiomycete cell is Ganoderma Sarasinii. 2286 2037. The bioactive agent according to item 1864, 2317 2068. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma polychromum. wherein Basidiomycete cell is Ganoderma schomburgkii. 2287 2038. The bioactive agent according to item 1864, 2318, 2069. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma polymorphum. wherein Basidiomycete cell is Ganoderma sculpturatum. 2288. 2039. The bioactive agent according to item 1864, 2319 2070. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma praelongum. wherein Basidiomycete cell is Ganoderma septatum. 2289 2040. The bioactive agent according to item 1864, 2320 2071. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma praetervisum. wherein Basidiomycete cell is Ganoderma sequoiae. 2290 2041. The bioactive agent according to item 1864, 2321 2072. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma preussii. wherein Basidiomycete cell is Ganoderma sessile. 2291) 2042. The bioactive agent according to item 1864, 2322 2073. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma pseudoboletus. wherein Basidiomycete cell is Ganoderma sessiliforme. 2292) 2043. The bioactive agent according to item 1864, 2323 2074. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma pseudofer wherein Basidiomycete cell is Ganoderma Shandongense. FeliFi. 2324 2075. The bioactive agent according to item 1864, 2293 2044. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma Shangsiens. wherein Basidiomycete cell is Ganoderma puberulum. 2325 2076. The bioactive agent according to item 1864, 2294 2045. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma Sichuanense. wherein Basidiomycete cell is Ganoderma pugilisii. 2326 2077. The bioactive agent according to item 1864, 2295 2046. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma Sikorae. wherein Basidiomycete cell is Ganodermapulchella. 2327 2078. The bioactive agent according to item 1864, 2296 2047. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma silveirae. wherein Basidiomycete cell is Ganoderma pullatum. 2328 2079. The bioactive agent according to item 1864, 2297 2048. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma Simaoense. wherein Basidiomycete cell is Ganoderma pulverulentum. 2329 2080. The bioactive agent according to item 1864, 2298) 2049. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma simulans. wherein Basidiomycete cell is Ganoderma pygmoideum. 2330 2081. The bioactive agent according to item 1864, 2299| 2050. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma sinense. wherein Basidiomycete cell is Ganoderma ranosissimum. 2331, 2082. The bioactive agent according to item 1864, 2300 2051. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma Soniense. wherein Basidiomycete cell is Ganoderma ravenelii. 2332) 2083. The bioactive agent according to item 1864, 2301. 2052. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma soveri. wherein Basidiomycete cell is Ganoderma renidens. 2333 2084. The bioactive agent according to item 1864, 2302. 2053. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma sprucei. wherein Basidiomycete cell is Ganoderma renii. 2334 2085. The bioactive agent according to item 1864, 2303 2054. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma staneri. wherein Basidiomycete cell is Ganoderma resinaceum. 2335 2086. The bioactive agent according to item 1864, 2304 2055. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma Stevaertanum. wherein Basidiomycete cell is Ganoderma reticu 2336 2087. The bioactive agent according to item 1864, latosporum. wherein Basidiomycete cell is Ganoderma stipitatum. 2305 2056. The bioactive agent according to item 1864, 2337) 2088. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma rhacode. wherein Basidiomycete cell is Ganoderma Stratoideum. US 2010/0O86647 A1 Apr. 8, 2010 77

2338 2089. The bioactive agent according to item 1864, 2367 2118. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma subamboin wherein Basidiomycete cell is Ganoderma tuberculosum. aSé. 2368 2119. The bioactive agent according to item 1864, 2339 2090. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma tumidium. wherein Basidiomycete cell is Ganoderma subformica 2369. 2120. The bioactive agent according to item 1864, titlin. wherein Basidiomycete cell is Ganoderma umbraculum. 2340 2091. The bioactive agent according to item 1864, 2370 2121. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma subfiulvum. wherein Basidiomycete cell is Ganoderma umbrinum. 2341 2092. The bioactive agent according to item 1864, 2371. 2122. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma subin wherein Basidiomycete cell is Ganoderma ungulatum. Crtist attlin. 2372. 2123. The bioactive agent according to item 1864, 2342 2093. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma valesiacum. wherein Basidiomycete cell is Ganoderma sublucidum. |2373. 2124. The bioactive agent according to item 1864, 2343 2094. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma vanheurnii. wherein Basidiomycete cell is Ganoderma subperforatum. 2374. 2125. The bioactive agent according to item 1864, 2344, 2095. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma vanmeelii. wherein Basidiomycete cell is Ganoderma subrenatum. 2375 2126. The bioactive agent according to item 1864, 2345. 2096. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma variabile. wherein Basidiomycete cell is Ganoderma subresinosum. 2376) 2127. The bioactive agent according to item 1864, 2346 2097. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma weberianum. wherein Basidiomycete cell is Ganoderma subrugosus. 2377 2128. The bioactive agent according to item 1864, 2347. 2098. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma williamsianum. wherein Basidiomycete cell is Ganoderma substipitata. 2378 2129. The bioactive agent according to item 1864, 2348. 2099. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma wuhuense. wherein Basidiomycete cell is Ganoderma subtornatum. 2379 2130. The bioactive agent according to item 1864, 2349 2100. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma w’naadense. wherein Basidiomycete cell is Ganoderma subtuberculo 238.0 2131. The bioactive agent according to item 1864, St. wherein Basidiomycete cell is Ganoderma xanthocreas. 2350 2101. The bioactive agent according to item 1864, 2381 2132. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma subumbracu wherein Basidiomycete cell is Ganoderma Xingyiense. lum. 2382) 2133. The bioactive agent according to item 1864, 2351 2102. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma xylodes. wherein Basidiomycete cell is Ganoderma sulcatum. 2383 2134. The bioactive agent according to item 1864, 2352 2103. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma xylonoides. wherein Basidiomycete cell is Ganoderma tenue. 2384 2135. The bioactive agent according to item 1864, 2353 2104. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma Zhenningense. wherein Basidiomycete cell is Ganoderma testaceum. 2385 2136. The bioactive agent according to item 1864, 2354 2105. The bioactive agent according to item 1864, wherein Basidiomycete cell is Ganoderma Zonatum. wherein Basidiomycete cell is Ganoderma theaecolum. 2386 2137. The bioactive agent according to item 1498, 2355 2106. The bioactive agent according to item 1864, wherein said Basidiomycete cell belongs to a species wherein Basidiomycete cell is Ganoderma tibetanum. selected from the group consisting of Grifola acanthoides, 2356 2107. The bioactive agent according to item 1864, Grifola albicans, Grifola armeniaca, Grifola badia, Gri wherein Basidiomycete cell is Ganoderma tornatum. fola colensoi, Grifolia eos, Grifola fractipes, Grifola fron 2357 2108. The bioactive agent according to item 1864, dosa, Grifola gargal, Grifola gigantea, Grifola intybacea, wherein Basidiomycete cell is Ganoderma torosum. Grifola lentifrondosa, Grifola Obducta, Grifola platypora, 2358 2109. The bioactive agent according to item 1864, Grifola rosularis, Grifola SOrdulenta, Grifola suiphurea, wherein Basidiomycete cell is Ganoderma torrendii. Grifola sumstinei and Grifola tuckahoe. 2359 2110. The bioactive agent according to item 1864, 2387 2138. The bioactive agent according to item 2137, wherein Basidiomycete cell is Ganoderma trengganuense. wherein Basidiomycete cell is Grifola acanthoides. 2360 2111. The bioactive agent according to item 1864, 2388 2139. The bioactive agent according to item 2137, wherein Basidiomycete cell is Ganoderma triangulum. wherein Basidiomycete cell is Grifola albicans. 2361) 2112. The bioactive agent according to item 1864, 2389 2140. The bioactive agent according to item 2137, wherein Basidiomycete cell is Ganoderma triviale. wherein Basidiomycete cell is Grifola armeniaca. 2362. 2113. The bioactive agent according to item 1864, 2390 2141. The bioactive agent according to item 2137, wherein Basidiomycete cell is Ganoderma tropicum. wherein Basidiomycete cell is Grifola badia. 2363. 2114. The bioactive agent according to item 1864, 2391. 2142. The bioactive agent according to item 2137, wherein Basidiomycete cell is Ganoderma trulla. wherein Basidiomycete cell is Grifola colensoi. 2364 2115. The bioactive agent according to item 1864, 2392. 2143. The bioactive agent according to item 2137, wherein Basidiomycete cell is Ganoderma trulliforme. wherein Basidiomycete cell is Grifola eos. 2365 2116. The bioactive agent according to item 1864, 2393 2144. The bioactive agent according to item 2137, wherein Basidiomycete cell is Ganoderma tsugae. wherein Basidiomycete cell is Grifola fractipes. 2366 2117. The bioactive agent according to item 1864, 2394, 2145. The bioactive agent according to item 2137, wherein Basidiomycete cell is Ganoderma tsunodae. wherein Basidiomycete cell is Grifola frondosa. US 2010/0O86647 A1 Apr. 8, 2010

2395 2146. The bioactive agent according to item 2137, 2422 2173. The bioactive agent according to item 2157. wherein Basidiomycete cell is Grifola gargal. wherein Basidiomycete cell is Lentinus pulvinulus. 2396 2147. The bioactive agent according to item 2137, 2423. 2174. The bioactive agent according to item 2157. wherein Basidiomycete cell is Grifola gigantea. wherein Basidiomycete cell is Lentinus punctaticeps. 2397 2148. The bioactive agent according to item 2137, 2424. 2175. The bioactive agent according to item 2157. wherein Basidiomycete cell is Grifola inty bacea. wherein Basidiomycete cell is Lentinus pygmaeus. 2398 2149. The bioactive agent according to item 2137, 2425 2176. The bioactive agent according to item 2157. wherein Basidiomycete cell is Grifola lentifrondosa. wherein Basidiomycete cell is Lentinus Sajor-caju. 2399. 2150. The bioactive agent according to item 2137, 2426 2177. The bioactive agent according to item 2157. wherein Basidiomycete cell is Grifola obducta. wherein Basidiomycete cell is Lentinus squarrulosus. 2400 2151. The bioactive agent according to item 2137, 2427 2178. The bioactive agent according to item 2157. wherein Basidiomycete cell is Grifola platypora. wherein Basidiomycete cell is Lentinus Strigosus. 2401 2152. The bioactive agent according to item 2137, 2428 2179. The bioactive agent according to item 2157. wherein Basidiomycete cell is Grifola rosularis. wherein Basidiomycete cell is Lentinus suffrutescens. 2402. 2153. The bioactive agent according to item 2137, 2429. 2180. The bioactive agent according to item 2157. wherein Basidiomycete cell is Grifola sordulenta. wherein Basidiomycete cell is Lentinus tuber-regium. 2403 2154. The bioactive agent according to item 2137, 2430 2181. The bioactive agent according to item 2157. wherein Basidiomycete cell is Grifola sulphurea. wherein Basidiomycete cell is Lentinus Zelandicus. 2404 2155. The bioactive agent according to item 2137, 2431 2182. The bioactive agent according to item 1737, wherein Basidiomycete cell is Grifola sumstinei. wherein said Basidiomycete cell belongs to a species 2405 2156. The bioactive agent according to item 2137, selected from the group consisting of Trametes cervina, wherein Basidiomycete cell is Grifola tuckahoe. Trametes cingulata, Trametes cotonea, Trametes gibbosa, 2406. 2157. The bioactive agent according to item 1654, Trametes hirsuta, Trametes incerta, Trametes lactine, wherein said Basidiomycete cell belongs to a species Trametes maxima, Trametes meyenii, Trametes morganii, Selected from the group consisting of Lentinus albOveluti Trametes ochracea, Trametes pubescens, Trametes robin nus, Lentinus anthocephalus, Lentinus badius, Lentinus iophila, Trametes suaveolens, Trametes subsinuosa, Tram castoreus, Lentinus chrysopeplus, Lentinus cochleatus, etes tegularis, Trametes tenuis, Trametes trabea, Trametes Lentinus concinnus, Lentinus delicatus, Lentinus edodes, umbrina, Trametes unicolor; Trametes versicolor; Trametes Lentinus fasciatus, Lentinus hyracinus, Lentinus lepideus villosa and Trametes Zonata. sensu, Lentinus lepideus, Lentinus novaezelandiae, Lenti nus pulvinulus, Lentinus punctaticeps, Lentinus punctati 2432 2183. The bioactive agent according to item 2182, Ceps, Lentinus pygmaeus, Lentinus Sajor-Caju, Lentinus wherein Basidiomycete cell is Trametes cervina. squarrulosus, Lentinus Strigosus, Lentinus suffrutescens, 2433) 2184. The bioactive agent according to item 2182, Lentinus tuber-regium and Lentinus Zelandicus. wherein Basidiomycete cell is Trametes cingulata. 24.07 2158. The bioactive agent according to item 2157. 2434) 2185. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus albovelutinus. wherein Basidiomycete cell is Trametes Cotonea. 2408 2159. The bioactive agent according to item 2157. 2435 2186. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus albovelutinus. wherein Basidiomycete cell is Trametes gibbosa. 2409 2160. The bioactive agent according to item 2157. 2436 2187. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus anthocephalus. wherein Basidiomycete cell is Trametes hirsuta. 2410 2161. The bioactive agent according to item 2157. 2437. 2188. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus badius. wherein Basidiomycete cell is Trametes incerta. 2411) 2162. The bioactive agent according to item 2157. 2438 2189. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus castoreus. wherein Basidiomycete cell is Trametes lactine. 2412. 2163. The bioactive agent according to item 2157. 2439. 2190. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus chrysopeplus. wherein Basidiomycete cell is Trametes maxima. 2413, 21.64. The bioactive agent according to item 2157. 2440 2191. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus cochleatus. wherein Basidiomycete cell is Trametes meyenii. 2414) 2165. The bioactive agent according to item 2157. 2441) 2192. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus concinnus. wherein Basidiomycete cell is Trametes morganii. 2415 2166. The bioactive agent according to item 2157. 2442. 2193. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus delicatus. wherein Basidiomycete cell is Trametes ochracea. 2416 2167. The bioactive agent according to item 2157. 2443 2194. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus edodes. wherein Basidiomycete cell is Trametes pubescens. 2417 2168. The bioactive agent according to item 2157. 2444) 2195. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus fasciatus. wherein Basidiomycete cell is Trametes robiniophila. 2418. 21.69. The bioactive agent according to item 2157. 2445 2196. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus hyracinus. wherein Basidiomycete cell is Trametes suaveolens. 2419, 2170. The bioactive agent according to item 2157. 2446 2197. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus lepideus sensu. wherein Basidiomycete cell is Trametes subsinuosa. 2420 2171. The bioactive agent according to item 2157. 2447 2198. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus lepideus. wherein Basidiomycete cell is Trametes tegularis. 2421. 2172. The bioactive agent according to item 2157. 2448 2199. The bioactive agent according to item 2182, wherein Basidiomycete cell is Lentinus novaezelandiae. wherein Basidiomycete cell is Trametes tenuis. US 2010/0O86647 A1 Apr. 8, 2010 79

2449 2200. The bioactive agent according to item 2182, product. In one embodiment the feed products do not com wherein Basidiomycete cell is Trametes trabea. prise living animals apart from microorganisms. Zooplankton 2450 2201. The bioactive agent according to item 2182, may be incubated with above-mentioned emulsion. A rela wherein Basidiomycete cell is Trametes umbrina. tively short time interval, such as 1 hour to 7 days may be 2451 2202. The bioactive agent according to item 2182, Sufficient for incubation, however longer time may also be wherein Basidiomycete cell is Trametes unicolor. employed. For example, Zooplankton may continuously 2452 2203. The bioactive agent according to item 2182, hatch and be removed and fresh emulsion may continuously wherein Basidiomycete cell is Trametes versicolor. be added 2453 2204. The bioactive agent according to item 2182, wherein Basidiomycete cell is Trametes villosa. Method of Feeding Animals 2454 2205. The bioactive agent according to item 2182, 2462) The invention also relates to methods of feeding wherein Basidiomycete cell is Trametes Zonata. animals, wherein the methods involve obtaining a food or 2455 2206. A composition comprising the bioactive agent feed product as described herein above and feed said product according to any of the items above and a physiologically to an animal. The feed or food product should be adjusted to acceptable carrier. the specific animal and may thus be a conventional feed or 2456 2207. A pharmaceutical composition comprising food product conventionally fed said animal further compris ing the extracellular liquid, the extracellular composition or the bioactive agent according to any of the items above and the biomass according to the invention. a pharmaceutically acceptable carrier. 2463. The animals may be fed the feed products of the 2457 2208. Use of the pharmaceutical composition invention from day 0. Such as day 1, for example day 2, Such according to item 2207 in the manufacture of a medica as week 1, for example week 2. Such as week 3, for example ment. week 4. Such as month2 after birth or hatching. For mammals, the feed products of the invention are preferably fed from day Preparing Feed or Food Product 0. Such as day 1, for example day 2, such as week 1, for 2458 In general the feed or food product is prepared by example week 2. Such as week 3, for example week 4. Such as admixing a biomass, a composition isolated from biomass, an month 2 after weaning. extracellular liquid or an extracellular composition according 2464. The products may be fed continuously, or they may to the invention to a conventional feed or food product either be fed only for one or more predetermined time intervals. Said during preparation of said food or feed product or after said predetermined time interval could be for one day, such as 2 food or feed product has been prepared. For example the days, for example in the range of 3 to 7 days, such as in the admixing may be performed immediately prior to feeding. range of 1 to 2 weeks, for example in the range of 2 weeks to 2459. In embodiments of the invention, wherein a dry 1 month, such as for more than 1 month. product is preferable, then dried biomass may be employed. It 2465 By way of example, chickens may be fed with the is however also possible to use the extracellular liquid. The feed products from day 7 to day 14 after hatching and with extracellular composition may for example be isolated from conventional feed for the remaining period. the extracellular liquid or from a liquid composition isolated 2466 Depending on the animals, various amounts of the from the extracellular liquid by precipitation, Such as by product may be fed. Chickens may be fed from 0.1 to 1000 ml, alcohol precipitation and the precipitate can be used after such as from 0.5 to 100 ml, such as from 0.5 to 10 ml extra drying. It is also possible to adsorb a liquid onto a solid. Any cellular liquid per day or with an amount of extracellular Solid capable of adsorbing large amounts of liquids may be composition corresponding thereto. Pigs may for example be used, provided that the solid is not toxic to the animal or fed in the range of 0.1 to 1000 mg, such as from 0.5 to 100 mg. human being to be fed with the product. For example, the for example from 0.5 to 10 mg dried biomass per kg per day. Solid may comprise cellulose. Thus the Solid may for example 2467. In one embodiment the method comprises feeding a be microcrystalline cellulose. prey organism the feed product and Subsequently feeding said 2460 Zooplankton feed products, such as artemia, Cala prey organism to an animal. This embodiment is in particular nus or rotifer feed products may be prepared by preparing an relevant for animals preferring living feed. emulsion of an organic phase in water, wherein the organic 2468 Thus if the animal is a marine fish or shell fish then phase comprises the Survival enhancing agent. The Survival the feed product may be fed to Zoo plankton, Such as artemia enhancing agent may be introduced to the organic phase by or rotifer and said artemia or rotifer may subsequently be fed different methods. In the event that the survival enhancing said marine fish or shellfish, such as marine fish larvae. agent is comprised in a dry composition, then the dry com position may be grinded to a particle size of in the range of 1 EXAMPLES to 500 um, preferably in the range of 5 to 100 um, more 2469. The following examples describe illustrative preferably in the range of 10 to 50 lum. The grinded particles embodiments of the invention and should not be regarded as may then be mixed with the organic phase. Methods for limiting for the invention. preparing dry compositions are described herein above in this section. The organic phase may be any organic solvent, pref Example 1 erably an organic solvent which is not toxic to Zooplankton. The organic phase may thus for example be marine oil. Such 2470 Protocol for cultivation of Basidiomycete cells as fish oil or train oil, such as cod liver oil or whale oil or according to the present invention. The protocol is used in the Vegetable oil. Such as Soy oil or calamus oil. The aqueous further examples unless otherwise stated. phase may for example be water, such as sea water or lake Water. Cultivation Conditions: 2461 One kind of marine fish or shell fish feed product Temperature: 25°C.:1 may be prepared by feeding above-mentioned Zooplankton feed products to Zooplankton, wherein said Zooplankton, pH: Medium pH either living or dead constitutes the marine fish or shell fish 2471 Water: Tap water US 2010/0O86647 A1 Apr. 8, 2010 80

Medium: Glucose 30 g/l; fermentation broth by filtration. The supernatant was sub 2472 Mycological peptone 10 g/l; jected to ultrafiltration using a membrane with a nominal pore 2473 Yeast extract 6 g/1 size of 50,000 Da. The retentate (herein designated the (2474 Malt extract 6 g/1 “MediMush product’) was used for analysis of monosaccha ride content. Plate Cultivation of Basidiomycete Cells 2482 Samples were hydrolysed to their constituent 2475 15 cm Petri dishes containing about 60 ml of the monosaccharides in 1N HCl at 100°C. The hydrolysates were medium+agar at a concentration corresponding to 15 g/l. analysed by HPLC using a Dionex MA-1 column with 600 Inoculate the plates by Scraping off the top layer of mycelium mM NaOH as the mobile phase; detection was by pulsed on a Petri dish using a sterile scalpel and spread it onto the amperometry. new plate. One Petri dish will yield enough mycelium to 2483. The major monosaccharides of the MediMush prod inoculate three new plates. Cultivate the plates at 25°C. for at uct was mannose and glucose and some galactose. Table 1 least three weeks prior to use. They can be kept at this tem displays the relative monosaccharide content of the Medi perature for a total of 7 more weeks before they should be Mush product and as well as of another product, Eureka discarded. (Lentinan for injection, Eureka, Australia).

Shake Flask Cultivation of Basidiomycete Cells TABLE 2 2476 500 ml Ehrlenmeyer flasks containing 200 ml of medium. Scrape off the top layer of mycelium on two plates SAMPLE MANNOSE GLUCOSE GALACTOSE using a sterile scalpel and place in a 300 ml Ehrlenmeyer flask MediMush 13.40.4 12.6 1.3 1 containing 100 ml of medium. Homogenise the resulting mixture. Inoculate the 500 ml flasks with 50 ml of the homogenised material per flask. Put on orbital shaker at 25° C. and 140 rpm and leave for 7-10 days. If required, longer Example 3 fermentation periods can also be used. Such as e.g. 15-30 days. Molecular Weight Fractionation 2484 For molecular weight characterisation of their bio Fermenter (3 Litres) Cultivation of Basidiomycete Cells logical activity, the MediMush sample was centrifuged 2477. Place 1.7 litres of the medium in the fermenter and through Microsep (Pall Life Sciences) centrifugal ultrafilters sterilise at 121° C. for 20 mins. Set the fermentation condi at 6° C. and 7,500xg. Filters with nominal MWCO values of tions: 25°C., 200-300 rpm and air at 0.2-0.5 VVm. Decant as 50,000-1,000,000 were used. Analytical results (see table 2) much liquid as possible from two shake flasks and inoculate showed that material yielding mannose, glucose and galac the fermenter with the remaining broth (this will normally tose on acid hydrolysis passed through all four MWCO mem amount to 300-500 ml). Add a suitable antifoam agent when branes used: required (normally throughout the run). Harvests after 6-8 days. If required, longer fermentation periods can also be TABLE 3 used. Such as e.g. 15-30 days. MWCO MANNOSE GLUCOSE GALACTOSE

Harvesting of Basidiomycete Cells 1OOOOOO 10.3 2.9 1 3OOOOO 9.9 3.1 1 2478 Biomass: Remove the biomass from the broth using 1OOOOO 7.3 2.9 1 a nylon cloth with pore size 45 as a filter medium. Wash the SOOOO 8.9 2.9 1 biomass thoroughly with water and dry in a microwave oven set at defrost until dry (normal sample size will require about 15 mins). Store in a desiccator until cool and weigh. 2479 Fermentation liquor: The concentration of bioactive Example 4 agent in the fermentation liquor is determined by precipita tion with abs ethanol. Sterile, distilled water is added if nec Soluble Protein essary to adjust the concentration to the desired level. The resulting liquid is autoclave and stored. 2485 Soluble protein in the samples was measured by a 2480 Medical grade: Pass the biomass-free fermentation microScale version of the Coomassie dye-binding assay liquor through a UF filter having a suitable cut-off value, such (Mousdale, D. M. Campbell, M. S., Coggins, J. R. as e.g. a cut-off value of 300 kD. When 70-80% of the liquid 2486) “Purification and characterisation of bifunctional has been removed add water to the retentate to wash the dehydroquinase-shikimate:NADP dehydrogenase from pea Solution. Repeat until the Solution has lost much (at least most seedlings'. Phytochemistry 367, 217-222 (1987). The of) its colour and appears clean. amounts of Soluble protein in the two products are shown below: Example 2 Carbohydrate Composition 2481 Lentinus edodes was cultivated in liquid culture in SAMPLE SOLUBLE PROTEIN (ig/L) medium comprising 15 g/l glucose, 3 g/1 malt extract, 3 g/1 MediMush sample 31.5 +/- 3.43 yeast extract and 5 g/l peptone in shake flasks at 25°C. After cultivation the biomass was separated from the rest of the US 2010/0O86647 A1 Apr. 8, 2010 81

Example 5 TABLE 6 Breeding of Piglets Effect of the bioactive agent on the feed factor in piglets (gida

2487 5a. Week 1 Week 1-2 Week 1-3 Week 1-4 2488 Tests in piglets are performed in models with diar Feed 4 (2 mg) 1.31 1.34 1.38 1.44 rhoea provoked with E. coli. Piglets are being fed for 4 weeks Feed 3 (0.2 mg) 1.27 1.30 1.31 1.38 (from weaning) with different feed products of the invention, Feed 2 (0.02 mg) 1.19 1.26 1.33 1.39 wherein the different feed products vary e.g. 10 fold in their Feed 1 (control) 1.24 1.31 1.32 1.37 content of extracellular or biomass material from liquid cul ture (for example starting from 1 mg/kg/day dried biomass). 2494 Conclusion: In weeks 1-3 the weight increase in A negative control is included in the experiment wherein the pigs feed with feeds 2 and 4 is higher than in the control. This piglets are fed with the same feed without fungal material. is also the case for pigs feed with feed 3 in weeks 3 and 4 (FIG. Each study group consist of 8 piglets with individual habita 1). In addition feed 2 also has a lower feed factor in weeks 1-2, tion. where its effect on the weight increase is most significant 2489 Intestinal sampling is performed on 2 piglets of each (FIG. 2). Thus the bioactive agent is shown to have a positive group on day 7, and again on day 28. Blood samples are taken effect on the weight increase and feed factor in pigs. upon completion of the study. Example 6 2490. The following parameters are assessed upon Bacteriostatic Effect completion of the study: 2495. In this example it is demonstrated that the bioactive Growth, Survival, Diarrhoea health status, Clinical health agent obtained by the method as described in example 1 status, Relevant systemic and intestinal immunological (precipitated from Fermentation liquor) has a bacteriostatic parameters: Faecal concentration of IgA, macrophages, effect on E. coli K12. attachment of bacteria (E. coli), Blood parameters: T and B 2496 Method: The bacteriostatic effect of the bioactive lymphocytes. TGF-beta, heptoglobin, cytokines. Faeces: E. agent was determined by measuring the cell-density of E. coli coli, intestinal flora composition. K12 cultures grown in Antibiotic assay medium 3 with dif 5b. ferent dilutions of the bioactive agent. A culture without the 2491. In this example it is demonstrated that the bioactive bioactive agent in the medium was used as control. agent obtained by the method as described in example 1 2497 Cells were grown in a 50 ml conical flask at 34°C. (precipitated from Fermentation liquor) has a positive effect for 26 h. The dilutions of the bioactive agent in the growth on the weight increase and feed factor in pigs. medium were 1:10, 1:20 and 1:40. The optical density was measured robotically every 2 h at 660 nm. 2492 Method: The effect on the weight increase and feed 2498 Results: Results are shown in FIG. 3. The optical factor in pigs of the bioactive agent was determined by density significantly decreased in the cultures with a 1:10 and weekly registering the feed uptake and life weight of each pig. 1:20 dilution of the bioactive agent in the stationary phase Weaned NOROC piglets were feed with feed containing dif (between 15 and 26 h). The incubation with a 1:40 dilution of ferent amounts of the bioactive agent according to the inven the bioactive agent does not lead to a significant decrease in tion from day 1 after weaning to day 35. Feeds 1-4 (see Table optical density in comparison with the control. 4) were each given to one group of 32 pigs. Pigs were feed 2499 Conclusion: The bioactive agent is shown to have a according to appetite via automat. bacteriostatic effect on E. coli K12. TABLE 4 Example 7 Anti-Tumor Effect Feed No. bioactive agentiFeed (mg/kg) 2500. In this example it is demonstrated that human and 1 0.0 (control) mouse cancer cell lines are sensitive to treatment with bioac 2 O.O2 3 O.2 tive agent obtained by the method as described in example 1 4 2.0 (precipitated from Fermentation liquor). 2501 Method: The anti-tumor effect of the bioactive agent was determined by measuring the cell-viability of different 2493 Results: Results are shown in Tables 5 and 6 and in human and mouse cell lines after exposure to different con FIGS. 1 and 2. centrations of Lentinex. The MRC-5 cell line from normal human fetal lung fibroblasts was used as control. TABLE 5 2502 Cells were grown in a 96 well dish to a sub confluent Effect of the bioactive agent on average weight increase in cell layer. The medium was removed and the cells washed piglets (g/day with PBS. Fresh medium without the bioactive agent (nega tive control) or containing 0.1; 0.2; 0, 3 or 0.4 mg/mlbioactive Week 1 Week 2 Week 3 Week 4 agent was added and cells were incubated for 24h at 37°C. Feed 4 (2 mg) 297 366 463 566 2503 A MTT-Assay, which measures the activity of the Feed 3 (0.2 mg) 231 325 460 569 mitochondrial Succinate-dehydrogenase, was used to deter Feed 2 (0.02 mg) 288 359 451 S62 mine the cytotoxic effect of the bioactive agent. In living cells Feed 1 (control) 250 326 447 565 this enzyme converts the yellow water-soluble 3-(4,5-dimeth ylthiazol-2yl)-2,5-diphenyl-tetrazolium-bromide (MTT) to blue water-insoluble formazan, whereas there is no conver US 2010/0O86647 A1 Apr. 8, 2010

sion in dead cells. Thus the amount of formazan directly be well within the ability of the skilled person to use the correlates to the number of living cells. teaching provided therewith to prepare other products of the 2504 10 ul MTT solution was added to each well and the invention. plates were incubated for additional 2 h. 70 ul of supernatant were removed from each well and 100 ul acidic isopropanol Example 10 was added to extract the formazan. After 1 h the absorption Bar was measured at 590 nm. 2505. Results: Results are shown in FIG. 4. The number of 2518 75 g of dark chocolate are melted at 70 degrees C. viable cells was significantly decreased in all cancer cell lines and subsequently mixed with 600 mg of Medimush product. after incubation with the bioactive agent for 24 h. This effect The mixture is poured into a bar shaped mold and cooled increased with the concentration of the bioactive agent in the overnight. medium. In all cancer cell lines, fewer than 50% of the cells were viable after incubation with 0.4 mg/ml bioactive agent Example 11 for 24 h. The most severe effect of the bioactive agent was Milkshake observed in the mouse colon cancer cell line C-26, where there were almost no viable cells after the incubation with 0.4 2519 100 ml of vanilla flavoured ice-cream are mixed mg/ml bioactive agent for 24 h. with 100 ml of cooled milk, 10 ml of strawberry syrup and 1 2506 Conclusion: The bioactive agent is shown to have a ml extracellular liquid from mushroom cultivation. The mix cytotoxic effect specifically directed against cancer cells, and ture is fed through a blender and immediately served. not normal cells. Example 12 Example 8 Nougat Bar 2507 Tests in cod larvae is performed through feeding 2520 Ingredient weight (g) larvae with Artemia or rotifers, which are fed with an oil in water emulsion. The organic phase comprises particles (10 Water 70 50 um) and is prepared by one of the following methods. (2521) Hyfoama (emulsifier) 3.5 2508 an extracellular composition is prepared as described in example 1 herein above and precipitated Gelatin 2.0 with ethanol. The precipitate is dried and grinded to Sugar 515 Small particles. 2509) biomass is prepared by fermenting Lentinus 2522I Glucose syrup 60DE 250 edodes as described in example 1. The biomass is air Glucose syrup 35DE 250 dried and grinded to Small particles. Skimmed milk powder 115 2510 Artemia or rotifer is fed to the larvae continuously throughout the life-feed phase (35-40 days after hatching). Fat 50 2511 The cod larvae are evaluated according to the fol 2523) 1 g extracellular liquid from mushroom cultivation lowing parameters: improved Survival, improved growth or 2524 Method of preparation: dissolve hyfoama and gela reduction in occurrence of deformations. tin in water add 150 g of Sugar and beat to foam, heat remain ing Sugar to 130 degrees C. and add slowly to foam. Add fat, Example 9 glucose syrup, milkpowder and 1 g extracellular liquid from mushroom cultivation. Allow to cool and divide in bars of 50 2512 Tests in cod larvae is performed where cod larvae 9. are fed with feed particles containing proteins, lipids and carbohydrates in addition to particles (80-500 um) prepared Example 13 by one of the following methods. Fruit Drink 2513 an extracellular composition is prepared as described in example 1 herein above and precipitated 2525 11 Ingredients 200 g fruit juice concentrate (banana, with ethanol. The precipitate is dried and grinded to pine apple, orange, grape, apricot, lemon, passion fruit, particles. guava, mango) 5 g fructose 1 g inulin 10g, 0.1 g Medimush 2514 biomass is prepared by fermenting Lentinus product, 0.9 g plant sterol fatty acid ester (-0.54 g sterol edodes as described in example 1. The biomass is air equivalents) 5 g lecithin, 1.5 g calcium lactate 775 g water dried and grinded to particles. 1. A feed or food product comprising extracellular material 2515. The larvae are continuously fed with above men derived from a liquid culture of a fungus of the class of tioned particles. Basidiomycetes, wherein said extracellular material com 2516. The cod larvae are evaluated according to the fol prises a Survival enhancing agent and is obtainable by a lowing parameters: improved Survival, improved growth or method comprising the steps of i) fermenting a fungus of the class of Basidiomycetes in a reduction in occurrence of deformations. liquid culture, ii) isolating the extracellular material by removal of the Example of Functional Food Products biomass, thereby obtaining an extracellular liquid, 2517. The invention will now be further illustrated by the iii) optionally isolating an extracellular composition com description of suitable embodiments of the preferred func prising the Survival enhancing agent from the extracel tional food products for use in the invention. It is believed to lular liquid. US 2010/0O86647 A1 Apr. 8, 2010

2. The feed or food product according to claim 1, wherein 23. The food or feed product according to claim 1, wherein said Survival enhancing agent comprises polysaccharides. only fungal mycelium of said Basidiomycete is fermented. 3. The feed or food product according to claim 1, wherein 24. The food or feed product according to claim 1, wherein the Survival enhancing agent comprises polypeptides. said Basidiomycete is selected from the group consisting of 4. The feed or food product according to claim 2, wherein Agaricus bisporus, Cordiceps sinensis, Flammulina veluti at least part of the polysaccharides have a molecular weight of pes, Ganoderma lucidum, Grifola frondosa, Lentinus edodes, at least 30,000 Da. Pleurotus Ostreatus, Schizophyllum commune, Sclerotina 5. The feed product according to claim 1, wherein the feed sclerotium, Trametes (Coriolus) versicolor, Tremellafiucifor product is an aquatic animal feed product. mis, Agaricus blazei, Agrocybe aegerita, Agrocybe cylindra 6. The feed product according to claim 1, wherein the feed cea, Albatrellus confluens, Armillariella mellea, Auricularia product is a crustacean feed product. auriculajudae, Auricularia polytricha, Collybia maracula, 7. The feed product according to claim 1, wherein said Cordiceps militari, Dendropolyporus umbellatus, Fomes extracellular material is comprised within a living microor fomentarius, Fomes pinicola, Ganoderma applanatum, ganism to which the extracellular material has been fed, or Ganoderma tsugae, Hericium erinaceus, Hypsizygus mar administered in another way. moreus, Inonotus obliquus, Laetiporus sulphurous, Lenzites 8. The feed product according to claim 1, wherein said betulinus, Leucopaxillus giganteus, Lyophyllum cineras extracellular material is comprised within a dead organism to cens, Omphalina epichysium, Oudemansiella mucida, Panel which the extracellular material has been fed or administered lus serotinus, Piptoporus betulinus, Phellinus linteus, Pheli in another way. nus pini, Pholiota nameko, Pleurotus citrinopileatus, 9. The feed product according to claim 7, wherein said Pleurotus pulmonarius, Sarcedon asparatus, Trametes Sua organisms are artemia, rotifer and/or calanus. volens, Volvariella volvacea and Wolfiporia cocos. 10. The feed product according to claim 1, wherein the feed 25. The food or feed product according to claim 24, product is a farm animal feed product. wherein said Basidiomycete is selected from the group con 11. The feed product according to claim 1, wherein the feed sisting of Agaricus bisporus, Cordiceps sinensis, Flam product is an artemia or rotifer feed product. mulina velutipes, Ganoderma lucidum, Grifola frondosa, 12. The feed product of claim 11, wherein the feed product Lentinus edodes, Pleurotus Ostreatus, Schizophyllum com is in the form of an emulsion comprising an organic phase and mune, Sclerotina Sclerotium, Trametes (Coriolus) versicolor a water soluble phase. and Tremella fuciformis. 13. The food or feed product of claim 1, wherein the fungus 26. The food or feed product according to claim 1, wherein is a species of Tricholomatales. the Survival enhancing agent comprises a mixture of polysac 14. The food or feed product of claim 1, wherein the fungus charides comprising the monosaccharides galactose, man is a species of Agaricales. nose, and glucose in the ratio 1:0 to 25:1 to 50. 15. The food or feed product of claim 1, wherein the fungus 27. The food or feed product according to claim 1, wherein is a species of Marasmiaceae. the Survival enhancing agent comprises at least 10 ug/L 16. The food or feed product of claim 1, wherein the fungus soluble polypeptide. is a species of Lentinus (Lentinula). 17. The food or feed product of claim 1, wherein the fungus 28. The food or feed product according to claim 1, wherein is Lentinus (Lentinula) edodes. said Survival enhancing agent comprises in the range of 10 to 18. The food or feed product of claim 1, wherein the cul 1000 ug/L soluble polypeptide. turing in step i) is performed at 25°C., pH3 to 7 for 50 to 300 29. A method for producing a food or feed product of claim hours. 1 comprising the steps of 19. The food or feed product of claim 1, wherein the liquid i) fermenting a fungus of the class of Basidiomycetes in a culture comprises malt extract and optionally glucose, yeast liquid culture, extract and peptone. ii) isolating the extracellular material by removal of the 20. The food or feed product of claim 1, where step ii) biomass, comprises centrifugation and/or filtration of the liquid cul iii) optionally performing one or more of the steps speci ture. fied in claim 21 and 22, and 21. The food or feed product of claim 1, wherein isolation iv) incorporating the product of step ii) or iii) into a food or of the extracellular composition comprising the Survival feed product. enhancing agent, comprises one or more of the following 30. A method offeeding an animal comprising feeding said steps: animal a feed product as defined in claim 1. size fractionation and recovery of molecules above 30,000 31. The method of claim 30, wherein the feed product is an kD aquatic or farm animal feed product. ethanol precipitation and recovery of the pellet 32. The method according to claim30, wherein the method drying. Such as freeze drying or lyophilisation comprises feeding a prey organism the feed product and Sub spraying and drying sequently feeding said prey organism to an animal. removal of low molecular weight material 33. The method according to claim 32, wherein the prey removal of oxidants organism is Zoo plankton and the animal is a marine fish or a isolation of polysaccharides shell fish. production of an emulsion comprising of an organic phase 34. A farm animal feed product comprising biomass and a watersoluble phase. derived from a liquid culture of a fungus of the class of 22. The food or feed product according to claim 21, Basidiomycetes, wherein said biomass comprises a Survival wherein size fractionation is a method involving ultracen enhancing agent and is obtainable by a method comprising trifugation, ultrafiltration, microfiltration or gelfiltration. the steps of: US 2010/0O86647 A1 Apr. 8, 2010 84

i) fermenting a fungus of the class of Basidiomycetes in a i) fermenting a fungus of the class of Basidiomycetes in a liquid culture, liquid culture in the presence of malt extract, ii) isolating the biomass by removal of the extracellular ii) isolating the biomass by removal of the extracellular material material iii) optionally isolating a composition comprising the Sur iii) optionally isolating a composition comprising the Sur Vival enhancing agent. Vival enhancing agent. 35. An aquatic animal feed product comprising biomass 38. The feed product according to claim 34, wherein the derived from a liquid culture of a fungus of the class of Survival enhancing agent comprises polysaccharides. Basidiomycetes, wherein said biomass comprises a Survival 39. The feed product according to claim 34, wherein the enhancing agent and is obtainable by a method comprising Survival enhancing agent comprises polypeptides. 40. The feed product according to claim 34, wherein at the steps of: least part of the polysaccharides have a molecular weight of at i) fermenting a fungus of the class of Basidiomycetes in a least 30,000 Da. liquid culture, 41. The feed or food product according to claim 1, wherein ii) isolating the biomass by removal of the extracellular said product is a functional food Suitable for consumption by material humans beings. iii) optionally isolating a composition comprising the Sur 42. The functional food according to claim 41, wherein Vival enhancing agent. said functional food is a dairy product. 36. (canceled) 43. The functional food according to claim 41, wherein 37. A food or feed product comprising biomass derived said functional food is a bread. from a liquid culture of a fungus of the class of Basidi 44. The functional food according to claim 41, wherein omycetes, wherein said biomass comprises a Survival said functional food is a fruit juice-based product. enhancing agent and is obtainable by a method comprising the steps of: c c c c c